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A B S T R A C T
Background
Central serous chorioretinopathy (CSC) is characterized by serous detachment of the neural retina with dysfunction of the choroid
and retinal pigment epithelium (RPE). The effects on the retina are usually self limited, although some people are left with irreversible
vision loss due to progressive and permanent photoreceptor damage or RPE atrophy. There have been a variety of interventions
used in CSC, including, but not limited to, laser treatment, photodynamic therapy (PDT), and intravitreal injection of anti-vascular
endothelial growth factor (anti-VEGF) agents. However, it is not known whether these or other treatments offer significant advantages
over observation or other interventions. At present there is no evidence-based consensus on the management of CSC. Due in large part
to the propensity for CSC to resolve spontaneously or to follow a waxing and waning course, the most common initial approach to
treatment is observation. It remains unclear whether this is the best approach with regard to safety and efficacy.
Objectives
To compare the relative effectiveness of interventions for central serous chorioretinopathy.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2015, Issue 9), Ovid MEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to Febru-
ary 2014), EMBASE (January 1980 to October 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTri-
als.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP)
(www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched
the electronic databases on 5 October 2015.
Selection criteria
Randomized controlled trials (RCTs) that compared any intervention for CSC with any other intervention for CSC or control.
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Data collection and analysis
Two review authors independently selected studies and extracted data. We pooled data from all studies using a fixed-effect model. For
interventions applied to the eye (i.e. not systemic interventions), we synthesized direct and indirect evidence in a network meta-analysis
model.
Main results
We included 25 studies with 1098 participants (1098 eyes) and follow-up from 16 weeks to 12 years. Studies were conducted in Europe,
North and South America, Middle East, and Asia. The trials were small (most trials enrolled fewer than 50 participants) and poorly
reported; often it was unclear whether key aspects of the trial, such as allocation concealment, had been done. A substantial proportion
of the trials were not masked.
The studies considered a variety of treatments: anti-VEGF (ranibizumab, bevacizumab), PDT (full-dose, half-dose, 30%, low-fluence),
laser treatment (argon, krypton and micropulse laser), beta-blockers, carbonic anhydrase inhibitors, Helicobactor pylori treatment, and
nutritional supplements (Icaps, lutein); there were only one or two trials contributing data for each comparison. We downgraded for
risk of bias and imprecision for most analyses, reflecting study limitations and imprecise estimates. Network meta-analysis (as planned
in our protocol) did not help to resolve this uncertainty due to a lack of trials, and problems with intransitivity, particularly with respect
to acute or chronic CSC.
Low quality evidence from two trials suggested little difference in the effect of anti-VEGF (ranibizumab or bevacizumab) or observation
on change in visual acuity at six months in acute CSC (mean difference (MD) 0.01 LogMAR (logarithm of the minimal angle of
resolution), 95% confidence interval (CI) -0.02 to 0.03; 64 participants). CSC had resolved in all participants by six months. There
were no significant adverse effects noted.
Low quality evidence from one study (58 participants) suggested that half-dose PDT treatment of acute CSC probably results in a
small improvement in vision (MD -0.10 logMAR, 95% CI -0.18 to -0.02), less recurrence (risk ratio (RR) 0.10, 95% CI 0.01 to 0.81)
and less persistent CSC (RR 0.12, 95% CI 0.01 to 1.02) at 12 months compared to sham treatment. There were no significant adverse
events noted.
Low quality evidence from two trials (56 participants) comparing anti-VEGF to low-fluence PDT in chronic CSC found little evidence
for any difference in visual acuity at 12 months (MD 0.03 logMAR, 95% CI -0.08 to 0.15). There was some evidence that more
people in the anti-VEGF group had recurrent CSC compared to people treated with PDT but, due to inconsistency between trials, it
was difficult to estimate an effect. More people in the anti-VEGF group had persistent CSC at 12 months (RR 6.19, 95% CI 1.61 to
23.81; 34 participants).
Two small trials of micropulse laser, one in people with acute CSC and one in people with chronic CSC, provided low quality evidence
that laser treatment may lead to better visual acuity (MD -0.20 logMAR, 95% CI -0.30 to -0.11; 45 participants). There were no
significant adverse effects noted.
Other comparisons were largely inconclusive.
We identified 12 ongoing trials covering the following interventions: aflibercept and eplerenone in acute CSC; spironolactone,
eplerenone, lutein, PDT, and micropulse laser in chronic CSC; and micropulse laser and oral mifepristone in two trials where type of
CSC not clearly specified.
Authors’ conclusions
CSC remains an enigmatic condition in large part due to a natural history of spontaneous improvement in a high proportion of
people and also because no single treatment has provided overwhelming evidence of efficacy in published RCTs. While a number of
interventions have been proposed as potentially efficacious, the quality of study design, execution of the study and the relatively small
number of participants enrolled and followed to revealing endpoints limits the utility of existing data. It is not clear whether there is
a clinically important benefit to treating acute CSC which often resolves spontaneously as part of its natural history. RCTs comparing
individual treatments to the natural history would be valuable in identifying potential treatment groups for head-to-head comparison.
Of the interventions studied to date, PDT or micropulse laser treatment appear the most promising for study in future trials.
P L A I N L A N G U A G E S U M M A R Y
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Interventions for central serous chorioretinopathy
Review question
What is the effect of treatments for central serous chorioretinopathy (CSC)? Is any treatment better than any other treatment?
Background
CSC is a disorder of the back of the eye. The ’retina’ (which captures light and turns it into electric impulses to be sent to the brain)
becomes detached. CSC typically affects young and middle-aged adults, particularly men. It can lead to problems with vision. Most
people who develop CSC recover on their own but some people continue to have problems and can lose vision permanently. A variety
of treatments have been proposed for CSC including laser treatment and injections of biological agents to reduce the amount of fluid
in the back of the eye.
Study characteristics
The evidence is current to 5 October 2015. A total of 1098 participants were enrolled from Brazil, China, Germany, India, Iran, Italy,
Japan, Mexico, South Korea, Thailand, Turkey, the UK and the US. All enrolled participants were similar with respect to age and most
were men. The participants had varying severity of the disease; some displayed symptoms for less than 20 days up to six months. Most
studies did not report their source of funding, four studies were industry funded, and six studies were non-industry funded.
Key results
The studies considered a wide range of treatments. As a result, there were not enough studies of any one treatment to provide good
evidence of treatment effects. In general, no significant side effects were noted.
Quality of the evidence
The overall quality of the presently available published evidence was either low or very low. This finding indicates that future published
research is very likely to have an important impact on the conclusions currently provided in this review.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Interventions for central serous chorioretinopathy: direct comparisons
Patient or population: people with central serous chorioret inopathy
Settings: eye hospital
Comparison
(intervention vs. com-
parator)
Anticipated absolute effects (95% CI) Effect estimate from direct comparison Comments
Relative effect
(95% CI)
No of participants
(studies)
Quality
Risk with comparator M ean difference (95%
CI) Negative values are
in favor of intervention;
positive values in favor
of comparator
Change in visual acuity at 12 months (logM AR)
Anti-VEGF vs. observa-
t ion
- 0.01 LogMAR (-0.02 to
0.03)
- 64 (2) Low1,2 Both studies enrolled part icipants
with acute CSC and reported mean
change in visual acuity at 6 months
Anti-VEGF vs. low-f lu-
ence PDT
- 0.03 logMAR (-0.08 to
0.15)
- 56 (2) Low1,2 Both studies enrolled part icipants
with chronic CSC
Anti-VEGF and 50%PDT
vs. 50% PDT
- 0.30 logMAR (0.09 to 0.
51)
- 15 (1) Low1,2 Part icipants had chronic CSC
6-dose ant i-VEGF vs. 4-
dose ant i-VEGF
- -0.02 logMAR (-0.31 to
0.27)
- 12 (1) Low1,2 Part icipants had chronic CSC and
were followed to 6 months
50% PDT vs. observa-
t ion or sham treatment
- -0.10 logMAR (-0.18 to
-0.02)
- 58 (1) Low1,2 Part icipants had acute CSC
30% PDT vs. PDT - -0.16 logMAR (-0.22 to
-0.10)
- 60 (1) Low1,2 Type of CSC not specif ied
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30% PDT vs. 50% PDT - -0.12 logMAR (-0.15 to
-0.08)
- 60 (1) Low1,2 Type of CSC not specif ied
50% PDT vs. PDT - 0.04 logMAR (-0.04 to
0.12
- 60 (1) Low1,2 Type of CSC not specif ied
Select ive ret ina therapy
vs. observat ion
- -0.13 logMAR (-0.24 to
-0.01)
- 30 (1) Low1,2 Part icipants had acute CSC, fol-
lowed up to 3 months
Micropulse diode laser
vs. sham laser
- -0.38 logMAR (-0.56 to
-0.20)
- 15 (1) Low1,2 Part icipants had chronic CSC
Antioxidant vs. placebo - 0.01 logMAR (-0.04 to
0.06)
- 14 (1) Low1,2 Lutein and acute CSC
Propranolol vs. placebo - 0.01 logMAR (-0.07 to
0.09)
- 60 (1) Low1,2 Type of CSC not specif ied
Carbonic anhydrase in-
hibitors vs. placebo
See comment - - 13 (1) - Outcome not reported
Helicobacter pylori t reat-
ment vs. placebo
- -0.04 logMAR (-0.07 to
-0.02)
- 103 (2) Low1,2 Part icipants had acute CSC, fol-
low-up 12-16 weeks
Comparison
(intervention vs. com-
parator)
Anticipated absolute effects (95% CI) Effect estimate from direct comparison Comments
Risk with comparator* Risk with intervention Relative effect (95%CI) No of participants
(studies)
Quality
Persistent CSC at 12 months
Anti-VEGF vs. observa-
t ion
See comment - - 64 (2) - Part icipants had acute CSC. Both
trials reported that all part icipants
in treatment and control groups
were resolved by 6 months
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Anti-VEGF vs. low-f lu-
ence PDT
111 per 1000 688 per 1000 (179 to
1000)
RR 6.19 (1.61 to 23.81) 34 (1) Low1,2 Part icipants had chronic CSC
Anti-VEGF and 50%PDT
vs. 50% PDT
143 per 1000 126 (10 to 1000) RR 0.88 (0.07 to 11.54) 15 (1) Very low1,2,3 Part icipants had chronic CSC
6-dose ant i-VEGF vs. 4-
dose ant i-VEGF
See comment - - 12 (1) - Outcome not reported
50% PDT vs. sham
treatment
211 per 1000 25 per 1000 (2 to 215) RR 0.12 (0.01 to 1.02) 58 (1) Low1,2 Part icipants had acute CSC
30% PDT vs. PDT See comment - - 60 (1) - Outcome not reported
30% PDT vs. 50% PDT See comment - - 60 (1) - Outcome not reported
50% PDT vs. PDT See comment - - 60 (1) - Outcome not reported
Select ive ret ina therapy
vs. observat ion
See comment - - 30 (1) - Outcome not reported
Micropulse diode laser See comment - - 15 (1) - Outcome not reported
Antioxidant vs. placebo See comment - - 51 (1) - People in the ant ioxidant group
were less likely to have ‘‘complete
resolut ion’’ at 3 months (RR 0.35,
95% CI 0.13 to 0.95; 51 part ici-
pants)
Propranolol vs. placebo See comment - - 60 (1) - Outcome not reported
Brinzolamide vs.
placebo
167 per 1000 48 (2 to 1000) RR 0.29 (0.01 to 6.07) 13 (1) Very low2,3 Part icipants had acute CSC
Helicobacter pylori t reat-
ment vs. placebo
314 per 1000 210 (113 to 383) RR 0.67 (0.36 to 1.22) 103 (2) Low1,2 Part icipants had acute CSC
6
In
te
rv
e
n
tio
n
s
fo
r
c
e
n
tra
l
se
ro
u
s
c
h
o
rio
re
tin
o
p
a
th
y
:
a
n
e
tw
o
rk
m
e
ta
-a
n
a
ly
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Comparison
(intervention vs. com-
parator)
Anticipated absolute effects (95% CI) Effect estimate from direct comparison
Risk with comparator* Risk with intervention Relative effect (95%CI) No of participants
(studies)
Quality Comment
Recurrent CSC at 12 months
Anti-VEGF vs. observa-
t ion
See comment - - 64 (2) - Outcome not reported
Anti-VEGF vs. low-f lu-
ence PDT
See comment - - 56 (2) Very low1,2,4 Part icipants had chronic CSC. The
2 studies had dif ferent results for
this outcome (I2 = 71%). In Bae
2011, there was a much higher
risk of recurrence in the ant i-
VEGF group (ranibizumab) com-
pared with the PDT group (RR 19.
83, 95%CI 1.19 to 330.50; 21 eyes)
; in Semeraro 2012, there was also
an increased risk of recurrence
in the ant i-VEGF (bevacizumab)
group but the size of the ef fect
was much smaller and the CIs in-
clude 1 (no ef fect) (RR 1.46, 95%
CI 0.59 to 3.58; 22 eyes)
Ant i-VEGF and 50%PDT
vs. 50% PDT
See comment - - 15 (1) - Outcome not reported
6-dose ant i-VEGF vs. 4-
dose ant i-VEGF
See comment - - 12 (1) - Outcome not reported
50% PDT vs. sham
treatment
267 per 1000 27 per 1000 (3 to 216) RR 0.10 (0.01 to 0.81) 53 (1) Low1,2 Part icipants had acute CSC
30% PDT vs. PDT See comment - - 60 (1) - Outcome not reported
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30% PDT vs. 50% PDT See comment - - 60 (1) - Outcome not reported
50% PDT vs. PDT 270 per 1000 338 per 1000 (154 to
737)
RR 1.25 (0.57 to 2.73) 60 (1) - Type of CSC not specif ied
Select ive ret ina therapy
vs. observat ion
See comment - - 30 (1) - Outcome not reported
Micropulse diode laser See comment - - 15 (1) - Outcome not reported
Antioxidant vs. placebo 143 per 1000 46 (4 to 456) RR 0.32 (0.03 to 3.19) 36 (1) Very low2,3 Part icipants had acute CSC
Propranolol vs. placebo 167 per 1000 100 (27 to 382) RR 0.60 (0.16 to 2.29) 60 (1) Low1,2 Type of CSC not reported
Brinzolamide vs.
placebo
314 per 1000 140 (20 to 953) RR 0.21 (0.03 to 1.43 13 (1) Low1,2 Part icipants had acute CSC
Helicobacter pylori t reat-
ment vs. placebo
See comment - - 103 (2) - Outcome not reported
Adverse effects
All studies reported no ocular or systematic adverse ef fects, or did not comment on adverse ef fects
ant i-VEGF: ant i-vascular endothelial growth factor; CI: conf idence interval; CSC: central serous chorioret inopathy; logMAR:
logarithm of the minimal angle of resolut ion; PDT: photodynamic therapy; RR: risk rat io.
* Risk was est imated f rom the comparator group in the included studies
1 Downgraded for imprecision (-1)
2 Downgraded for risk of bias (-1)
3 Downgraded for imprecision (-2)
4 Downgraded for inconsistency (-1)
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B A C K G R O U N D
Description of the condition
Central serous chorioretinopathy (CSC) has been known by
many names including capillarospastic central retinitis, central an-
giospastic retinopathy and central serous retinopathy (CSR). The
hallmark of CSC is the accumulation of subretinal fluid between
the neurosensory retina and the retinal pigment epithelium (RPE).
The incidence of CSC is greater in men than women; a survey
conducted in Minnesota (US) reported that the annual incidence
of CSC was higher among men (9.9 per 100,000; 95% confi-
dence interval (CI) 7.4 to 12.4) compared with women (1.7 per
100,000; 95% CI 0.7 to 2.7) (Kitzmann 2008). The odds of CSC
is higher among people taking corticosteroids than people not tak-
ing corticosteroids (odds ratio (OR) 37.1, 95% CI 6.2 to 221.8)
(Haimovici 2004). Type A personality, body type and age are also
potential factors correlated with CSC (Nicholson 2013; Yannuzzi
1987). The precise etiology of CSC remains unknown, but the
pathogenesis appears to involve dysfunction of the choroid (the
major blood vessel network serving the outer portion of the retina)
and RPE (Prunte 1996).
The location and amount of subretinal fluid determines what
symptoms are experienced.CSC is commonly associatedwith fluid
accumulation under the macula and detachment of the retina.
When the detachment occurs in the central macula, symptoms
may include reduction of best-corrected visual acuity (BCVA),
distortion of vision, changes in image size, altered color vision,
a decrease in contrast sensitivity, the perception of blind spots,
or a combination of these symptoms (Cassin 2006; Gass 1967;
Wang 2008). Symptoms typically present acutely in one eye with-
out pain. There may be no symptoms when the fluid is located
outside themacula. Cases of bilateral involvement are not uncom-
mon, though symptoms may be present in one eye only. People
seeking treatment generally have reduced vision, distorted vision,
or both. The physician’s goal is to improve the visual acuity and
other visual symptoms and prevent permanent vision loss related
to RPE and outer retinal atrophy by eliminating the fluid between
the neurosensory retina and RPE.
CSC is classified as acute or chronic depending onmultiple consid-
erations. Various clinical investigators have used different cut-off
time points (e.g. persistent fluid for less than six months or longer
than six months) to define acute versus chronic CSC (Nicholson
2013). Others have approached the classification differently: for
example acute CSC is defined as the first attempted treatment to
improve visual acuity and chronic CSC is defined as being refrac-
tory to treatment (Chan 2008; Quin 2013).
The diagnosis of CSC is made by dilated fundus exam combined
with imaging of the retina and choroid with optical coherence
tomography (OCT), fluorescein angiography (FA), indocyanine
green angiography (ICGA), or combinations of these imaging
techniques (Nicholson 2013;Quin 2013;Wang 2008).OCT is an
imaging technique that allows for the identification of and quan-
tification of subretinal fluid as well as estimation of the thickness of
the choroid, which may be abnormally thickened in the setting of
CSC. In some cases, OCT may reveal pathologic changes of CSC
that are subtle on fundoscopy, such as shallow subretinal fluid,
small pigment epithelial detachments, and retinal atrophy that can
occur with chronic disease (Montero 2005). FA and ICGA are
imaging techniques that allow for the identification of abnormal
leakage of fluid from the choroidal and retinal vessels as well as
through the RPE layer. Serial exams and strategic choices among
these imaging techniques are used to follow the progress of disease
and response to treatment.
Many diseases of the choroid, RPE, and retina can produce serous
detachment of the neurosensory retina. Considerations for dif-
ferential diagnosis in CSC include disorders that involve central
vision loss associated with central neurosensory retinal detach-
ment. These include choroidal neovascularization (CNV), pat-
tern dystrophy, optic disc pits, polypoidal choroidal vasculopa-
thy, choroidal melanoma, and choroidal metastasis (Yanoff 2013).
Choroidal hemangioma, uveitis, Harada disease, optic neuritis,
papilledema, vitreous traction, macular holes, and systemic hyper-
tension can also produce neural retinal detachments (Gass 1967).
While in its earliest stages retinal detachment due to small tears
or holes may present as subretinal fluid, the peripheral location,
subsequent course, and discovery of retinal defect usually removes
it from the differential diagnosis. Pigment epithelial detachments
most often in the setting of macular degeneration are sometimes
confused with CSC.
Generally, acute CSC has an excellent prognosis including full vi-
sual recovery to premorbid levels (Klein 1974; Loo 2002; Maruko
2010). However, people with chronic CSC with long-standing
subretinal fluid accumulation may develop RPE atrophy and
changes in the neurosensory retina that result in a permanent loss
of visual function (Baran 2005). While recovery of visual acuity
usually occurs within one to four months (Klein 1974; Mudvari
2007; Nicholson 2013), some visual abnormalities, such as alter-
ations in night vision, contrast sensitivity, and color vision, may
persist. It has also been observed that the severity of the disease is
directly proportional to its duration (Castro-Correia 1992). One-
third to one-half of CSC cases will recur in one year (Loo 2002).
A waxing and waning course is not unusual and contributes to
the difficulty in attributing visual improvement to treatment ben-
efit. A minority of cases become chronic in nature and these may
progress to diffuse abnormalities in the RPE and permanently poor
vision (Baran 2005). Certain features and coexistent conditions
are associatedwith lower final visual acuity, such as recurrent foveal
detachments, chronic foveal detachment, CNV, subretinal fibro-
sis, subfoveal RPE atrophy, and diffuse involvement.
Management of CSC usually involves careful observation with
risk factor modification. Corticosteroid use is the most frequent
modifiable risk factor for CSC and physicians first may reduce
corticosteroid use to treat CSC (Bouzas 2002). While discontin-
9Interventions for central serous chorioretinopathy: a network meta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
uation of corticosteroids can benefit some people, some people
do not respond and many are not taking corticosteroids at all.
Persistent submacular fluid or reduced visual acuity are potential
indications for next treatment, as are cases where untreated CSC
has previously resulted in a poor visual outcome in the fellow eye
(Nicholson 2013). Rare indication may include vocational needs
in, for example, airline pilots, professional athletes, or police/mil-
itary officers.
Description of the intervention
Treatments for CSC generally target the RPE, choroid, or both.
The RPE is responsible for maintaining the blood-retinal barrier
between the retina and choroid as well as for removing any sub-
retinal fluid that accumulates. In CSC, the source of the subreti-
nal fluid is the choroidal vasculature. Treatments for CSC aim to
improve the ability of the RPE to remove the subretinal fluid, to
diminish leakage from the choroidal vessels, or to decrease fluid
flux across the RPE barrier. Determining the effectiveness of treat-
ments for CSC is difficult as a waxing and waning of disease ac-
tivity is typical of the natural history. This natural variation and
the tendency for people to present when their symptoms are worse
creates uncertainty of whether disease improvement is the result of
an intervention or the natural course of the disease. Further con-
founding the assessment of treatment response is a lack of direct
correlation between the person’s visual symptoms and the amount
of subretinal fluid present (Maalej 2014; Nicholson 2013; Quin
2013; Shuler 2006; Wang 2008).
There have been a variety of interventions used, or proposed for
use, in CSC. These interventions include laser treatments, most
commonly photodynamic therapy (PDT); intravitreal injections
of anti-vascular endothelial growth factor (anti-VEGF) agents;
medications that alter steroid hormones; and others.
How the intervention might work
The interventions have various potential modes of action directed
at either accelerating absorption of subretinal fluid or decreasing
the production of fluid that accumulates in the subretinal space.
Presently the target cells are in the choroidal vascular network and
the RPE.
Laser treatments
Argon laser photocoagulation
Argon laser photocoagulation uses a low-intensity green or yellow
argon laser to coagulate tissue by heat generated from an intense
beam of light focused on the RPE (Hofstetter 2000). Lower in-
tensity laser with longer duration and moderate spot size (100 to
200 microns) is preferred to minimize the likelihood of rupture
of Bruch’s membrane, subsequent development of CNV, and de-
velopment of progressive atrophy over time in the area of the laser
treatment (Robertson 1983). This procedure is commonly used to
accelerate the absorption of subretinal fluid in acute and chronic
CSC. Typically, laser burns are applied to areas of focal leakage
that have been identified on FA as the principal sources of sub-
retinal fluid. The mechanism of subretinal fluid resolution after
laser photocoagulation treatment is not well understood. Benefit
has been hypothesized to result from the sealing of focal defects
in the RPE monolayer, the recruitment of healthy RPE cells af-
ter laser injury as a healing response, or the direct stimulation of
improved pumping function of RPE cells near the treated areas
(Mitsui 1969).
Micropulse diode laser photocoagulation
Micropulse diode laser treatment involves a series of repetitive ul-
trashort laser pulses that more broadly treat the RPE (Sivaprasad
2010). Improved RPE function is proposed to result from the tar-
geted cells’ response to therapy. Direct effects on points of leakage
at the level of the RPE also have been postulated. Because of the
relatively small amounts of energy delivered, little adverse thermal
effect on the underlying neural retina and choroid is anticipated
(Chen 2008; Ricci 2004; Roisman 2013). Historically, targeting
of focal leaks outside of the macula with thermal laser has been
more common than with micropulse laser; however, treatment of
diffuse disease with micropulse treatment is increasing in use.
Verteporfin photodynamic therapy
Verteporfin photodynamic therapy (VPDT) has been used to
treat acute CSC and to prevent recurrences (Nicholson 2013).
The exact mechanism of PDT in treating chronic CSC is not
known, but the treatment effects are postulated to result from
short-term choriocapillaris hypoperfusion (decreased blood flow
through choroid vessels) and long-term choroidal vascular remod-
eling, leading to reduction in choroidal congestion, vascular hyper-
permeability, and extravascular leakage (Chan 2003). At present,
PDT typically is used in cases of CSC involving the macula that
have not responded to other treatments or observation. Despite
potential benefits of PDT, theremay be dose-dependent complica-
tions such as the development of RPE atrophy, choriocapillaris is-
chemia, CNV, and RPE tear (Cardillo Piccolino 2003; Kim 2009;
Schlötzer-Schrehardt 2002; Schmidt-Erfurth 2002). Some stud-
ies have reported the treatment of CSC with modified PDT pa-
rameters, including reduced dose of verteporfin, reduced time of
treatment, or reduced fluence (energy/area/second) of laser. These
modifications to treatment parameters have been hypothesized to
reduce the risk of complications while maintaining the potential
treatment benefit (Chan 2008; Lai 2006; Reibaldi 2010).
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Anti-vascular endothelial growth factor agents
The aim of anti-VEGF therapy is to stop neovascular vessel growth
and leakage. Anti-VEGF agents bind to, and block the effects of,
vascular endothelial growth factor (VEGF) thereby slowing down
the growth of new blood vessels in the eye and reducing vascular
permeability. Therefore, anti-VEGFs may have a role in eyes with
CSC that are complicated by secondaryCNV. Anti-VEGF therapy
is typically not expected to provide benefit in cases of CSC that
are not complicated by active CNV. Increased levels of VEGF
have not been found in aqueous humor of people with CSC (Lim
2010).
There are several anti-VEGF agents used by ophthalmologists:
aflibercept (Eylea®), bevacizumab (Avastin®), ranibizumab (Lu-
centis®), and pegaptanib (Macugen®). Currently each of these,
with the exception of bevacizumab, has been approved by the US
Food and Drug Administration (FDA) for use in the eye (FDA
2015). Anti-VEGF agents often are used for, and have been shown
to be effective for, a number of ocular diseases; however, none of
these medications has been approved specifically for use in the
treatment of CSC or for the treatment of CNV in the setting of
CSC.
Medications that alter steroid hormones
The exact role of steroids in CSC pathogenesis is not well un-
derstood. Proposed mechanisms in the choroid include effects on
vascular autoregulation, potentiation of vascular reactivity, or pro-
thrombotic steroid effect (Nicholson 2013). The following medi-
cations that target steroid hormone pathways have been proposed
for treatment of CSC but are not currently licensed for that indi-
cation.
Ketoconazole
Ketoconazole is an anti-fungal agent used to treat candidiasis,
chronic mucocutaneous candidiasis, oral thrush, candiduria, blas-
tomycosis, coccidioidomycosis, histoplasmosis, chromomycosis,
or paracoccidioidomycosis (FDA 2015).
Ketoconazole is an anti-fungal agent that is thought to halt en-
dogenous glucocorticoid production in part by inhibiting the con-
version of 11-deoxycortisol to cortisol. Because of this inhibition,
ketoconazole was established as effective in the treatment of Cush-
ing disease (Chou 2000;Winquist 1995). Thus, it is believed that,
given the association of corticosteroids in the pathogenesis of CSC,
lowering endogenous cortisol production by pharmacologic inter-
vention would be a rational approach to the treatment of CSC
(Jampol 2002; Meyerle 2007).
Mifepristone
Mifepristone (RU-486) is classified as a high-affinity, glucocorti-
coid receptor antagonist (Clark 2008). It is used to end an early
pregnancy for women who have been pregnant for 49 days (seven
weeks) or less since their last menstrual period began. The ratio-
nale for its use in CSC is similar to that for ketoconazole.
Rifampin
Rifampin, also known as rifampicin, is an antibacterial drug that is
typically used to treat tuberculosis and meningococcal carriers. It
is believed to suppress endogenous glucocorticoid production by
inducing cytochrome P450 3A4 (Guengerich 1999); and altering
reactions in steroid synthesis.
Finasteride
In addition to glucocorticoids, androgens, such as testosterone,
have been implicated in the pathophysiology of CSC (Ahad 2006;
Grieshaber 2007). Finasteride is a 5-alfa-reductase inhibitor that
prevents conversion of testosterone to dihydrotestosterone, the
latter of which has a higher binding affinity to androgen receptors
(Forooghian 2011). Finasteride (5 mg) is used to treat benign
prostatic hyperplasia (enlarged prostate gland), while finasteride (1
mg) is used to treat male pattern hair loss (androgenetic alopecia).
Eplerenone and spironolactone
It has been proposed that CSC results from over-activation of the
mineralocorticoid receptor pathway in the choroid. These recep-
tors are bound and activated by mineralocorticoids, such as aldos-
terone, and by glucocorticoids. Eplerenone and spironolactone are
aldosterone receptor antagonists; therefore, they inhibit binding of
both aldosterone and glucocorticoids to mineralocorticoid recep-
tors. Eplerenone is used to treat hypertension among people with
stable left ventricle systolic dysfunction and congestive heart failure
after an acute myocardial infarction (FDA 2015). Spironolactone
is used to establish the diagnosis of primary hyperaldosteronism
by therapeutic trial. The retinal and choroidal vasculature of the
rat expresses glucocorticoid and mineralocorticoid receptors, and
aldosterone injection causes choroidal enlargement in this animal
model (Zhao 2012). Because of these findings, Bousquet 2013
treated 13 participants with chronic CSC with eplerenone and
noted a decrease in mean macular thickness and subretinal fluid.
Carbonic anhydrase inhibitors
Acetazolamide is a carbonic anhydrase inhibitor used to treat
chronic simple (open-angle) glaucoma, secondary glaucoma, pre-
operatively in acute angle-closure glaucoma to lower intraocular
pressure, and prevention of amelioration. It is being used off-label
to treat CSC. It has been investigated on the basis that inhibition
of carbonic anhydrase IV in the RPE seems to promote resorption
of subretinal fluid and retinal adhesion (Cox 1988).
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Helicobacter pylori treatment
Several studies indicated that people with CSC may have a higher
incidence of serum anti-Helicobacter pylori antibodies and that
the treatment for H. pylori could have a positive impact on the
outcome of the disease (Cotticelli 2006). It has been posited that
an immune response to host proteins of the choroidal vasculature
and RPE may be caused by molecular mimicry with antigens of
H. pylori (Giusti 2004).
Aspirin
In some cases of CSC, increased levels of plasminogen activator
inhibitor have been demonstrated compared with controls (Iijima
1999).Consequently, it has been suggested that hypercoagulability
(abnormal blood coagulation that may lead to blood clots) may
play a role in CSC pathogenesis (Cotticelli 2006).
Hypothalamic-pituitary-adrenal axis regulation
The hypothalamic-pituitary-adrenal (HPA) axis is a complex
feedback system among the hypothalamus, pituitary gland, and
adrenal glands. The HPA axis responds to stress by modifying
hormone levels released by the glands. Increased stress levels can
increase the amount of glucocorticoid in the body. Hormone level
information feeds back to the HPA axis; high levels of glucocorti-
coids are believed to suppress HPA axis activity. Medications that
may alter theHPA axis regulation include anti-glucocorticoids and
antidepressants.
Why it is important to do this review
Currently there is no consensus on the management of CSC. Due
to the recurrent and chronic nature of some cases of CSC and
uncertainty relating to best therapy, CSC remains a significant
threat to vision and vocational stability. An evidence synthesis is
needed to assess the relative effectiveness of interventions in order
to determine which are the most promising and to identify any
necessary future primary research.
As there are several different possible interventions, not all of which
will have been compared in head-to-head studies, a network meta-
analysis, if possible, will provide quantitative comparisons of in-
terventions and a treatment hierarchy useful for decision makers.
O B J E C T I V E S
To compare the relative effectiveness of interventions for central
serous chorioretinopathy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomized controlled trials (RCTs) in this
review.
Types of participants
We included studies of adults (aged 18 years or over) with CSC
diagnosed using either OCT or FA, or as defined by study inves-
tigators.
Types of interventions
We included trials that compared any intervention for CSC with
any other intervention for CSC or control. The control could be
placebo, sham treatment, no treatment, or observation. We ex-
cluded trials of traditional Chinese medicine. This was a protocol
amendment - see Differences between protocol and review.
We specified the following interventions in our protocol:
• argon laser photocoagulation;
• micropulse diode laser photocoagulation;
• VPDT (full-dose, half-dose or half-fluence);
• anti-VEGF agents;
• any other intervention (including the use of the specific
medical treatments detailed above).
Figure 1 presents a theoretical treatment network based on in-
terventions in current use and the classes of treatment as listed
above. In our protocol, we planned to construct an alternative
formulation of the network using specific anti-VEGF agents (i.e.
ranibizumab, bevacizumab, and aflibercept) and possibly different
treatment regimens for laser and PDT); however, due to the sparse
number of trials identified, this alternative formulation resulted in
two disconnected networks and we felt it was unwise to proceed.
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Figure 1. Theoretical treatment network.
A key assumption of the network is that any participant that met
the inclusion criteria is, in principle, equally likely to be random-
ized to any of the interventions included in the network. In our
protocol, we planned to exclude trials of treatment for H. pylori
from the network as it is likely that these trials have only recruited
participants with evidence ofH. pylori infection and, therefore, the
participants are unlikely to be comparable to participants enrolled
in other trials. We identified a few trials of systemic treatments
(e.g. antioxidant supplements, beta-blockers). We felt that it was
unlikely that participants would be randomized to a comparison
of these interventions and ocular interventions (i.e. interventions
applied directly to the eye), so we excluded these systemic inter-
ventions from the network. This was a protocol amendment - see
Differences between protocol and review.
Types of outcome measures
Primary outcomes
• Mean change in BCVA of CSC eyes from baseline (before
treatment) to 12 months, measured by a LogMAR (logarithm of
the minimal angle of resolution) chart or equivalent.
Secondary outcomes
• Proportion of CSC eyes with a recurrence of CSC between
baseline and 12 months, as defined by study investigators.
• Proportion of CSC eyes with persistent CSC, as defined by
study investigators.
• Mean change in contrast sensitivity from baseline to 12
months, measured using the Pelli-Robson chart or equivalent.
• Mean change in central retinal subfield thickness (CRST)
from baseline and 12 months, measured using OCT.
• Proportion of CSC eyes with BCVA 20/40 or better at 12
months.
• Proportion of CSC eyes with BCVA 20/200 or worse at 12
months.
• Quality of life at 12 months, measured using a validated
questionnaire.
• Adverse events (e.g. loss of vision due to treatment, retinal
atrophy, CNV).
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Follow-up: we analyzed any measurement within the period of six
to 18 months’ follow-up as the 12-month measurement when a
measurement at 12 months was not available.
BCVA; when logMAR score was not reported, we used the fol-
lowing formula to convert the number of letters read on an Early
Treatment Diabetic Retinopathy Study (ETDRS) chart to log-
MAR score: logMAR = (total number of letters on the chart-num-
ber of letters read correctly) x 0.02.
The total number of participant at risk of recurrence of CSC
between baseline and 12 months was calculated using:
• total number of participants at risk for each group =
number randomized - number lost to follow-up - number of
participants with persistent CSC.
We planned to estimate the relative ranking of the competing
interventions according to the following outcomes:
• mean change in BCVA of CSC eyes from baseline and 12
months;
• proportion with a recurrence of CSC between baseline and
12 months;
• proportion of participants with one or more adverse events.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes
and Vision Trials Register) (2015, Issue 9), Ovid MEDLINE,
Ovid MEDLINE In-Process and Other Non-Indexed Citations,
Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to
February 2014), EMBASE (January 1980 to October 2015), the
ISRCTN registry (www.isrctn.com/editAdvancedSearch), Clini-
calTrials.gov (www.clinicaltrials.gov) and theWorld Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en).We did not use any date
or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 5 October 2015.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix 3),
ISRCTN (Appendix 4), ClinicalTrials.gov (Appendix 5), and the
ICTRP (Appendix 6).
Searching other resources
We searched the reference lists of all included studies and the Sci-
ence Citation Index for papers that have cited included studies.
We did not handsearch conference proceedings or journals specif-
ically for the purposes of this review.
Data collection and analysis
Selection of studies
Two review authors independently screened titles and abstracts
identified from searches using web-based software (Covidence);
and classified each reference as ’relevant’, ’possibly relevant’, or ’def-
initely not relevant’. We resolved any discrepancy by discussion.
We retrieved full-text reports of all records classified as ’relevant’
or ’possibly relevant’, and grouped citations by study. Two review
authors independently assessed the eligibility for each study based
on the full-text reports. We resolved any discrepancy during full-
text assessment by discussion. We documented reasons for exclud-
ing studies after review of the full-text reports. We contacted trial
investigators for clarification of study eligibility as needed.
For potentially eligible studies identified from trial registers we did
the following:
• if the study had a completion date more than two years
previously, we looked for publications of this trial and contacted
the investigators as necessary to obtain published or unpublished
data from the trial;
• if an eligible study had a completion date less than two
years previously, or in the future, we documented the study in
the ongoing studies section of the review.
Data extraction and management
We adapted data collection forms developed and piloted by
Cochrane Eyes and Vision using web-based software (Systematic
Review Data Repository). Two review authors independently ex-
tracted data from each study using all available study reports (pro-
tocols, journal publications, conference abstracts, etc.). We re-
solved any discrepancy by discussion. We abstracted data relevant
to study design, methods, participants’ characteristics, interven-
tion, table of included studies, and outcomes (Appendix 7). We
contacted trial investigators at the email address listed in their
publications where we needed clarification. If we received no re-
sponse after two weeks or we were unable to find current contact
information, we used the data as available.
Assessment of risk of bias in included studies
We used the ’Risk of bias’ tool described in Chapter 8 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). Two review authors independently assessed each trial for
each of the risk of bias domains listed below. We classified each
domain as ’low risk’, ’high risk’, or ’unclear risk’ for each trial.
We resolved any disagreement by discussion. We discussed the
potential impact of trials with high or unclear risks of bias on the
treatment effect.
Sequence generation (selection bias)
• Low risk of bias: computer-generated, random number
table.
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• Unclear risk of bias: not clearly described or not reported.
• High risk of bias: non-random process (e.g. alternation)
(we excluded these trials).
Allocation concealment (selection bias)
• Low risk of bias: data co-ordination center, opaque sealed
envelope.
• Unclear risk of bias: low risk (random) sequence
generation but not described clearly how this was assigned/
stored.
• High risk of bias: investigator was involved in sequence
generation or assignment, or both.
Masking (blinding) of participants and study personnel
(performance bias)
• Low risk of bias: masking reported.
• Unclear risk of bias: masking not reported or not reported
clearly (e.g. ’double blinded’ without explicit description of
masking) but treatments similar.
• High risk of bias: no masking or masking not reported
clearly (e.g. ’double blinded’ without explicit description of
masking) and treatments different (e.g. intervention versus
observation).
Masking of outcome assessors (detection bias)
• Low risk of bias: masking of outcome assessors reported.
• Unclear risk of bias: masking of outcome assessors not
reported or not reported clearly (e.g. ’double blinded’ without
explicit description of masking) but treatments similar.
• High risk of bias: no masking of outcome assessors or
masking not reported clearly (e.g. ’double blinded’ without
explicit description of masking) and treatments different (e.g.
intervention versus observation).
Incomplete outcome data (attrition bias)
• Low risk of bias: missing data less than 20% and no
obvious reason why loss to follow-up should be related to
outcome.
• Unclear risk of bias: not reported or 20% or greater loss to
follow-up but follow-up similar in both groups.
• High risk of bias: loss to follow-up different in different
groups or follow-up clearly related to outcome.
Selective outcome reporting (reporting bias)
• Low risk of bias: all outcomes reported as per protocol or
trial registry entry.
• Unclear risk of bias: protocol and trial registry not
available for comparison.
• High risk of bias: reported primary/secondary outcomes
different from protocol/trial registry or outcomes mentioned in
methods section not reported in results.
Other biases (e.g. funding source)
• Low risk of bias: reported either non-industry funding or
reported no conflict of interest, or both, but did not report either
industry funded or conflict of interest.
• Unclear risk of bias: source of funding and conflict of
interest not reported.
• High risk of bias: industry funding or declared conflict of
interest, or both.
Measures of treatment effect
Dichotomous data
For dichotomous outcome variables, we used risk ratios (RRs)
with corresponding 95% confidence intervals (CIs) to measure
the treatment effect. Dichotomous variables were BCVA 20/40 or
better, BCVA20/200orworse, recurrence/persistence, and adverse
events at one year.
Continuous data
For continuous variables, we used mean differences (MDs) and
95%CIs tomeasure the treatment effect. The continuous variables
were change in BCVA, CRST, contrast sensitivity, and quality-of-
life scores.
None of the included studies reported continuous outcomes us-
ing different scales. However, when future studies are included in
the review, we will use the standardized mean difference (SMD)
whenever a continuous outcomehas been measured on different
scales, as may be the case for quality-of-life outcomes. The SMD
expresses the size of the intervention effect in each study relative
to the variability observed in that study. If one scale increases with
severity while another decreases, we will ensure that all the scales
point in the same direction either by multiplying the mean values
of studies using one type of scale by -1 or by subtracting the mean
from the maximum possible value for the scale.
We presented results from the network meta-analysis as summary
effect sizes (RRs or MDs) for each possible pair of treatments.
Unit of analysis issues
Eyes and people
The unit of analysis was the person as CSC generally involves
one symptomatic eye at the time of presentation. As far as we
could determine, all included studies only included one eye per
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participant andnone of the included studies enrolled bilateral CSC
cases.
Studies with multiple treatment groups
We treated multi-arm studies as multiple independent two-arm
studies in the network meta-analysis.
Dealing with missing data
We contacted all study authors, but they were unable to provide
more data. Authors were given two weeks to respond to our re-
quest. When we received no response, we proceeded using the
available data. We did not attempt imputation for missing data.
We conducted meta-analysis only when there was sufficient quan-
titative information (e.g. measures of variability, number of par-
ticipants at risk). Otherwise, we described the results narratively.
Assessment of heterogeneity
Assessment of clinical and methodological
heterogeneity within treatment comparisons
To evaluate the presence of clinical heterogeneity, we generated
descriptive statistics for trial and study population characteristics
across all eligible trials that compared each pair of interventions.
We assessed the presence of clinical heterogeneity within each pair-
wise comparison by comparing these characteristics.
Assessment of transitivity across treatment
comparisons
We planned to assess the assumption of transitivity epidemiologi-
cally by comparing the clinical and methodological characteristics
of sets of studies grouped by treatment comparisons. We expected
the transitivity assumption will hold as long as treatment compar-
isons were not related to:
• study design (parallel group or within-person);
• acute or chronic CSC;
• date the study was conducted;
• whether the trial was industry sponsored.
In the event, all trials were parallel group, so we did not consider
this factor.
Assessment of reporting biases
None of the meta-analyses included 10 or more studies, so we did
not prepare a funnel plot as planned in our protocol. We assessed
selective outcome reporting bias using the ’Risk of bias’ tool.
Data synthesis
Methods for direct treatment comparisons
We performed standard pairwise meta-analyses using a random-
effects model in Review Manager 5 (RevMan 2014). We used a
fixed-effect model when there were fewer than three studies.
Methods for indirect and mixed comparisons
We performed network meta-analysis using the methodology of
multivariate meta-analysis model where different treatment com-
parisons are treated as different outcomes (White 2012). For this
analysis, we used the ’mvmeta’ command in STATA (StataCorp,
2011; Stata Statistical Software: Release 13. College Station, TX)
(White 2009; White 2011).
We planned to estimate the ranking probabilities for all treatments
of being at each possible rank of intervention effectiveness (e.g. best
to worst) and then to calculate the surface under the cumulative
ranking curve (SUCRA) and mean ranks, but did not do so due
to a lack of data in the network.
Assessment of statistical heterogeneity
Assumptions when estimating the heterogeneity
In standard pairwise meta-analyses, we estimated heterogeneity
variances for each pairwise comparison. In network meta-analysis,
we assumed a common estimate for the heterogeneity variance
across the different comparisons.
Measures and tests for heterogeneity
We assessed statistically the presence of heterogeneity within each
pairwise comparison using the I2 statistic (Higgins 2003). The I
2 statistic measures the percentage of variability that cannot be
attributed to random error.
The assessment of statistical heterogeneity in the entire network
was based on the magnitude of the heterogeneity variance param-
eter (τ2) estimated from the network meta-analysis models.
Assessment of statistical inconsistency
Local approaches for evaluating inconsistency
To evaluate the presence of inconsistency locally, we used the loop-
specific approach (Bucher 1997). This method evaluates the con-
sistency assumption in each closed loop of the network separately
as the difference between direct and indirect estimates for a specific
comparison in the loop (inconsistency factor). Then, the magni-
tude of the inconsistency factors and their 95% CIs can be used
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to infer the presence of inconsistency in each loop. We assumed
a common heterogeneity estimate within each loop. We planned
to present the results of this approach graphically in a forest plot
using the ’ifplot’ command in STATA (Chaimani 2013), but in
the event, there were not enough loops to make this necessary.
Global approaches for evaluating inconsistency
To check the assumption of consistency in the entire network,
we used the ’design-by-treatment’ model using the ’mvmeta’ com-
mand in STATA (Higgins 2012). This method accounts for dif-
ferent sources of inconsistency that can occur when studies with
different designs (two-arm trials versus three-arm trials) give dif-
ferent results as well as disagreement between direct and indirect
evidence. Using this approach, we judged the presence of incon-
sistency from any source in the entire network based on a Chi2
test.
Subgroup analysis and investigation of heterogeneity
There were insufficient data available to perform subgroup analy-
ses by type of CSC (acute versus chronic).
Sensitivity analysis
We planned the following sensitivity analyses but there were not
enough studies contributing to each analysis to enable this.
In standard pairwise comparisons or meta-analyses, we planned to
exclude the following studies to determine their impact on effect
size for the primary outcome:
• studies with high risk of bias on any domain;
• studies with unpublished data only; and
• industry-funded studies.
’Summary of findings’ table
We prepared a ’Summary of findings’ table for all comparisons
including relative and absolute effects for the following outcomes:
mean change in BCVA, persistent CSC, recurrence of CSC and
adverse effects.We usedGRADE (Guyatt 2011) to assess the over-
all quality of the evidence for each outcome in pairwise and net-
work meta-analyses (Puhan 2014).
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded 1168 references (Figure 2). The
Trials Search Co-ordinator scanned the search results, removed
299 duplicates and then removed 229 references that were not
relevant to the scope of the review. We screened the remaining 640
reports and discarded 554 records as not relevant. We obtained
86 full-text reports for potential inclusion in the review and we
included 25 studies (see Characteristics of included studies table)
and excluded 49 studies (see Characteristics of excluded studies
table). We also included 12 reports of ongoing studies and will
assess the data for these studies when the results become available
(see Characteristics of ongoing studies table).
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Figure 2. Study flow diagram.
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Included studies
We included 25 studies of 30 full-text articles, of which four stud-
ies only had abstracts available (Boscia 2008; Brancato 1994; Chan
2006; Coskun 2014). We contacted the authors of studies with
abstracts only; authors of Boscia 2008 and Brancato 1994 did not
respond, authors of Coskun 2014 reported not publishing the ab-
stract as a full-text article, and authors of Chan 2006 were not able
to provide the corresponding full-text. We provided a summary
describing each of the included studies in the Characteristics of
included studies table. Thirteen of 25 included studies did not re-
port either the number of eyes or number of participants enrolled;
we assumed that all included studies were parallel RCTs, where
only one eye per participant was enrolled (Bae 2011; Boscia 2008;
Brancato 1994; Browning 1993; Chan 2006; Klatt 2011; Leaver
1979;Ontiveros-Orozco2004; Rahbani-Nobar 2011; Sawa 2014;
Shang 1999; Verma 2004; Zhang 2012).
Types of participants
A total of 1098 participants from25 included studies were enrolled
from Brazil, China, Germany, India, Iran, Italy, Japan, Mexico,
South Korea, Thailand, Turkey, the UK, and the US. The baseline
characteristics of participants in all trials were similar with respect
to age (mean age ranged from 35.0 to 50.8 years). However, 79%
(685 of 872 participants) of participants were men; three studies
did not report the number of men and women enrolled (Boscia
2008; Coskun 2014; Shang 1999). One study enrolled men only
(Pitcher 2015).
Nine studies enrolled participants with acute CSC alone, six stud-
ies enrolled participants with chronic CSC alone, and two stud-
ies enrolled participants with both acute and chronic CSC. Seven
studies did not specify type of CSC. The definition of acute CSC
varied between studies; the duration of onset ranged from less than
20 days to six months. Likewise, the definition of chronic CSC
varied; the duration of onset ranged from greater than 12 weeks
to six months.
Types of interventions
Five classes of interventions were investigated: laser treatments (ar-
gon laser photocoagulation, micropulse diode laser photocoagula-
tion, PDT), anti-VEGF, medications that alter steroid hormones
(carbonic anhydrase inhibitors), H. pylori treatment, and other
treatments (antioxidant, calcium antagonist, beta-blocker). In the
studies of PDT, where it was specified, treatment was applied to ar-
eas of choroidal hyperpermeability, usually identified using ICGA.
The 25 included studies alluded to 19 pair-wise comparisons:
• anti-VEGF versus observation;
• anti-VEGF versus PDT;
• 50% PDT plus anti-VEGF versus 50% PDT;
• different dose regimens of anti-VEGF (six-dose versus four-
dose aflibercept);
• 50% PDT versus observation or sham treatment;
• 50% PDT versus PDT;
• 30% PDT versus PDT;
• 30% PDT versus 50% PDT;
• laser versus observation or sham treatment;
• micropulse diode laser versus argon laser;
• indirect argon laser versus direct argon laser;
• antioxidant supplements versus placebo;
• beta-blocker versus placebo;
• beta-blocker versus calcium antagonist;
• H. pylori treatment versus placebo or observation;
• carbonic anhydrase inhibitors versus placebo;
• yellow versus red wavelength laser;
• yellow versus green wavelength laser;
• red versus green wavelength laser.
Types of outcomes
Fourteen studies were include in the quantitative analysis. Studies
reported BCVA was measured using Snellen chart and LogMAR.
When authors reported the number of letters read on a logMAR
chart, we converted it to a LogMAR score (Types of outcome
measures). Many included studies did not clearly describe the ad-
verse events reported, often not reporting which adverse events
were collected.
Follow-up duration ranged from 16 weeks to 12 years. None of
the studies reported the proportion of CSC with BCVA 20/40 or
better at 12 months, proportion of CSC with BCVA 20/200 or
better at 12 months, or quality of life at 12 months.
Excluded studies
We excluded 49 studies of 47 full-text articles and two trial
registries. We documented our reasons for exclusion in the
Characteristics of excluded studies table. The reasons for exclusion
were: 37 studies were not RCTs, 10 studies were of traditional
Chinese medication, one study (a trial registry) was terminated
early due to lack of enrollment, and one study (a trial registry)
enrolled participants with age-related macular degeneration.
Ongoing studies
We identified 12 ongoing studies from the trials registers. These
studies are evaluating the following interventions and compara-
tors.
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In acute CSC:
• PDT versus observation (EUCTR2009-017959-98-NL);
• aflibercept versus sham injection (NCT01971190);
• eplerenone versus placebo (NCT01990677;
NCT02215330).
In chronic CSC;
• lutein versus placebo (JPRN-UMIN000005372);
• spironolactone versus placebo (NCT01552044);
• eplerenone versus placebo (NCT01990677;
NCT02153125);
• three doses of PDT (50%, 40%, 30%) (NCT01630863);
• half-dose versus half-fluence PDT (NCT01019668);
• half dose PDT versus micropulse diode laser
(NCT01797861).
Note: trial NCT01990677 includes both acute and chronic CSC
separately.
Type of CSC not clearly specified:
• micropulse diode laser versus observation (NCT01982383);
• short-term oral mifepristone versus placebo
(NCT02354170).
Risk of bias in included studies
Figure 3 provides a summary of our judgments for each risk of
bias domain for the included studies.
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Figure 3. Risk of bias summary: review authors’ judgments about each risk of bias item for each included
study.
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Allocation
We judged 12 of 25 included studies at low risk of bias as the
authors explicitly reported the method used to generate a random
sequence (e.g. computer-generated, randomization software, ran-
dom table, random block size design). We judged the remaining
13 studies at unclear risk of bias as the authors did not clearly
describe or report the method of randomization. None of the in-
cluded studies were judged at high risk of bias.
We judged eight of 25 included studies at low risk of bias as the
authors explicitly reported appropriate methods to conceal the
assignment sequence (e.g. data coordination center, opaque sealed
envelope). We judged 16 of 24 included studies at unclear risk
of bias as they had an appropriate method of random sequence
generation, but did not clearly describe how the random sequence
was assigned or stored, or they did not clearly describe how the
random sequencewas generated or stored.We judged one included
study at high risk of bias as one of the investigators was involved
in the sequence generation and assignment (Ratanasukon 2012).
Masking of participants and personnel (performance
bias)
We judged each study based on the interventions administered
to each group; studies had different treatments (e.g. laser versus
observation) and studies with similar treatments (e.g. 50% PDT
versus 30% PDT). Nine studies compared different treatments
(Bae 2011; Boscia 2008; Coskun 2014; Kim 2013; Klatt 2011;
Leaver 1979; Lim 2010; Rahbani-Nobar 2011; Semeraro 2012).
None of these studies explicitly reportedmasking and sowe judged
them at high risk of performance bias.
The remaining 16 studies had similar treatments. Nine of these 16
studies were judged at low risk of bias as the authors had explicitly
stated that participants were masked. We judged seven of these
15 studies at unclear risk of bias as there was no information on
masking or reported ’double blinded’ without explicit description
of how they were masked.
Masking of outcome assessors (detection bias)
Eight studies reported that outcome assessorsweremasked to treat-
ment group and we judged them at low risk of detection bias (Bae
2011; Browning 1993; Chan 2008; Dang 2013; Ratanasukon
2012; Roisman 2013; Sawa 2014; Zhao 2015). Eight studies did
not report any masking and the treatments were different and
so we judged them at high risk of detection bias (Boscia 2008;
Coskun 2014; Kim 2013; Klatt 2011; Leaver 1979; Lim 2010;
Rahbani-Nobar 2011; Semeraro 2012). In the remainder, it was
unclear in general because the groups were similar but masking
was not explicitly reported.
Incomplete outcome data
We judged five studies at high risk of attrition bias. Kim 2013 did
not report the number of people randomized and loss to follow-up
by group and the final numbers analyzed were identical between
treatment andobservation group (20/20). Lim 2010 didnot follow
up 25% of participants and did not report which group they were
in. Sawa 2014 excluded 5/39 participants after randomization but
did not report which group they were in. Ratanasukon 2012 lost
3/29 participants to follow-up at three months in intervention
group and 4/29 in the control group (4/29) but at 12 months,
only assessed seven participants in each group. So there was a low
risk at three months and high risk for 12 months outcomes. In
Zhao 2015, there were different losses to follow-up in each group
(13% compared with 6%).
We judged 12 studies at low risk of attrition bias because loss to
follow-up was less than 20% and there was no obvious reason
why loss to follow-up should be related to outcome (Bae 2011;
Chan 2008; Klatt 2011; Leaver 1979; Ontiveros-Orozco 2004;
Pitcher 2015; Rahbani-Nobar 2011; Roisman 2013; Semeraro
2012; Shang 1999; Verma 2004; Zhang 2012).
In the remaining studies, it was unclear whether attrition bias was
a problem, usually because of a lack of information.
Selective reporting
Only five studies were at low risk of selective reporting, that is,
outcomes reported a priori (usually on a trials registry entry) were
reported in the published paper (Bae 2011; Klatt 2011; Rahbani-
Nobar 2011; Ratanasukon 2012; Roisman 2013). In most cases it
was unclear because we did not have access to the trial protocol and
the trial was not registered with a publicly available database. For
Pitcher 2015, Sawa2014, andZhao 2015, therewas some evidence
of selective reporting. Sawa 2014 measured, but did not report,
BCVA and only reported resolution of CSC for the intervention
(lutein) group. Pitcher 2015 included additional outcomes that
were not specified in the trial registry entry. Zhao 2015 specified
the primary outcome at clinicaltrials.gov (NCT01574430) was
“change from baseline in BCVA”, but primary outcomes specified
in the published report were OCT-based improvement rate and
FA-based improvement rate at six and 12 months. They did report
BCVA, but it was not defined as primary outcome (Zhao 2015).
Other potential sources of bias
We judged four studies at risk of bias either because they were
industry funded or there was a declared conflict of interest (Bae
2011; Klatt 2011; Pitcher 2015; Sawa 2014). Six studies were at
low risk of bias because they were non-industry funded or the
authors declared they had no conflicts of interest, or both (Dang
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2013; Kim 2013; Lim 2010; Roisman 2013; Verma 2004; Zhao
2015). For the remainder of the studies, it was unclear, usually
because the studies did not report funding sources and conflicts
of interest.
Effects of interventions
See: Summary of findings for the main comparison
Interventions for central serous chorioretinopathy: direct
comparisons
Pairwise meta-analysis (direct comparisons)
Anti-vascular endothelial growth factor versus observation
Two trials compared anti-VEGF therapy to observation; both
studies were conducted in South Korea (Kim 2013; Lim 2010).
Both studies enrolled participants with acute CSC, which was de-
fined as CSC of less than three months’ duration. A total of 82
people (82 eyes) were randomized in these two trials and 64 people
were followed up to six months. Both trials were at high risk of
performance, detection, and attrition bias.
In Kim 2013, a single dose of ranibizumab (0.5 mg/0.05 mL) was
given at baseline and participants followed up for six months. In
Lim 2010, a single dose of bevacizumab (1.25 mg/0.05 mL) was
given within one week of diagnosis and participants were followed
up for six months.
Mean change in best-corrected visual acuity between baseline
and 12 months
Both trials reported visual acuity at six months, which was similar
in the anti-VEGF and observation groups (MD 0.01 LogMAR,
95% CI -0.02 to 0.03; 64 eyes; I2 = 0%; Analysis 1.1). We judged
this to be low quality evidence downgrading for risk of bias (-1)
and indirectness (-1) as the outcome was only measured at six and
not 12 months.
Recurrence of central serous chorioretinopathy at 12 months
Neither trial reported recurrence of CSC at 12 months.
Persistent central serous chorioretinopathy at 12 months
Both trials reported that all participants in treatment and control
groups (total of 64 eyes) were resolved by six months (i.e. did not
have persistent CSC).
Mean change in contrast sensitivity between baseline and 12
months
Neither trial reported mean change in contrast sensitivity between
baseline and 12 months.
Mean change in central retinal thickness between baseline
and 12 months
Both studies measured central retinal thickness using an OCT.
There was no evidence for a difference between the two groups
(MD 8.73 µm, 95% CI -18.08 to 35.54; 64 participants; I2 =
20%; Analysis 1.2) We judged this to be low quality evidence
downgrading for risk of bias (-1) and indirectness (-1).
Best-corrected visual acuity 20/40 or better at 12 months
Neither trial reported BCVA 20/40 or better at 12 months.
Best-corrected visual acuity 20/200 or worse at 12 months
Neither trial reported BCVA 20/200 or worse at 12 months.
Quality of life at 12 months
Neither trial reported quality of life at 12 months.
Adverse events
Both studies reported that there were no adverse effects of anti-
VEGF treatment.Kim2013 specified that they looked for systemic
and ocular adverse events.
Anti-vascular endothelial growth factor versus
photodynamic therapy
Two studies compared anti-VEGF to PDT and were conducted in
South Korea (Bae 2011) and Italy (Semeraro 2012). Both studies
enrolled participants with chronic CSC: in Bae 2011 this was
defined as “chronic CSC with visual disturbance persisting for >6
months or recurrent CSC”; in Semeraro 2012 this was defined as
“either persistence of subretinal fluid detected onoptical coherence
topography (OCT) for at least 3 months after diagnosis or more
than 3 recurrences in at least 3 months with gravitational RPE
atrophy”. A total of 54 participants (56 eyes) were randomized in
these trials and all were followed up to nine months (Semeraro
2012) and 12 months (Bae 2011). We judged both studies at high
risk of performance bias; Semeraro 2012 was also at high risk of
detection bias; Bae 2011 was industry funded.
In both studies, PDT was “low fluence”, which means that they
used a light dose of 25 J/cm2. In Bae 2011, ranibizumab (0.5 mg/
0.05 mL) was given at baseline, one month, and two months; in
Semeraro 2012, bevacizumab (1.25 mg) was given at baseline and
then as needed after four weeks.
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Mean change in best-corrected visual acuity between baseline
and 12 months
Visual acuity was similar between the two groups (MD 0.03 log-
MAR, 95% CI -0.08 to 0.15; 56 eyes; I2 = 0%; Analysis 2.1).
We judged this to be low quality evidence downgrading for risk
of bias (-1) and imprecision (-1) as we cannot exclude a clinically
important effect.
Recurrence of central serous chorioretinopathy at 12 months
The two studies had different results for this outcome (I2 = 71%;
Analysis 2.2). In Bae 2011, there was a much higher risk of re-
currence in the anti-VEGF group (ranibizumab) compared with
the PDT group (RR 19.83, 95% CI 1.19 to 330.50; 21 eyes); in
Semeraro 2012 there was also an increased risk of recurrence in
the anti-VEGF (bevacizumab) group but the size of the effect was
much smaller and the CIs included 1 (i.e. no effect) (RR 1.46,
95% CI 0.59 to 3.58; 22 eyes). Note the denominator in these
studies is smaller as only the eyes where CSC had resolved were
at risk of recurrence. We judged this to be very low quality of
evidence downgrading for risk of bias (-1), imprecision (-1), and
inconsistency (-1); we are very uncertain as to the size of the effect.
Persistent central serous chorioretinopathy at 12 months
Only Bae 2011 reported persistent CSC at 12 months. People
in the anti-VEGF group (ranibizumab) were more likely to have
persistent CSC at 12 months (RR 6.19, 95% CI 1.61 to 23.81;
34 eyes; Analysis 2.3). We judged this to be low quality evidence
and downgraded for risk of bias (-1) and imprecision (-1).
Mean change in contrast sensitivity between baseline and 12
months
Neither trial reported mean change in contrast sensitivity between
baseline and 12 months.
Mean change in central retinal thickness between baseline
and 12 months
The two studies found different results for central retinal thick-
ness (I2 = 69%; Analysis 2.4). In Bae 2011, there was a greater
reduction in thickness in the PDT group (MD 31.30 µm, 95%CI
-3.46 to 66.06); in Semeraro 2012, there was a greater reduction
in the anti-VEGF group (bevacizumab) (MD -13.00, 95% CI -
46.05 to 20.05). We judged this to be very low quality of evidence
downgrading for risk of bias (-1), imprecision (-1), and inconsis-
tency (-1); we are very uncertain as to the size of the effect.
Best-corrected visual acuity 20/40 or better at 12 months
Neither trial reported BCVA 20/40 or better at 12 months.
Central serous chorioretinopathy eyes with best-corrected
visual acuity 20/200 or worse at 12 months
Neither trial reported CSC eyes with BCVA 20/200 or worse at
12 months.
Quality of life at 12 months
Neither trial reported quality of life at 12 months.
Adverse events
Both studies reported that no systemic or ocular adverse events
related to the drugs or procedures were observed.
Anti-vascular endothelial growth factor plus 50%
photodynamic therapy versus 50% photodynamic therapy
alone
One study conducted in Turkey compared anti-VEGF (beva-
cizumab 1.25 mg single dose three days after PDT) plus PDT to
PDT alone (Coskun 2014). The PDT was “half dose” (i.e. the
dose of verteporfin used was half that usually delivered (3 mg/m
2)). The study enrolled 15 participants with chronic CSC (dura-
tion six months) and followed them up for a mean of 12 months
in the anti-VEGF plus PDT group and nine months in the PDT
alone group. This study was reported in an abstract only and was
largely judged at unclear risk of bias apart from performance and
detection bias where we judged them at high risk of bias because
masking was not mentioned and the treatments were obviously
different.
Mean change in best-corrected visual acuity between baseline
and 12 months
At follow-up, the mean logMAR visual acuity in the anti-VEGF
plus PDT group was 0.36 (standard deviation (SD) 0.25) and in
the PDT alone group was 0.06 (SD 0.15). This gives anMD in fa-
vor of PDT alone of 0.30 logMAR (95%CI 0.09 to 0.51; Analysis
3.1). We judged this to be low quality evidence downgrading for
risk of bias (-1) and imprecision (-1) as the CIs include clinically
unimportant effects.
Recurrence of central serous chorioretinopathy at 12 months
The trial did not report recurrence of CSC at 12 months.
Persistent central serous chorioretinopathy at 12 months
CSC resolved in 7/8 eyes in the anti-VEGF plus PDT group and
6/7 eyes in the PDT alone group (RR 0.88, 95%CI 0.07 to 11.54;
Analysis 3.2). We judged this to be very low quality evidence and
downgraded for risk of bias (-1) and imprecision (-2) due to very
wide CIs. We are very uncertain as to the size of the effect.
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Mean change in contrast sensitivity between baseline and 12
months
The trial did not report mean change in contrast sensitivity be-
tween baseline and 12 months.
Mean change in central retinal thickness between baseline
and 12 months
In the anti-VEGF plus PDT group, the central macular thickness
was 203 µm (SD 45) and in the PDT alone group it was 187 µm
(SD 15) (MD 16.00 µm, 95% CI -17.10 to 49.10; Analysis 3.3).
We judged this to be low quality evidence; we downgraded for risk
of bias (-1) and imprecision (-1).
Best-corrected visual acuity 20/40 or better at 12 months
The trial did not report BCVA 20/40 or better at 12 months.
Best-corrected visual acuity 20/200 or worse at 12 months
The trial did not report BCVA 20/200 or worse at 12 months.
Quality of life at 12 months
The trial did not report quality of life at 12 months.
Adverse events
The trial did not report adverse events.
Six-dose anti-vascular endothelial growth factor versus four-
dose anti-vascular endothelial growth factor
One study from theUS compared two treatment regimens: afliber-
cept 2.0 mg/0.05 mL administered six times (at baseline, one,
two, three, four, and five weeks) versus four times (at baseline,
one, two, and four weeks) (Pitcher 2015). The study enrolled 12
participants and followed them for six months. This study was
poorly reported with mostly unclear risk of bias and high risk of
reporting bias. The study received industry funding.
Mean change in best-corrected visual acuity between baseline
and 12 months
There was a similar change in logMAR acuity over six months in
the two groups. In the group given six doses, on average visual
acuity improved by 0.1 logMAR (SD 0.32) and in the group given
four doses it improved by 0.08 logMAR (SD 0.16). This was an
MD of 0.02 logMAR units greater improvement (95% CI -0.31
to 0.27) in the six-doses group but with wide CIs (Analysis 4.1).
We judged this to be low quality evidence downgrading for risk
of bias (-1) and imprecision (-1).
Recurrence of central serous chorioretinopathy at 12 months
The trial did not report recurrence of CSC at 12 months.
Persistent central serous chorioretinopathy at 12 months
The trial did not report persistent CSC at 12 months.
Mean change in contrast sensitivity between baseline and 12
months
The trial did not report mean change in contrast sensitivity be-
tween baseline and 12 months.
Mean change in central retinal thickness between baseline
and 12 months
The two groups had similar change in central macular thickness
over six months with an MD of 26.50 µm (95% CI -123.41 to
176.41; 12 participants). Both groups experienced a decrease: in
the six-dose group of -80 µm (SD 103.7) and in the four-dose
group of -103 µm (SD 156). We judged this to be low quality
evidence downgrading for risk of bias (-1) and imprecision (-1).
Best-corrected visual acuity 20/40 or better at 12 months
The trial did not report BCVA 20/40 or better at 12 months.
Best-corrected visual acuity 20/200 or worse at 12 months
The trial did not report BCVA 20/200 or worse at 12 months.
Quality of life at 12 months
The trial did not report quality of life at 12 months.
Adverse events
The trial reported there were no adverse events.
Photodynamic therapy versus observation or sham
treatment
Two studies compared PDT to no PDT and were conducted in
Italy (Boscia 2008) and China (Hong Kong) (Chan 2008).
Boscia 2008 was reported in an abstract only and there was no
information on our review outcomes. We contacted the investiga-
tors (twice) for more information but did not receive a reply. In
the abstract report of Boscia 2008 no actual data were reported.
In the results section, the following statement was made “No sig-
nificant changes in all parameters were seen in untreated group.
An improvement of far and near BCVA were seen in comparison
with both baseline (ANOVA, p=0,008 and 0,000), and control
group (t-TEST, p=0,010 at p=0,000), with the greatest effect at
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week 24. In all treated eyes a complete resolution of subretinal
fluid was observed, with significant reduction of central macular
thickness. On week 24, in treated eyes, a significant improvement
in mean fixation stability was also observed (ANOVA, p=0,011).
No recurrence and/or adverse event occurred in any of the treated
patients during the follow-up”.
Therefore, the following review outcomes were only available for
Chan 2008.
Chan 2008 enrolled people with acute CSC, which was defined as
less than threemonths’ duration. The study enrolled 63 people (63
eyes) and followed up 58 people to 12 months. The study was low
risk of bias in most domains and unclear for two domains: selective
outcome reporting (where we did not have access to protocol or
trials register entry to check this) and other bias (one of the authors
declared a conflict of interest but this was only one of five authors
and not the first author). Chan 2008 compared ’half dose’ PDT
(verteporfin 3 mg/m2) to sham PDT treatment (saline infusion
and laser application as for PDT).
Mean change in best-corrected visual acuity between baseline
and 12 months
At 12 months, the visual acuity in the PDT group was better
than the visual acuity in the sham PDT group (MD -0.10, 95%
CI -0.18 to -0.02). We judged this to be low quality evidence,
downgrading for imprecision (-1) (as the CIs included a clinically
unimportant effect) and risk of bias (-1) (Analysis 5.1).
Recurrence of central serous chorioretinopathy at 12 months
CSC resolved in 38 eyes in the PDT group and one of these 38
eyes had a recurrence by 12 months. In the control group, 15/
19 resolved and four of these 15 had a recurrence (RR 0.10, 95%
CI 0.01 to 0.81; Analysis 5.2). We judged this to be low quality
evidence downgrading for risk of bias (-1) and imprecision (-1),
as there were very few events.
Persistent central serous chorioretinopathy at 12 months
One of 29 eyes had persistent CSC in the PDT group compared
with 4/39 eyes in the control group (RR 0.12, 95% CI 0.01 to
1.02; Analysis 5.2). We judged this to be low quality evidence;
downgrading for risk of bias (-1) and imprecision (-1).
Mean change in contrast sensitivity between baseline and 12
months
The trial did not report mean change in contrast sensitivity be-
tween baseline and 12 months
Mean change in central retinal thickness between baseline
and 12 months
The CRTwas thinner in the PDT group compared with the sham
PDT group at 12 months (MD -117.00 µm, 95% CI -205.71 to
-28.29; Analysis 5.3). We judged this to be low quality evidence,
downgrading for risk of bias (-1) and imprecision (-1), as the CIs
included a clinically unimportant effect.
Best-corrected visual acuity 20/40 or better at 12 months
The trial did not report BCVA 20/40 or better at 12 months.
Best-corrected visual acuity 20/200 or worse at 12 months
The trial did not report BCVA 20/200 or worse at 12 months.
Quality of life at 12 months
The trial did not report quality of life at 12 months.
Adverse events
Chan 2008 reported that no systemic or ocular adverse events
related to the PDT procedure were observed.
30% photodynamic therapy compared with 50%
photodynamic therapy compared with photodynamic
therapy
One study compared 30% PDT, 50% PDT, and PDT (Zhang
2012). This study was conducted in China and enrolled 90 eyes
of 90 participants with 30 participants in each group and followed
them up to 12 months. The type of CSC was not specified. We
largely judged this study to be at unclear risk of bias because of
problems with reporting.
One additional study, also conducted in China, compared 30%
PDT with 50% PDT (Zhao 2015). This study enrolled 129 par-
ticipants (129 eyes) and followed 117 participants to 12 months.
We judged this study to be at low risk of bias in most domains
with the exception of attrition bias (6% of the 30% PDT group
were lost to follow-up compared to 13% of the 50% PDT group)
and selective outcome reporting (primary and secondary outcomes
were designated differently on the trial register entry and the pub-
lished report).
Both studies applied 50 J/cm2 light energy for 83 seconds but
varied the dose of verteporfin: full dose (6 mg/m2), 50% dose (3
mg/m2), and 30% dose (2 mg/m2) (Zhang 2012), and 1.8 mg/m
2 (Zhao 2015).
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Mean change in best-corrected visual acuity between baseline
and 12 months
30% photodynamic therapy compared with photodynamic
therapy
The mean change in visual acuity for the 30% PDT group was
0.03 logMAR (SD 0.02) and the mean change in the PDT group
was 0.19 logMAR (SD 0.16). This gives an MD in favor of 30%
PDT group (MD -0.16 logMAR, 95%CI -0.22 to -0.10; Analysis
6.1).We judged this to bemoderate quality evidence downgrading
for risk of bias (-1).
50% photodynamic therapy compared with photodynamic
therapy
The mean change in visual acuity for the 50% PDT group was
0.23 logMAR (SD 0.15) and the mean change in the PDT group
was 0.19 logMAR (SD 0.16). We judged this to be low quality
evidence downgrading for risk of bias (-1) and imprecision (-1)
due to wide CIs. We are uncertain as to the size of the effect (MD
0.04, 95% CI -0.04 to 0.12; Analysis 7.1).
30% photodynamic therapy compared with 50%
photodynamic therapy
The MD was favor of 30% PDT group over 50% PDT (MD -
0.12, 95% CI -0.15 to -0.08; 177 participants; 2 studies; Analysis
8.1).We judged this to bemoderate quality evidence downgrading
for risk of bias (-1).
Recurrence of central serous chorioretinopathy at 12 months
30% photodynamic therapy compared with photodynamic
therapy
CSC resolved in 30 eyes in the 30% PDT group and 22 of these 30
eyes had a recurrence by 12 months. In the control group, 30 eyes
resolved and eight of these 30 had a recurrence (RR 2.75, 95% CI
1.46 to 5.17; Analysis 6.2). We judged this to be moderate quality
evidence downgrading for risk of bias (-1).
50% photodynamic therapy compared with photodynamic
therapy
CSC resolved in 30 eyes in the 50% PDT group and 10 of these
30 eyes had a recurrence by 12 months. In the PDT group, 30
eyes resolved and eight of these 30 had a recurrence (RR 1.25,
95% CI 0.57 to 2.73; 60 participants; 1 study; Analysis 7.2). We
judged this low quality evidence, downgrading for risk of bias (-
1) and imprecision (-1).
30% photodynamic therapy compared with 50%
photodynamic therapy
The risk of recurrence of CSC for 30% PDT at 12 months was
2.5 times higher than that of 50% PDT group (RR 2.50, 95% CI
1.54 to 4.06; 153 participants; Analysis 8.2). We judged this to
be moderate quality evidence downgrading for risk of bias (-1).
Persistent central serous chorioretinopathy at 12 months
30% photodynamic therapy compared with photodynamic
therapy
Zhang 2012 did not report 30% PDT compared with PDT.
50% photodynamic therapy compared with photodynamic
therapy
Zhang 2012 did not report 50% PDT compared with PDT.
30% photodynamic therapy compared with 50%
photodynamic therapy
Data from Zhao 2015 showed that CSC was persistent in 19 of
61 eyes in the 30% PDT group and in four of 56 eyes in the 50%
PDT group (RR 4.36, 95% CI 1.58 to 12.04; Analysis 8.3). We
judged this to be moderate quality evidence downgrading for risk
of bias (-1).
Mean change in contrast sensitivity between baseline and 12
months
Neither study reported mean change in contrast sensitivity be-
tween baseline and 12 months.
Mean change in central retinal thickness between baseline
and 12 months
30% photodynamic therapy compared with photodynamic
therapy
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The mean change in central retinal thickness was reduced by 10.8
µm (SD 6.52) in the 30% PDT group and reduced by 52.13 µm
(SD 9.06) in the PDT group. This means that on average there
was a greater reduction in central retinal thickness in the PDT
group (MD 41.33 µm, 95% CI 37.34 to 45.32; 60 participants;
Analysis 6.3). We judged this to be moderate quality evidence
downgrading for risk of bias (-1).
50% photodynamic therapy compared with photodynamic
therapy
The mean change in central retinal thickness was reduced 55.66
µm (SD 0.21) in the 50% PDT group and reduced by 52.13
µm (SD 9.06) in the PDT group. This means that there was a
small greater reduction in central retinal thickness in the 50%
PDT group (MD -3.53, 95% CI -6.77 to -0.29; Analysis 7.3).
We judged this to be low quality evidence downgrading for risk
of bias (-1) and imprecision (-1).
30% photodynamic therapy compared with 50%
photodynamic therapy
There was a greater mean reduction in central retinal thickness in
the 50% PDT group (MD 44.90, 95% CI 42.57 to 47.23; 177
participants; Analysis 8.4). We judged this to be moderate quality
evidence downgrading for risk of bias (-1).
Best-corrected visual acuity 20/40 or better at 12 months
Neither study reported BCVA 20/40 or better at 12 months.
Best-corrected visual acuity 20/200 or worse at 12 months
Neither study reported BCVA 20/200 or worse at 12 months.
Quality of life at 12 months
Neither study reported quality of life at 12 months.
Adverse events
Zhang 2012 did not report on adverse events.
Zhao 2015 reported that no ocular adverse event occurred; one
participant developed nausea because of an allergic reaction to
verteporfin.
Laser versus observation or sham treatment
Four studies compared laser to observation or sham laser treat-
ment.
Klatt 2011 was conducted in Germany and enrolled 30 eyes
with acute CSC (30 participants) in a trial of micropulse laser
(“selective retina therapy”) compared with observation with fol-
low-up of three months. Selective retina therapy was Q-switched
neodymium-doped yttrium lithium fluoride (Nd:YLF) laser with
a wavelength of 527 nm. They used a spot diameter of 200 µm
and pulse repetition rate of 100 Hz. We judged this study at high
risk of performance and detection bias and the authors reported
conflict of interest.
Leaver 1979 was conducted in the UK and compared direct argon
laser photocoagulation to observation in 67 people with acute
CSC. Four participants were lost to follow-up at 12 months. With
the exception of two subfoveal leaks, direct treatment was applied
using the “Coherent Radiation 800” argon laser to the leaking
spot using burns of 50 to 200 µm in diameter. The study was at
high risk of performance and detection bias and otherwise was
not clearly reported (being quite an old study) and was largely at
unclear risk of bias for the other domains.
Robertson 1983 was conducted in the US and enrolled 41 par-
ticipants (42 eyes) with acute CSC. The study sample was strati-
fied according to the site of leakage. In eyes where the leakage site
was in the papillomacular bundle, or within 500 µm of the cap-
illary-free zone of the macula, eyes were randomly assigned either
to indirect argon laser photocoagulation or sham treatment. In
eyes where the leakage site was outside the papillomacular bundle,
and more than 500 µm from the capillary-free zone, eyes were
randomly allocated to direct or indirect laser photocoagulation -
this comparison is discussed below. Participants receiving indirect
laser photocoagulation received three argon laser burns directed
to the pigment epithelium in an area remote from the fovea, the
papillomacular bundle, and the fluorescein leakage site. The laser
beam diameter was 200 µm and the burn duration was 0.2 sec-
onds at a power setting of 80 to 120 mW. In the sham technique,
the laser beam was switched in the “off” position. We judged the
study at low risk of performance and detection bias but unclear
risk for other domains (being an older study relevant aspects were
not reported).
Roisman 2013 was conducted in Brazil and compared micropulse
diode laser to sham photocoagulation in 15 people with chronic
CSC. The laser treatment consisted of subthreshold 810-nmdiode
micropulse laser. We judged the study to be largely at low risk of
bias.
Mean change in best-corrected visual acuity between baseline
and 12 months
This outcome was available for only two of the four studies (
Klatt 2011; Roisman 2013). In Leaver 1979, Snellen acuities were
converted to a numerical scale from 1 (6/4) to 5 (6/12). The mean
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acuity at six months was 3.1 in the laser group and 2.9 in the
control group. In Robertson 1983, mean visual acuity was not
reported.
The two studies that reported mean change in BCVA between
baseline and 12 months had high statistical heterogeneity (I2 =
82%) but both were in favor of laser treatment (Analysis 9.1). In
Klatt 2011, the difference between treatment and control at three
months in improvement in vision was -0.13 logMAR (95% CI
-0.24 to -0.01) in favor of selective retina therapy. In Roisman
2013, the difference between final visual acuity at six months was
-0.38 logMAR (95% CI -0.56 to -0.20) in favor of micropulse
diode laser treatment.
Recurrence of central serous chorioretinopathy at 12 months
One study reported on recurrence of CSC at 12 months (
Robertson 1983). Similar numbers of the indirect laser group (5/
15) compared with the sham laser group had a recurrence dur-
ing the study (RR 1.25, 95% CI 0.41 to 3.77; Analysis 9.2). We
judged this to be very low quality evidence downgrading for risk
of bias (-1) and imprecision (-2).
Persistent central serous chorioretinopathy at 12 months
None of the studies clearly reported persistent CSC at 12 months.
Mean change in contrast sensitivity between baseline and 12
months
None of the studies reported mean change in contrast sensitivity
between baseline and 12 months
Mean change in central retinal thickness between baseline
and 12 months
None of the studies reported mean change in central retinal thick-
ness between baseline and 12 months.
Best-corrected visual acuity 20/40 or better at 12 months
None of the studies reported BCVA 20/40 or better at 12 months.
Best-corrected visual acuity 20/200 or worse at 12 months
None of the studies reportedBCVA20/200orworse at 12months.
Quality of life at 12 months
None of the studies reported quality of life at 12 months.
Adverse events
Klatt 2011 reported that no adverse effects related to micropulse
laser were observed.
Roisman 2013 did not specifically report on adverse events but did
note “no evidence of retinal damage induced by the treatment”.
Leaver 1979 andRobertson 1983 did not provide any information
on adverse effects.
Micropulse diode laser versus argon laser
One trial conducted in India compared micropulse diode laser
to argon laser (Verma 2004). The study enrolled 30 people with
CSC (not specified whether acute or chronic) and allocated them
to 810-nm diode laser or 514-nm argon laser and followed them
up for 12 weeks. We judged the trial to be at low/unclear risk of
bias.
Mean change in best-corrected visual acuity between baseline
and 12 months
This was reported in Snellen decimal acuity.
Mean (SD) Snellen decimal acuity
Micropulse diode laser
(15 participants)
Argon laser
(15 participants)
Baseline 0.29 (0.14) 0.32 (0.16)
12 weeks 1.06 (0.09) 0.98 (0.14)
Recurrence of central serous chorioretinopathy at 12 months
None of the 30 participants had a recurrence before 12 weeks.
Persistent central serous chorioretinopathy at 12 months
None of the 30 participants had persistent CSC at 12 weeks.
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Mean change in contrast sensitivity between baseline and 12
months
Mean absolute value of contrast sensitivity
(Cambridge low contrast gratings)
Micropulse diode laser
(15 participants)
Argon laser
(15 participants)
Baseline 98.4 (24.77) 130.66 (31.95)
12 weeks 306.0 (46.57) 215.33 (23.25)
Mean change in central retinal thickness between baseline
and 12 months
The study did not report mean change in central retinal thickness
between baseline and 12 months.
Best-corrected visual acuity 20/40 or better at 12 months
The study did not report BCVA 20/40 or better at 12 months
Best-corrected visual acuity 20/200 or worse at 12 months
The study did not report BCVA 20/200 or worse at 12 months
Quality of life at 12 months
The study did not report quality of life at 12 month.
Adverse events
None of the participants developed subretinal neovascularization.
No other complications or adverse effects were mentioned.
Indirect argon laser versus direct argon laser
One study compared indirect and direct argon laser (Robertson
1983). This study was conducted in the US and enrolled 41 par-
ticipants (42 eyes) with acute CSC. In eyes where the leakage site
was outside the papillomacular bundle, and more than 500 µm
from the capillary-free zone, eyes were randomly allocated to direct
or indirect laser photocoagulation. Participants receiving indirect
laser photocoagulation received three argon laser burns directed
to the pigment epithelium. The laser beam diameter was 200 µm
and the burn duration was 0.2 seconds at a power setting of 80
to 120 mW. We judged the study at low risk of performance and
detection bias but unclear risk for other domains (being an older
study relevant aspects were not reported).
Mean change in best-corrected visual acuity between baseline
and 12 months
The study did not report mean change in BCVA between baseline
and 12 months.
Recurrence of central serous chorioretinopathy at 12 months
Three of five participants in the indirect group experienced a re-
currence by 24 weeks compared with 0/7 in the direct laser group
(RR 9.33, 95% CI 0.59 to 148.60; Analysis 10.1). We judged this
to be very low quality evidence downgrading for risk of bias (-1)
and imprecision (-2); we are very uncertain as to the size of the
effect.
Persistent central serous chorioretinopathy at 12 months
The study did not report persistent CSC at 12 months.
Mean change in contrast sensitivity between baseline and 12
months
The study did not report mean change in contrast sensitivity be-
tween baseline and 12 months.
Mean change in central retinal thickness between baseline
and 12 months
The study did not report mean change in central retinal thickness
between baseline and 12 months.
Best-corrected visual acuity 20/40 or better at 12 months
The study did not report BCVA 20/40 or better at 12 months.
30Interventions for central serous chorioretinopathy: a network meta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Best-corrected visual acuity 20/200 or worse at 12 months
The study did not report BCVA 20/200 or worse at 12 months.
Quality of life at 12 months
The study did not report quality of life at 12 months.
Adverse events
The study did not report adverse events.
Yellow versus red versus green wavelength laser
One study conducted in China compared yellow, red, and green
wavelength laser in 90 participants with CSC of duration longer
than eight weeks (Shang 1999). We largely judged the trial to be
at unclear risk of bias.
Mean change in best-corrected visual acuity between baseline
and 12 months
The study did not report mean change in BCVA between baseline
and 12 months.
Recurrence of central serous chorioretinopathy at 12 months
The relative effects of these wavelengths on this outcome were
uncertain (Analysis 11.1).We graded these estimates as lowquality
evidence downgrading for risk of bias (-1) and imprecision (-1).
Yellow compared with red
RR 0.60, 95% CI 0.16 to 2.29; 60 eyes.
Yellow compared with green
RR 0.72, 95% CI 0.18 to 2.96; 59 eyes.
Red compared with green
RR 1.21, 95% CI 0.36 to 4.06; 59 eyes.
Persistent central serous chorioretinopathy at 12 months
The study did not report persistent CSC at 12 months.
Mean change in contrast sensitivity between baseline and 12
months
The study did not report mean change in contrast sensitivity be-
tween baseline and 12 months.
Mean change in central retinal thickness between baseline
and 12 months
The study did not report mean change in central retinal thickness
between baseline and 12 months.
Best-corrected visual acuity 20/40 or better at 12 months
The study did not report BCVA 20/40 or better at 12 months.
Best-corrected visual acuity 20/200 or worse at 12 months
The study did not report BCVA 20/200 or worse at 12 months.
Quality of life at 12 months
The study did not report quality of life at 12 months.
Adverse events
The study did not report adverse events.
Antioxidant supplements versus placebo
Two studies compared antioxidant supplements to placebo.
Ratanasukon 2012 was conducted in Thailand and enrolled 58
participants (58 eyes) with acute CSC (onset within six weeks).
These participants were randomly allocated to antioxidants or
placebo and followed up at three and 12 months. There was high
attrition at 12 months with only 14 people seen at that time point.
The antioxidants were supplied as ICaps (Alcon Laboratories) in a
version that contained vitamin A (6600 IU), vitamin C (400 mg),
vitamin E (150 IU), riboflavin (10 mg), zinc (60 mg), copper (4
mg), selenium (40 mg), manganese (4 mg), and lutein/zeaxanthin
(4000 µg). We judged the study at high risk of selection bias and
attrition bias.
Sawa 2014 was conducted in Japan and investigated the effects of
a lutein supplement (20 mg/day) with follow-up of four months.
The type of CSC and the total number of people randomized was
not specified. The total number analyzed was 39. We judged the
study at high risk of attrition bias and selective outcome reporting
bias and it was funded by the manufacturer of the supplement.
The main aim of Sawa 2014 was to examine at changes in mac-
ular pigment optical density; none of our review outcomes were
reported. The following outcomes are discuss for Ratanasukon
2012.
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Mean change in best-corrected visual acuity between baseline
and 12 months
Visual acuity at 12 months was similar in the antioxidant and
placebo groups (MD 0.01, 95% CI -0.04 to 0.06; 14 participants;
Analysis 12.1). We judged this to be low quality evidence down-
grading for risk of bias (-2).
Recurrence of central serous chorioretinopathy at 12 months
Only three participants had a recurrence, one in the antioxidant
group and two in the control group (RR 0.32, 95% CI 0.03 to
3.19; 36 participants; Analysis 12.2). With so few events, we are
very uncertain as to the effect and judged this to be very lowquality
evidence downgrading for risk of bias (-1) and imprecision (-2).
Persistent central serous chorioretinopathy at 12 months
The paper did not report persistent CSC at 12 months clearly
but the number of people with complete resolution was reported.
People in the antioxidant group were less likely to have complete
resolution (RR 0.35, 95% CI 0.13 to 0.95; 51 participants; Anal-
ysis 12.3). We judged this to be low quality evidence downgrading
for risk of bias (-1) and indirectness (-1), as it was not precisely
the outcome required.
Mean change in contrast sensitivity between baseline and 12
months
The study did not report mean change in contrast sensitivity be-
tween baseline and 12 months.
Mean change in central retinal thickness between baseline
and 12 months
There was a mean reduction of 180 µm (SD 15.05) in the an-
tioxidant group compared to 186.22 µm reduction in the placebo
group (MD -6.22, 95%CI -25.13 to 12.69; 14 participants; Anal-
ysis 12.4).
Best-corrected visual acuity 20/40 or better at 12 months
The study did not report BCVA 20/40 or better at 12 months.
Best-corrected visual acuity 20/200 or worse at 12 months
The study did not report BCVA 20/200 or worse at 12 months.
Quality of life at 12 months
The study did not report quality of life at 12 months.
Adverse events
The study reported “no significant side effects” at three months.
Beta-blocker versus placebo
Two studies compared beta-blocker to placebo. They were con-
ducted in US (Browning 1993) and Iran (Kianersi 2008). The
studies enrolled a total of 76 eyes (possibly 76 people) and fol-
lowed them up to four months (Browning 1993) and 12 months
(Kianersi 2008).
Browning 1993 looked at the effect of nadolol 40 mg/day in 16
participants and Kianersi 2008 investigated propranolol 40 mg/
day delivered as 20 mg twice a day in 60 participants.
We judged both studies at low risk of detection bias because they
were placebo controlled, but were largely judged at unclear risk of
bias for the other domains because of poor reporting.
Browning 1993 was a short report and did not report any of the re-
view outcomes. The following outcomes are discussed for Kianersi
2008 only (60 eyes).
Mean change in best-corrected visual acuity between baseline
and 12 months
Meanvisual acuity in the propranolol group at 12monthswas 0.98
logMAR (SD 0.13) and in the placebo group was 0.97 logMAR
(SD 0.18) (MD 0.01 logMAR, 95% CI -0.07 to 0.09; 60 eyes;
Analysis 13.1). We judged this to be moderate quality evidence
downgrading for risk of bias (-1).
Recurrence of central serous chorioretinopathy at 12 months
The effect of beta-blocker on recurrence was uncertain (RR 0.60,
95% CI 0.16 to 2.29; 60 eyes; Analysis 13.2). We judged this
to be low quality evidence, downgrading for risk of bias (-1) and
imprecision (-1).
Persistent central serous chorioretinopathy at 12 months
The study did not report persistent CSC at 12 months.
Mean change in contrast sensitivity between baseline and 12
months
The study did not report mean change in contrast sensitivity be-
tween baseline and 12 months.
Mean change in central retinal thickness between baseline
and 12 months
The study did not report mean change in central retinal thickness
between baseline and 12 months.
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Best-corrected visual acuity 20/40 or better at 12 months
Similar numbers of people in the beta-blocker and placebo groups
had visual acuity 20/40 or better at 12 months (RR 1.10, 95%
CI 0.81 to 1.49; 60 participants; Analysis 13.3). We judged this
to be low quality evidence, downgrading for risk of bias (-1) and
imprecision (-1).
Best-corrected visual acuity 20/200 or worse at 12 months
The study did not report BCVA 20/200 or worse at 12 months.
Quality of life at 12 months
The study did not report quality of life at 12 months.
Adverse events
The study reported that no adverse events occurred.
Beta-blocker versus calcium antagonist
One study compared beta-blocker (propranolol) to a calcium an-
tagonist in 25 participants affected with acute and chronic CSC
(Brancato 1994). The study was reported in abstract form only
and the abstract did not include any results. We contacted the
trialists twice but received no reply.
Topical carbonic anhydrase inhibitors versus placebo
One study conducted in Mexico enrolled 13 participants with
acute CSC (less than 20 days’ duration) and randomly allocated
them to brinzolamide (2%, twice a day) or placebo (polyvinyl
alcohol) with follow-up of six months (Ontiveros-Orozco 2004).
We largely judged the trial to be at unclear risk of bias.
Mean change in best-corrected visual acuity between baseline
and 12 months
The study did not report mean change in BCVA between baseline
and 12 months.
Recurrence of central serous chorioretinopathy at 12 months
One of seven participants in the brinzolamide group had a recur-
rence compared with 4/6 participants in the placebo group (RR
0.21, 95% CI 0.03 to 1.43; Analysis 14.1). We judged this to be
low quality evidence downgrading for risk of bias (-1) and impre-
cision (-1).
Persistent central serous chorioretinopathy at 12 months
None of seven participants in the brinzolamide group had persis-
tent CSC compared with 1/6 participants in the placebo group
(RR 0.29, 95% CI 0.01 to 6.07; Analysis 14.1). We judged this
to be very low quality evidence downgrading for risk of bias (-1)
and imprecision (-2).
Mean change in contrast sensitivity between baseline and 12
months
The study did not report mean change in contrast sensitivity be-
tween baseline and 12 months.
Mean change in central retinal thickness between baseline
and 12 months
The study did not report mean change in central retinal thickness
between baseline and 12 months.
Best-corrected visual acuity 20/40 or better at 12 months
The study did not report BCVA 20/40 or better at 12 months.
Best-corrected visual acuity 20/200 or worse at 12 months
The study did not report BCVA 20/200 or worse at 12 months.
Quality of life at 12 months
The study did not report quality of life at 12 months.
Adverse events
The study noted no adverse effects of brinzolamide.
Helicobacter pylori treatment versus placebo or
observation
Two studies compared H. pylori treatment to no treatment in peo-
ple with acute CSC who also had H. pylori infection. Dang 2013
was conducted inChina and comparedH. pylori therapy to placebo
in 53 participants with follow-up of 12 weeks. Rahbani-Nobar
2011 was conducted in Iran and compared H. pylori treatment
with no treatment in 50 participants with follow-up of 16 weeks.
We judged Dang 2013 at low risk of bias in most domains; and
Rahbani-Nobar 2011 at high risk of performance and detection
bias.
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Mean change in best-corrected visual acuity between baseline
and 12 months
Visual acuity was slightly better in the H. pylori-treated group
(MD -0.04 logMAR, 95% CI -0.07 to -0.02; 103 participants;
Analysis 15.1) Heterogeneity was high (I2 = 82%) but the two
studies showed similar direction and order of effect. We judged
this to be low quality evidence downgrading for risk of bias (-1)
and imprecision (-1) as the CIs included a clinically unimportant
effect.
Recurrence of central serous chorioretinopathy at 12 months
The studies did not report recurrence of CSC at 12 months.
Persistent central serous chorioretinopathy at 12 months
Fewer people in the H. pylori-treated group had persistent CSC at
12 weeks (Dang 2013) or 16 weeks (Rahbani-Nobar 2011) of fol-
low-up (RR 0.67, 95%CI 0.36 to 1.22; 103 participants; Analysis
15.2). We judged this to be low quality evidence, downgrading
for risk of bias (-1) and imprecision (-1).
Mean change in contrast sensitivity between baseline and 12
months
The studies did not report mean change in contrast sensitivity
between baseline and 12 months.
Mean change in central retinal thickness between baseline
and 12 months
The studies did not reportmean change in central retinal thickness
between baseline and 12 months.
Best-corrected visual acuity 20/40 or better at 12 months
The studies did not report BCVA 20/40 or better at 12 months.
Best-corrected visual acuity 20/200 or worse at 12 months
The studies did not report BCVA 20/200 or worse at 12 months.
Quality of life at 12 months
The studies did not report quality of life at 12 months.
Adverse events
Dang 2013 noted that no systemic or ocular adverse events oc-
curred during follow-up.
Rahbani-Nobar 2011 noted that no systemic adverse effects of
medication were observed.
Network meta-analyses (direct and indirect
comparisons)
As specified in Types of interventions section, we restricted our
network to interventions applied directly to the eye.
We planned to look at three outcomes: visual acuity, recurrence,
and adverse events. Almost all studies reported no adverse events,
so we are unable to do this analysis.
Visual acuity
Description of network
Figure 4 shows the network plots. With so few trials included in
the network it was difficult to assess transitivity (Table 1). It is
possible that the inclusion of people with acute or chronic CSC
may be different in the different comparisons. This would affect
the validity of the network. Overall, there was no evidence for
statistical inconsistency (P value = 0.3208). There was only one
closed loop (anti-VEGF, PDT, control) and again no evidence
for inconsistency (inconsistency factor = 0.073, P value = 0.321).
However, the power of these testswill be lowandwe cannot exclude
the possibility of important inconsistency in the network.
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Figure 4. Visual acuity network: network plot, interval plot, contribution matrix and risk of bias.AVG: Anti-
VEGF PDT: photodynamic therapy LAS: laser AVPDT: anti-VEGF plus PDT.1 = control; 2 = anti-VEGF; 3 =
PDT; 4 = laser; 5 = anti-VEGF plus PDT.
Comparative effects
Table 2 summarizes the comparative effects. These are plotted in
Figure 4.
An alternative formulation of the network based on the specific
type of intervention resulted in two disconnected networks and
we considered it unwise to proceed further.
Recurrence of central serous chorioretinopathy
Description of network
Figure 5 shows the network plot. There were no closed loops and,
therefore, it was not possible to assess consistency. Table 3 shows
the assessment of transitivity. Again with few trials it was difficult
to assess but type of CSC was a concern.
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Figure 5. Recurrence CSC network: network plot, interval plot, contribution matrix and risk of bias.AVG:
Anti-VEGF; PDT: photodynamic therapy; LAS: laser: CTL: control.1 = control; 2 = anti-VEGF; 3 = PDT; 4 =
laser.
Comparative effects
Table 4 summarizes the comparative effects. These are plotted in
Figure 5. All estimates were very uncertain. The contribution ma-
trix shows that all the evidence either came from direct or indirect
estimates, reflecting the lack of closed loops in the network (Figure
5).
D I S C U S S I O N
Summary of main results
Given that there were fewer than three studies per treatment com-
parison, that the available studies generally contained small num-
bers of participants, and given themethodological limits identified
by this method of review, there are at the present time, insufficient
data to make robust treatment recommendations. Of note, the
present review did not identify a contraindication to observation
as an initial management strategy in acute CSC.
Reporting of systemic or ocular adverse events were vague formost
included studies. Studies would report “no systemic or ocular ad-
verse events occurred” without reporting which systemic or ocu-
lar adverse events were being monitored. Thus, we were unable
to make robust conclusions on potential adverse events for each
intervention.
A brief summary of themains results can be found in the Summary
of findings for the main comparison.
We also identified 12 ongoing trials. In separate trials of acute
CSC, PDT, aflibercept, and eplerenone are being compared to
control (observation versus PDT, sham injection versus afliber-
cept, or placebo versus eplerenone). In separate trials of chronic
CSC, spironolactone, eplerenone, and lutein are being compared
to placebo, PDT is being compared to micropulse diode laser, and
there are several head-to-head comparisons of PDT dose. In two
trials, the type of CSC is not clearly specified on the trials register
- in these trials, micropulse diode laser is compared to observation
and oral mifepristone to placebo.
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Overall completeness and applicability of
evidence
The present review did not identify a contraindication to current
practice, which is observation as an initial management strategy
in acute CSC. However, the identified studies do not sufficiently
address all of the review objectives as there were too few included
studies for each comparison to make robust conclusions. Further-
more, each study identified in this review had varying definitions
of acute and chronic CSC, therefore, the review conclusions can-
not be isolated to people with either acute or chronic CSC.
One further difficulty with the applicability of the evidence is that
different treatments are indicated for different types of CSC: con-
ventional laser may be directed to extrafoveal well-defined leaks,
micropulse laser to juxtafoveal leaks, PDT to subfoveal leaks (but
may be less applicable to very large and ill-defined leaking areas).
Oral drugs are often used in any long-standing fluid.
Quality of the evidence
Overall, with one or two exceptions, we judged the quality of the
evidence to be low or very low. This means that further research is
very likely to have an important impact on our confidence in the
estimates of effect and is likely to change the estimates.
We included 25 studies that enrolled 1098 participants. In general,
these trials were small, with fewer than 50 participants. These
studies considered a variety of treatments and, in general, there
was only one or two trials contributing data for each comparison.
The studies were poorly reported and often it was unclear whether
key aspects of the trial, such as allocation concealment, had been
done. A substantial proportion of the trials were not masked (nine
trials), which may put them at risk of performance and detection
bias. Problems with follow-up that may lead to attrition bias was
also a potential problem in five trials.
We downgraded for risk of bias and imprecision for most analyses,
reflecting the study limitations and imprecise estimates because
of the small size of the included studies and few number of trials
contributing to the analyses. Network meta-analysis did not help
to resolve this uncertainty due to a lack of trials to construct a
reliable network and potential problems with intransivity with
respect to acute or chronic CSC.
Potential biases in the review process
This review followed standard Cochrane methods and limited any
potential biases in the review process.
Agreements and disagreements with other
studies or reviews
To our knowledge, there is no systematic review that has included
all interventions of CSC. We identified two reviews evaluating
isolated comparisons. Specifically, authors of Chung 2013 evalu-
ated the effects of intravitreal bevacizumab injection and reported
that their results were inconclusive. The authors of Ma 2014 com-
pared PDT with other therapy or compared different parameters
of PDT. Overall, they concluded that “PDT is a promising ther-
apy for CSC patients”. They included case series and observational
studies, which are at higher risk of bias and uncontrolled con-
founding, and they did not distinguish trials and citations, leading
to some double counting of results.
For outcomes such as adverse effects that may occur infrequently,
trial evidence may not be the best source of information. One re-
view of over 200 participants with chronic CSC treated with PDT
concluded that adverse effects were rare. RPE atrophy occurred
in 4% of participants and acute severe visual decrease occurred in
1.5% (Lim 2014).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Given that there were fewer than three studies per treatment com-
parison, that the available studies generally contained small num-
bers of participants, and given themethodological limits identified
by this method of review, there are, at the present time, insufficient
data to inform treatment decisions. Of note, the present study did
not identify a contraindication to observation as an initial man-
agement strategy in acute central serous chorioretinopathy (CSC).
Implications for research
Overall, when considering all of the studies reviewed, and the
methods applied, the quality of the presently available data is low
or very low. This means that further research is very likely to have
an important impact on confidence in the estimates of effect, and
is also very likely to change the estimates. This finding identi-
fies well-designed, prospectively randomized controlled trials with
larger numbers of participants, examining the safety and efficacy
of treatments for CSC, as potentially high impact areas of study.
Due to the recurrent and chronic nature of CSC, the appropriate
treatment is one that can result in visual improvement, shorten the
duration of symptoms, and reduce the recurrent rate. The bene-
fit will likely extend to patients, care providers, and funders. The
somewhat stronger evidence in the areas of thermal laser for focal
leakage and the various photodynamic therapy (PDT) regimens
suggests that further work to define their risks and benefits, as well
as to identify the pertinent patients and entry points for such in-
terventions, is a logical point of emphasis for future trials. Given
the complexity of CSC, the following features could be considered
in future trials: duration of symptoms and fluid, extent of retinal
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pigment epithelium derangement, and number and delimitation
of leaks. For laser/PDT whether treatment is applied to leaks or
RPE abnormalities or choroidal hyperpermeability should be con-
sidered. Future research on CSC would benefit from development
of a ’core outcome set’ including standardized measures of visual
acuity and definition of persistence and recurrence, potentially in-
cluding these as one outcome.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bae 2011
Methods Study design: parallel randomized controlled trial
Number randomized:
16 eyes of NR participants in anti-VEGF group
18 eyes of NR participants in PDT group
Exclusions after randomization:
0 in anti-VEGF group
0 in PDT group
Number analyzed:
16 eyes of NR participants in anti-VEGF group
18 eyes of NR participants in PDT group
Unit of analysis: mixed, some participants had 1 eye included, some participants had
both eyes included
Losses to follow-up:
2 eyes of participants in anti-VEGF group
0 in PDT group
How were missing data handled?: NA
Power calculation: power = 80% and sample size = 34 eyes total (17 eyes in each group)
Participants Country: South Korea
Mean age (SD) (years):
50.8 (7.7) overall
48.9 (7.5) in anti-VEGF group
51.4 (8.2) in PDT group
Gender (%): 28 men (82%) and 6 women (18%) in Total group
13 men (81%) and 3 women (19%) in anti-VEGF group
15 men (83%) and 3 women (17%) in PDT group
Participants with chronic CSCwere included as defined as: “chronic CSCwith visual
disturbance persisting for >6 months or recurrent CSC. Recurrent CSC was defined as
the recurrence of serous retinal detachment on optical coherence tomography (OCT)
associated with visual symptoms after complete recovery of ocular manifestations; the
first episode occurred >6 months before screening and the current episode persisted >3
months with sustained SRF on OCT”
Inclusion criteria: BCVA 0-1.0 logMAR; presence of SFF persisting for > 3 months on
OCT; presence of multifocal/diffuse RPE decompensation with leakage on the FA; and
choroidal vascular hyperpermeability and abnormal dilation of the choroidal vasculature
on ICGA
Exclusion criteria: history of treatment including PDT, focal laser photocoagulation,
intravitreal injection of steroid or anti-VEGF agent in the study eye; evidence of CNV
or polypoidal choroidal vasculopathy; any other ocular diseases that can affect visual
acuity, including diabetic retinopathy, retinal vascular occlusion, or ocular inflammatory
diseases; media opacity that interferes with adequate image acquisition; history of any
intraocular surgery except uncomplicated cataract surgery > 3months before enrollment;
history of systemic steroid or anti-VEGF treatment in the preceding 12 months; uncon-
trolled glaucoma with intraocular pressure > 21 mmHg despite treatment; uncontrolled
46Interventions for central serous chorioretinopathy: a network meta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bae 2011 (Continued)
hypertension, diabetes, or history of cerebrovascular accident or myocardial infarction;
and pregnancy
Equivalence of baseline characteristics: NR
Interventions Intervention: anti-VEGF (ranibizumab)
Dose: 0.5 mg/0.05 mL
Frequency: baseline, 1 and 2 months
Control: low-fluence PDT
Light dose: 25 J/cm2
Verteporfin concentration: 6 mg/m2
Outcomes Length of follow-up: 12 months
Primary outcome, as defined in study reports: primary efficacy outcome was propor-
tion of eyes that maintained the complete absorption of SRF until 12 months without
any rescue treatment
Secondary outcomes, as defined in study reports: serial changes from baseline of mean
change in logMAR BCVA; mean change in CRT obtained by OCT; proportion of eyes
with resolved leakage on FA; proportion of eyes with resolved choroidal hyperperme-
ability on ICGA; and fluid-free interval, which was defined as the interval between the
time when the SRF was completely absorbed without any rescue treatment and when
re-accumulation of the fluid occurred
Adverse events reported: yes
Intervals at which outcomes assessed: 1, 3, 6, 9, and 12 months
Notes Full study name: Low-fluence photodynamic therapy versus ranibizumab for chronic
central serous chorioretinopathy: one-year results of a randomized trial
Type of study: published full-text
Funding sources: Novartis Korea, Seoul, Korea
Disclosures of interest: reported explicitly none of the authors had any financial rela-
tionship
Trial registry: NCT01325181 (clinicaltrials.gov)
Study period: July 2009 to September 2012 (as reported in the trial registry)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomized to receive low-
fluence PDT or the intravitreal injections
of ranibizumab with an equal allocation ra-
tio by means of permuted block random-
ization” p. 559
Allocation concealment (selection bias) Unclear risk “Subjects and the treating ophthalmologist
(S.H.B.) were not masked to the treatment
modalities” p. 559
Unclear if the allocation was masked before
enrollment
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Bae 2011 (Continued)
Masking of participants and personnel
(performance bias)
High risk “Subjects and the treating ophthalmologist
(S.H.B.) were not masked to the treatment
modalities” p. 559
Masking of outcome assessment (detection
bias)
Low risk “The investigator (J.H.) and the other ex-
aminers for BCVA measurement, OCT,
FA, and ICGA were masked to treatment
allocation” p. 559
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/34 participants (< 10%) lost to follow-
up
Selective reporting (reporting bias) Low risk All outcomes on trial registry entry re-
ported in paper
Other bias High risk Received industry funding (Novartis Ko-
rea, Seoul, Korea). Stated that “the sponsor
or funding organization had no role in the
design or conduct of this research. No con-
flicting relationship exists for any author”
Boscia 2008
Methods Study design: unclear - refers only to eyes
Number randomized:
8 eyes of NR participants in PDT group
8 eyes of NR participants in observation group
Exclusions after randomization: not reported
Number analyzed: NR
Unit of analysis: unclear
Losses to follow-up:NR
How were missing data handled?: NA
Power calculation: NR
Participants Country: Italy (probably)
Mean age (SD) (years):
NR for overall and by group
Gender (%): did not report number of men and women overall or by group
Participants with chronic CSC were included as defined as: not defined
Inclusion criteria: BCVA 0.2-1 logMAR; presence of SRF or serous pigment epithelial
detachment on OCT (or both) without regression for ≥ 3 months, RPE leakage on FA
and choroidal vascular hyperpermeability on confocal SLO-ICGA
Exclusion criteria: any previous treatment for CSC; evidence of other chorioretinal
disorders; media opacities; and treatment with systemic steroids
Equivalence of baseline characteristics: NR
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Boscia 2008 (Continued)
Interventions Intervention: low-fluence PDT
light dose: 25 J/cm2
Verteporfin concentration: NR
Control: observation
Outcomes Length of follow-up: 24 weeks
Primary outcome, as defined in study reports: far BCVA (logMAR, using ETDRS
charts) and near BCVA (logMAR, using MNRead Acuity Charts); CMT (OCT3, Zeiss-
Humphrey)
Secondary outcomes, as defined in study reports: macular sensitivity and stability of
fixation determined using microperimetry (Nidek MP1)
Adverse events reported: yes
Intervals at which outcomes assessed: 1, 4, 12, and 24 weeks
Notes Full study name: Low fluence photodynamic therapy in chronic central serous chori-
oretinopathy: blind randomized clinical trial of efficacy and safety
Type of study: published abstract
Funding sources: NR
Disclosures of interest: NR
Trial registry: not registered
Study period: NR
Contacted study authors and received no response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Masking of participants and personnel
(performance bias)
High risk Different groups and the study described as
being “blind” but no information onmask-
ing
Masking of outcome assessment (detection
bias)
High risk Different groups and the study described as
being “blind” but no information onmask-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry entry not
available for comparison
Other bias Unclear risk Conflict of interest and source of funding
not reported
49Interventions for central serous chorioretinopathy: a network meta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Brancato 1994
Methods Study design: cross-over randomized controlled trial
Number randomized:
NR eyes of 25 participants in total,
By group NR
Exclusions after randomization: NR
Number analyzed: NR
Unit of analysis: unclear
Losses to follow-up:NR
How were missing data handled?: NA
Power calculation: NR
Unusual study design: “two weeks of treatment with propranolol, then one week of
wash-out; two weeks of treatment with nimodizin and again one of wash-out; two weeks
of placebo treatment”
Participants Participants with both acute or chronic CSC were enrolled
Country: NR
Inclusion criteria: NR
Equivalence of baseline characteristics: unclear
Interventions Intervention: beta-blocker (propranolol)
Dose: NR
Frequency: NR
Duration: NR
Control: calcium antagonist (nimodizin)
Dose: NR
Frequency: NR
Duration: NR
Outcomes Length of follow-up:NR
Primary outcome: no outcomes defined
Secondary outcomes: no outcomes defined
Adverse events reported: no
Intervals at which outcomes assessed: NR
Notes Full study name: Treatment of central serous chorioretinopathy with beta-blockers and
calcium antagonists
Type of study: published abstract
Funding sources: NR
Disclosures of interest: NR
Trial registry: not registered
Study period: NR
Contacted study authors and received no response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
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Brancato 1994 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Masking of participants and personnel
(performance bias)
Unclear risk Both interventions were pills but no infor-
mation on how similar the pills were
Masking of outcome assessment (detection
bias)
Unclear risk Both interventions were pills but no infor-
mation on how similar the pills were
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry entry not
available for comparison
Other bias Unclear risk Conflict of interest and source of funding
not reported
Browning 1993
Methods Study design: parallel randomized controlled trial
Number randomized:
NR eyes of 8 participants in beta-blocker group
NR eyes of 8 participants in placebo group
Exclusions after randomization: NR
Number analyzed: NR
Unit of analysis: individual
Losses to follow-up:NR
How were missing data handled?: NR
Power calculation: NR
Participants Country: US
Mean age (SD) (years):
41.5 (NR) in total
41 (NR) in beta-blocker group
42 (NR) in placebo group
Gender (%):
9 men (56%) and 7 women (44%) in total
4 men (50%) and 4 women (50%) in beta-blocker group
5 men (63%) and 3 women (38%) in placebo group
Type of CSC not specified
Inclusion criteria: “all patients had serous retinal detachments and consistent fluorescein
angiograms. no patient had vitreous cells, uncontrolled hypertension, recent pregnancy,
or other causes of serous retinal detachment”
Equivalence of baseline characteristics: NR
Interventions Intervention: beta-blocker (nadolol)
Dose: 40 mg
Frequency: daily
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Duration: NR
Control: placebo
Outcomes Length of follow-up: 4 months
Primary and secondary outcomes not differentiated
Adverse events reported: no
Intervals at which outcomes assessed: 4 months
Notes Full study name: Nadolol in the treatment of central serous retinopathy
Type of study: published full-text
Funding sources: NR
Disclosures of interest: NR
Trial registry: not registered
Study period: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “I evaluated the effect of the nonselective
beta-blocker nadolol in a prospective, ran-
domized, double-masked trial” p. 770
No further information on sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Not reported
Masking of participants and personnel
(performance bias)
Low risk Placebo-controlled trial
Masking of outcome assessment (detection
bias)
Low risk Placebo-controlled trial
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry entry not
available for comparison
Other bias Unclear risk Conflict of interest and source of funding
not reported
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Chan 2006
Methods Study design: parallel randomized controlled trial
Number randomized:
15 eyes of 15 participants in total
By group NR
Exclusions after randomization: NR
Number analyzed: NR
Unit of analysis: individual
Losses to follow-up:NR
How were missing data handled?: NR
Power calculation: NR
Participants Type of CSC not specified
Country: US
Mean age (SD) (years):
Total and by group NR
Gender (%): total and by group NR
Inclusion criteria: NR
Equivalence of baseline characteristics: unclear
Interventions Intervention: low-dose transpupillary thermotherapy
Control: sham laser
Outcomes Length of follow-up: 3 months
Primary and secondary outcomes not differentiated
Outcomes: proportion of eyes with resolved CSC
Adverse events reported: no
Intervals at which outcomes assessed: 3 months
Notes Full study name: Low-dose transpupillary thermotherapy for the treatment of central
serous chorioretinopathy
Type of study: published abstract
Funding sources: NR
Disclosures of interest: NR
Trial registry: not registered
Study period: NR
Contacted study authors who were unable to provide a reference to the full-text
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Fifteen eyes of 15 patients with CSR
[CSC] were randomly assigned”
No further information on sequence gen-
eration
Allocation concealment (selection bias) Unclear risk Not reported
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Chan 2006 (Continued)
Masking of participants and personnel
(performance bias)
Unclear risk Control group had sham therapy but no
details on how this was done
Masking of outcome assessment (detection
bias)
Unclear risk Control group had sham therapy but no
details on how this was done
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry not avail-
able for comparison
Other bias Unclear risk Conflict of interest and source of funding
not reported
Chan 2008
Methods Study design: parallel randomized controlled trial
Number randomized:
42 eyes of 42 participants in PDT group
21 eyes of 21 participants in placebo group
Exclusions after randomization:
0 in PDT group
0 in placebo group
Number analyzed:
39 eyes of 39 participants in PDT group
19 eyes of 19 participants in placebo group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
3 eyes of 3 participants in PDT group
2 eyes of 2 participants in placebo group
How were missing data handled?: NR
Power calculation: power = 85% and sample size = yes, power = 85% and sample size
= 63 participants total (42 participants in PDT group and 21 participants in placebo
group)
Participants Participants with acute CSC were included and defined as: acute symptomatic CSC
of ≤ 3 months’ duration
Country: China
Mean age (SD) (years):
41.0 (6.7) in total
40.3 (5.8) in PDT group
42.4 (8.4) in placebo group
Gender (%):
54 men (86%) and 9 women (14%) in total
38 men (90%) and 4 women (10%) in PDT group
16 men (76%) and 5 women (24%) in placebo group
Inclusion criteria: people with BCVA ≥ 20/200; presence of SRF involving the fovea
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on OCT; presence of active angiographic leakage on FA caused by CSC but not CNV or
other diseases; and abnormal dilated choroidal vasculature and other features on ICGA
consistent with the diagnosis of CSC
Equivalence of baseline characteristics: NR
Interventions Intervention: 50% PDT
Light dose: 50 J/cm2
Verteporfin concentration: 3 mg/m2
Control: placebo (30 mL normal saline infused instead of verteporfin, and laser applied
in the same manner as in the verteporfin group)
Outcomes Length of follow-up: 12 months
Primary outcome, as defined in study reports: proportion of eyes with complete
absorption of SRF at 12 months
Secondary outcomes, as defined in study reports: serial changes in logMAR BCVA,
OCT CFT, FA, and ICGA, and systemic and ocular complications during the study
Adverse events reported: yes
Intervals at which outcomes assessed: 1, 3, 6, 9, and 12 months
Notes Full study name: Half-dose verteporfin photodynamic therapy for acute central serous
chorioretinopathy: one-year results of a randomized controlled trial
Type of study: published full-text
Funding sources: NR
Disclosures of interest: “Dr Lai has served as a consultant to an advisory board of
Novartis, Inc”
Trial registry: not registered
Study period: December 2004 to December 2005, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization sequence was gener-
ated using a computerized randomization
table kept centrally by a research nurse, and
the group allocation was performed before
drug preparation and infusion” p. 1757
Allocation concealment (selection bias) Low risk “The randomization sequence was gener-
ated using a computerized randomization
table kept centrally by a research nurse, and
the group allocation was performed before
drug preparation and infusion. All patients
and investigators were masked to the treat-
ment allocation group by wrapping the in-
fusion syringes externally with aluminum
foil” p. 1757
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Masking of participants and personnel
(performance bias)
Low risk “All patients and investigators weremasked
to the treatment allocation group by wrap-
ping the infusion syringes externally with
aluminum foil” p. 1757
Masking of outcome assessment (detection
bias)
Low risk “All patients and investigators weremasked
to the treatment allocation group by wrap-
ping the infusion syringes externally with
aluminum foil” p. 1757
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall 5/58 participants (< 10%)were lost
to follow-up; 3/39 PDT group lost to fol-
low-up; 2/19 of placebo group
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry entry not
available for comparison
Other bias Unclear risk Source of funding not reported. A conflict
of interest was declared but only for 1 of
the 5 authors and not the first author: “Dr
Lai has served as a consultant to an advisory
board of Novartis, Inc. All other authors
have no financial interest to declare”
Coskun 2014
Methods Study design: parallel randomized controlled trial
Number randomized:
8 eyes of 8 participants in anti-VEGF group
7 eyes of 7 participants in PDT group
Exclusions after randomization: NR
Number analyzed:
8 eyes of 8 participants in anti-VEGF group
7 eyes of 7 participants in PDT group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:NR
How were missing data handled?: NR
Power calculation: NR
Participants Country: Turkey
Mean age (SD) (years):
NR in total
46.5 (11.5) in anti-VEGF group
56.1 (7.5) in PDT group
Gender (%): NR
Participants with chronic CSC were included and defined as: eyes with symptomatic
chronic CSC (duration 6 months)
Inclusion criteria: eyes with symptomatic chronic CSC
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Equivalence of baseline characteristics: NR
Interventions Intervention: 50% PDT + anti-VEGF (bevacizumab)
Light dose: 50 J/cm2
Verteporfin concentration: 3 mg/m2
Bevacizumab dose: 1.25 mg
Bevacizumab duration: single dose, 3 days after PDT
Control: 50% PDT
Light dose: 50 J/cm2
Verteporfin concentration: 3 mg/m2
Outcomes Length of follow-up: 12 months
Primary and secondary outcomes not differentiated
Outcomes: time to CSC resolution; BCVA; CMT
Adverse events reported: no
Intervals at which outcomes assessed: 1, 3, 6, and 12 months
Notes Full study name: Combined half dose photodynamic therapy with verteporfin and
intravitreal bevacizumab for chronic central serous chorioretinopathy
Type of study: published abstract
Funding sources: NR
Disclosures of interest: NR
Trial registry: not registered
Study period: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Masking of participants and personnel
(performance bias)
High risk Groups different and no mention of mask-
ing
Masking of outcome assessment (detection
bias)
High risk Groups different and no mention of mask-
ing
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry entry not
available for comparison
Other bias Unclear risk Conflict of interest and source of funding
not reported
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Methods Study design: parallel randomized controlled trial
Number randomized:
32 eyes of 32 participants in Helicobacter pylori treatment group
32 eyes of 32 participants in placebo group
Exclusions after randomization: NR
Number analyzed:
27 eyes of 27 participants in H. pylori group
26 eyes of 26 participants in placebo group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
5 eyes of 5 participants in H. pylori group
6 eyes of 6 participants in placebo group
How were missing data handled?: NR
Power calculation: NR
Participants Country: China
Mean age (SD) (years):
NR in total
35.66 (5.47) in H. pylori group
34.85 (5.53) in placebo group
Gender (%):
43 men (81%) and 10 women (19%) in total
22 men (81%) and 5 women (19%) in H. pylori group
21 men (81%) and 5 women (19%) in placebo group
Participants with chronic CSC were included and defined as: duration > 12 weeks
Inclusion criteria: single idiopathic leakage detected by FA excluding any other diseases;
SRF confirmed by OCT (3D OCT-2000; TOPCON Corporation, Tokyo, Japan); H.
pylori infection diagnosed according to a specific protocol
1 pupillary diameter); diffused retinal pigment epitheliopathy; aged < 20 years old and
> 70 years old; and pregnancy, steroid use, and any other systemic diseases
Equivalence of baseline characteristics: NR
Interventions Intervention: Helicobacter pylori treatment
Drug (dose): omeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1000 mg
Frequency: twice a day
Duration: 14 days
Control: placebo
Outcomes Length of follow-up: 12 weeks
Primary and secondary outcomes not differentiated
Outcomes: disappearance rate of SRF; BCVA; and central retinal sensitivity
Adverse events reported: yes, but not descriptive; ”during the follow-up visit, no sys-
temic or ocular adverse events occurred“ p. 358
Intervals at which outcomes assessed: 2, 4, 8, and 12 weeks
Notes Full study name:The effect of eradicatingHelicobacter pylori on idiopathic central serous
chorioretinopathy patients
Type of study: published full-text
Funding sources: NR
Disclosures of interest: reported explicitly none of the authors has any financial rela-
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tionship
Trial registry: not registered
Study period: September 2010 to December 2012, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Participants were randomly assigned
through a web-based data entry sys-
tem maintained at the Data Coordinat-
ing Center (The MEDABC Corporation,
Zhengzhou, Henan, People’s Republic of
China), with equal probability of receiv-
ing either H. pylori eradication (referred to
as the active treatment group) or placebo
drugs (referred to as the control group) us-
ing a permuted-block design with random
block sizes“ p. 356
Allocation concealment (selection bias) Low risk Participants were ran-
domly assigned through a web-based data
entry systemmaintained at the Data Coor-
dinating Center (TheMEDABCCorpora-
tion, Zhengzhou, Henan, People’s Repub-
lic of China), with equal probability of re-
ceiving eitherH. pylori eradication (referred
to as the active treatment group) or placebo
drugs (referred to as the control group) us-
ing a permuted-block design with random
block sizes” p. 356
Masking of participants and personnel
(performance bias)
Low risk “The control group received an identical
placebo that was the same color, size, and
had the same identification name as the
treatment. The placebos were taken in the
same manner as the study drugs. Both
drugs were also in identical opaque bottles
and prepared by one nonclinician research
assistant” p. 356
Masking of outcome assessment (detection
bias)
Low risk “The control group received an identical
placebo that was the same color, size, and
had the same identification name as the
treatment. The placebos were taken in the
same manner as the study drugs. Both
drugs were also in identical opaque bottles
and prepared by one nonclinician research
assistant” p. 356
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “A total of 64 eyes in 64 patients were
enrolled and randomized equally into two
groups. Eleven eyes (17.18%) were lost to
follow-up or did not yield enough data (five
eyes in the active treatment group and six
eyes in the control group). A total of 53
eyes (82.81%) were included in the study.
” p. 357
Although similar drop-outs loss to follow-
up was approaching 20% and no informa-
tion on reasons for loss to follow-up
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry not avail-
able for comparison
Other bias Low risk Source of monetary support not reported
and conflict of interest was declared: “the
authors report no conflicts of interest in this
work”
Kianersi 2008
Methods Study design: parallel randomized controlled trial
Number randomized:
30 eyes of 30 participants in beta-blocker group
30 eyes of 30 participants in placebo group
Exclusions after randomization:
0 in beta-blocker group
0 in placebo group
Number analyzed:
30 eyes of 30 participants in beta-blocker group
30 eyes of 30 participants in placebo group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
0 in beta-blocker group
0 in placebo group
How were missing data handled?: NR
Power calculation: NR
Participants Country: Iran
Mean age (SD) (years):
35 (8) in total
34 (7) in beta-blocker group
36 (8) in placebo group
Gender (%):
44 men (73%) and 16 women (27%) in total
23 men (77%) and 7 women (23%) in beta-blocker group
21 men (70%) and 9 women (30%) in placebo group
60Interventions for central serous chorioretinopathy: a network meta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kianersi 2008 (Continued)
The type of CSC was not specified
Inclusion criteria: no contraindication for propranolol use; no other eye disease such as
cataract, retinal disorders, etc., which causes diminish visual activity; no indication for
laser therapy
Equivalence of baseline characteristics: NR
Interventions Intervention: beta-blocker (propranolol)
Dose: 20 mg
Frequency: twice daily
Duration: NR
Control: placebo
Outcomes Length of follow-up: 12 months
Primary and secondary outcomes not differentiated
Outcomes: psychological tension; subretinal fleck; recurrence of CSC; visual acuity
Adverse events reported: yes, laser therapy; kidney transplantation; multiple sclerosis;
kidney disease caused by steroid use
Intervals at which outcomes assessed: weekly for 1 year
Notes Full study name:Effects of propranolol in patients with central serous chorioretinopathy
Type of study: published full-text
Funding sources: NR
Disclosures of interest: NR
Trial registry: not registered
Study period: 2003 to 2004, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients met the inclusion criteria were re-
ferred to the second author (FF), and ac-
cording to the table of random numbers,
theywere assigned randomly in twogroups;
half of patients received propranolol (treat-
ment group) and the other half received
placebo with the shape and color similar to
propranolol” p. 104
Allocation concealment (selection bias) Unclear risk “Patients met the inclusion criteria were re-
ferred to the second author (FF), and ac-
cording to the table of random numbers,
theywere assigned randomly in twogroups;
half of patients received propranolol (treat-
ment group) and the other half received
placebo with the shape and color similar to
propranolol” p. 104
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Masking of participants and personnel
(performance bias)
Low risk “Patients met the inclusion criteria were re-
ferred to the second author (FF), and ac-
cording to the table of random numbers,
theywere assigned randomly in twogroups;
half of patients received propranolol (treat-
ment group) and the other half received
placebo with the shape and color similar to
propranolol” p. 104
Masking of outcome assessment (detection
bias)
Unclear risk “Patients met the inclusion criteria were re-
ferred to the second author (FF), and ac-
cording to the table of random numbers,
theywere assigned randomly in twogroups;
half of patients received propranolol (treat-
ment group) and the other half received
placebo with the shape and color similar to
propranolol” p. 104
This suggests that the research staff may
have been unmasked to the treatment as-
signment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clearly reported
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry not avail-
able for comparison
Other bias Unclear risk Conflict of interest and source of funding
not reported
Kim 2013
Methods Study design: parallel randomized controlled trial
Number randomized:
25 eyes of 25 participants in anti-VEGF group
25 eyes of 25 participants in placebo group
Exclusions after randomization: NR
Number analyzed:
20 eyes of 20 participants in anti-VEGF group
20 eyes of 20 participants in placebo group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
5 eyes of 5 participants in anti-VEGF group
5 eyes of 5 participants in placebo group
How were missing data handled?: NR
Power calculation: NR
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Participants Country: South Korea
Mean age (SD) (years):
43.05 (7.46) in anti-VEGF group
41.40 (7.80) in placebo group
Gender (%):
22 men (55%) and 18 women (45%) in total
12 men (60%) and 8 women (40%) in anti-VEGF group
10 men (50%) and 10 women (50%) in placebo group
Participants with acute CSC were included and defined as: < 3 months’ duration
Inclusion criteria: NR
Exclusion criteria: people who had received any previous treatment, including PDT or
focal thermal laser photocoagulation for CSC, or who had evidence of CNV, polypoidal
choroidal vasculopathy, or other maculopathy on fundus examination, FA, or ICGA
Equivalence of baseline characteristics: NR
Interventions Intervention: anti-VEGF (ranibizumab)
Dose: 0.5 mg/mL
Frequency: single dose at baseline
Control: observation
Outcomes Length of follow-up: 6 months
Primary outcome, as defined in study reports: time from baseline to complete reso-
lution of neurosensory retinal detachment during follow-up
Secondary outcomes, as defined in study reports: serial changes in logMAR BCVA,
OCT CFT, FA, and ICGA and the systemic and ocular complications during the study
Adverse events reported: yes
Intervals at which outcomes assessed: 1, 2, 3, 4, 5, 6 months
Notes Full study name: Intravitreal ranibizumab for acute central serous chorioretinopathy
Type of study: published full-text
Funding sources: 2012 Research Grant from Kangwon National University
Disclosures of interest: NR
Trial registry: not registered
Study period: January 2010 to December 2011, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomized into the IVRI
[anti-VEGF] group or the observation
group at a ratio of 1: 1” p. 153
No details on how the random allocation
generated
Allocation concealment (selection bias) Unclear risk Not reported
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Masking of participants and personnel
(performance bias)
High risk Masking not reported and treatments dif-
ferent (injection vs. no treatment)
Masking of outcome assessment (detection
bias)
High risk Masking not reported and treatments dif-
ferent (injection vs. no treatment)
Incomplete outcome data (attrition bias)
All outcomes
High risk Not reported how many were randomized
by group and loss to follow-up by group.
Final numbers analyzed identical between
treatment and observation group (20/20)
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry not avail-
able for comparison
Other bias Low risk Funding from non-profit and conflict of
interest was not reported. “This study was
supported by 2012 Research Grant from
Kangwon”
Klatt 2011
Methods Study design: parallel randomized controlled trial
Number randomized:
14 eyes of NR participants in micropulse laser group (“selective retina therapy”)
16 eyes of NR participants in placebo group
Exclusions after randomization:
0 in micropulse laser group (“selective retina therapy”)
0 in placebo group
Number analyzed:
14 eyes of number of participants NR in micropulse laser group (“selective retina ther-
apy”)
16 eyes of number of participants NR in placebo group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
0 in micropulse laser group (“selective retina therapy”)
0 in placebo group
How were missing data handled?: NR
Power calculation: power = 80% and sample size = 62 eyes
Participants Country: Germany
Mean age (SD) (years):
43.8 (5.6) in total
42.8 (5.5) in micropulse laser group (“selective retina therapy”)
44.7 (5.7) in placebo group
Gender (%):
26 men (87%) and 4 women (13%) in total
14men (100%) and 0women (0%) inmicropulse laser group (“selective retina therapy”)
12 men (75%) and 4 women (25%) in placebo group
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Participants with acute CSC were included and defined as: acute symptomatic CSC
and a documented disease progression of at least 3 months’ duration
Inclusion criteria:minimum age 18 years; minimum history 3months of reduced visual
acuity; minimum BCVA of 20 ETDRS letters (20/200); presence of SRF on OCT; and
presence of active angiographic leakage in FA
Exclusion criteria: other retinal diseases; glaucoma; cataract or other media opacities,
which preclude color fundus photography and FA; previous PDT or continuous wave
laser photocoagulation for CSC; systemic corticosteroid treatment, Cushing disease,
renal diseases, pregnancy, and breastfeeding
Equivalence of baseline characteristics: NR
Interventions Intervention: micropulse laser (“selective retina therapy”)
Q-switched neodymium-doped yttrium lithium fluoride (Nd:YLF) laser
wavelength: 527 nm
spot diameter; 200 µm
pulse repetition rate: 100 Hz
Control: observation
Outcomes Length of follow-up: 3 months
Primaryoutcome, as defined in study reports: change of best correctedEarlyTreatment
Diabetic Retinopathy Study visual acuity (BCVA); change in SRF as measured by OCT
Secondary outcomes, as defined in study reports: rate of complete absorption of SRF;
presence of leakage in FA; systemic or ocular adverse effects
Adverse events reported: yes
Intervals at which outcomes assessed: 1 and 3 months
Notes Full study name: Selective retina therapy for acute central serous chorioretinopathy
Type of study: published full-text
Funding sources: NR
Disclosures of interest: “Johann Roider, Ralf Brinkmann and Reginald Birngruber
hold patents on selective retina therapy. Carsten Klatt, Mark Saeger, Till Oppermann,
Erk Porksen, Felix Treumer, Jost Hillenkamp and Elfriede Fritzer have no competing
interests”
Trial registry: NCT00987077 (clinicaltrials.gov)
Study period: April 2007 to June 2008, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk “Sequentially numbered, opaque, sealed
envelopes were prepared on the basis of the
accomplished randomisation” p. 84
Masking of participants and personnel
(performance bias)
High risk Groups different and no mention of mask-
ing
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Masking of outcome assessment (detection
bias)
High risk “At all visits, BCVA was assessed using ET-
DRS charts at 4 m distance. The investiga-
tor was blinded” p. 84
Masking for other outcomes not reported
and visual acuity assessment may be af-
fected by the fact that the patient knew
which group they were in
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All patients kept their follow-up appoint-
ment and were included in the analysis” p.
84
Selective reporting (reporting bias) Low risk All outcomes reported as stated in the trials
registry entry (NCT00987077; clinicaltri-
als.gov)
Other bias High risk Source of monetary support was not re-
ported and conflict of interest was declared:
“JohannRoider, Ralf Brinkmann andRegi-
nald Birngruber hold patents on selec-
tive retina therapy. Carsten Klatt, Mark
Saeger, Till Oppermann, Erk Porksen, Fe-
lix Treumer, Jost Hillenkamp and Elfriede
Fritzer have no competing interests”
Leaver 1979
Methods Study design: parallel randomized controlled trial
Number randomized:
NR eyes of 35 participants in argon laser group
NR eyes of 35 participants in placebo group
Exclusions after randomization: NR
Number analyzed:
NR eyes of 32 participants in argon laser group
NR eyes of 31 participants in placebo group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
NR eyes of 3 participants in argon laser group
NR eyes of 4 participants in placebo group
How were missing data handled?: NR
Power calculation: NR
Participants Country: UK
Mean age (SD) (years):
40.1 (NR) in total
NR in argon laser group
NR in placebo group
Gender (%):
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53 men (84%) and 10 women (16%) in total
NR in argon laser group
NR in placebo group
Participants with both acute or chronic CSC were enrolled
Inclusion criteria: corrected visual acuity ≥ 6/12; retina detached at macula; RPE de-
fects < 1 disc diameter; no symptomatic improvement since onset; no subretinal exu-
dates present; no cystic retinal edema present; no associated ocular disease (e.g. drusen,
congenital pit of the disc, generalized RPE dystrophy, etc.); consent to participate in the
study after explanation of aims and methods
Equivalence of baseline characteristics: NR
Interventions Intervention: argon laser (direct)
Control: observation
Outcomes Length of follow-up: 12.1 years
Primary and secondary outcomes not differentiated
Outcomes: time to recovery; visual acuities; hue discrimination
Adverse events reported: no
Intervals at which outcomes assessed: “weekly intervals for 4weeks and then atmonthly
intervals until symptoms improved, the retina flattened, and there was no identifiable
leakage on fluoresce in fundus angiography (FFA). Thereafter examinations were carried
out at 3- and 6-monthly intervals. Longest follow-up 12 years”
Notes Full study name: Argon laser photocoagulation in the treatment of central serous
retinopathy
Type of study: published full-text
Funding sources: NR
Disclosures of interest: NR
Trial registry: not registered
Study period: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details on how the random allocation
generated: “randomised cards from sealed
envelopes” p. 675
Allocation concealment (selection bias) Unclear risk “...randomised cards from sealed en-
velopes” (p. 675) but not enough informa-
tion on how sealed envelopes were prepared
e.g. sequentially number? opaque?
Masking of participants and personnel
(performance bias)
High risk Groups different and no mention of mask-
ing
Masking of outcome assessment (detection
bias)
High risk Groups different and no mention of mask-
ing
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 7/70 (10%) missing data
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry entry not
available for comparison
Other bias Unclear risk Conflict of interest and source of funding
not reported
Lim 2010
Methods Study design: parallel randomized controlled trial
Number randomized:
32 eyes of number of participants NR in total
By group NR
Exclusions after randomization: NR
Number analyzed:
12 eyes of 12 participants in anti-VEGF group
12 eyes of 12 participants in placebo group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
8 eyes of number of participants NR in total; by group NR
How were missing data handled?: NR
Power calculation: NR
Participants Country: South Korea
Mean age (SD) (years):
43.2 (9.0) in total
45.6 (10.4) in anti-VEGF group
40.7 (7.0) in placebo group
Gender (%):
20 men (83%) and 4 women (17%) in total
9 men (75%) and 3 women (25%) in anti-VEGF group
11 men (92%) and 1 women (8%) in placebo group
Participants with acute CSC were included and defined as: “patients with symp-
tomatic CSC of less than a 3-month duration”
Inclusion criteria: diagnosis of CSC was established by the presence of serous macular
detachment on fundus examination and dilated choroidal vasculature and hyperperme-
ability on ICGA
Exclusion criteria: participants who had received any previous treatment, including
PDT or focal thermal laser photocoagulation for CSC, or who had evidence of CNV,
polypoidal choriovasculopathy, or other maculopathy on clinical examination, FA, or
ICGA
Equivalence of baseline characteristics: NR
Interventions Intervention: anti-VEGF (bevacizumab)
Dose: 1.25 mg/0.05 mL
Frequency: single dose injected < 1 week after diagnosis
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Control: observation
Outcomes Length of follow-up: 6 months
Primary outcome, as defined in study reports: time measured from baseline to com-
plete absorption of SRF during follow-up
Secondary outcomes, as defined in study reports: serial changes in the logMAR visual
acuity and OCT central 1-mm macular thickness
Adverse events reported: yes
Intervals at which outcomes assessed: 1, 2, 3, 4, 5, and 6 months
Notes Full study name: The effect of intravitreal bevacizumab in patients with acute central
serous chorioretinopathy
Type of study: published full-text
Funding sources: NR
Disclosures of interest: reported explicitly none of the authors has any financial rela-
tionship
Trial registry: not registered
Study period:March 2008 to August 2008, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization sequence was gener-
ated using a computerized randomization
table” p. 156
Allocation concealment (selection bias) Unclear risk Not reported
Masking of participants and personnel
(performance bias)
High risk Groups different and no mention of mask-
ing
Masking of outcome assessment (detection
bias)
High risk Groups different and no mention of mask-
ing
Incomplete outcome data (attrition bias)
All outcomes
High risk 8/32 (25%) of participants not followed up
and not reported which group they were in
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry entry not
available for comparison
Other bias Low risk Source of monetary support not reported
and conflict of interest declared: “no po-
tential conflict of interest relevant to this
article was reported”
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Methods Study design: parallel randomized controlled trial
Number randomized:
16 participants were included in the study, but allocation not reported
NR eyes of NR participants in carbonic anhydrase inhibitor group
NR eyes of NR participants in placebo group
Exclusions after randomization: 3
Number analyzed:
Number of eyes NR of 7 participants in carbonic anhydrase inhibitor group
Number of eyes NR of 6 participants in placebo group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:NR
How were missing data handled?: NA
Power calculation: NR
Participants Participants with acute CSC were included and define as: participants with “symp-
toms for less than 20 days, no previous treatment”
Country:Mexico
Mean age (SD) (years):
NR in total
NR in carbonic anhydrase inhibitors group
NR in placebo group
Gender (%):
9 men (69%) and 4 women (31%) in total
4 men (57%) and 3 women (43%) in carbonic anhydrase inhibitors group
5 men (83%) and 1 women (17%) in placebo group
Inclusion criteria: CSC idiopathic; fluorangiography showing hyperfluorescence asso-
ciated with serous retinal pigment epithelial detachment; with 3 months of follow-up
after recovery and provide informed consent
Exclusion criteria: “any patients older than 50 years, patients that had any additional
pre-existing ocular pathology or systematic pathology. Any patients were eliminated that
did not comply with their appointments, studies, or that had received any medications
during their development”
Equivalence of baseline characteristics: NR
Interventions Intervention: carbonic anhydrase inhibitors (brinzolamide)
Dose: 2%
Duration: twice daily
Control: placebo (polyvinyl alcohol)
Outcomes Length of follow-up: 6 months
Primary outcome, as defined in study reports: time to clinical recovery
Secondary outcomes, as defined in study reports: “complications: RPE atrophy, re-
currence, persistence of subretinal fluid and appearance of neovascular membranes. Each
complication received a value according to the severity (from 0 for the absence of com-
plications to 4 for the presence of neovascular membranes)”
Adverse events reported: reported no adverse effects
Intervals at which outcomes assessed: weekly for the first month, then monthly for 3
months, and 6 months
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Ontiveros-Orozco 2004 (Continued)
Notes Full study name: Brinzolamide for topical treatment coroidorretinopatía idiopathic
central serous
Type of study: published full-text
Funding sources: NR
Disclosures of interest: NR
Trial registry: not registered
Study period: June 2002 to October 2003, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk The labeling and drug control was done by
third person not related with the study p.
134
Masking of participants and personnel
(performance bias)
Unclear risk Similar groups (both groups’ treatment
were eye drops), but no information on
masking
Masking of outcome assessment (detection
bias)
Unclear risk Similar groups (both groups’ treatment
were eye drops), but no information on
masking
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry entry not
available for comparison
Other bias Unclear risk Conflict of interest and source of funding
not reported
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Pitcher 2015
Methods Study design: parallel randomized controlled trial
Number randomized:
6 eyes of 6 participants in 6-dose group
6 eyes of 6 participants in 4-dose group
Exclusions after randomization:
0 in 6-dose group
0 in 4-dose group
Number analyzed:
6 eyes of 6 participants in 6-dose group
6 eyes of 6 participants in 4-dose group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
0 in 6-dose group
0 in 4-dose group
How were missing data handled?: NA
Power calculation: NR
Participants Country: USA
Mean age (SD) (years):
NR in total
53.50 (9.61) in 6-dose group
53.83 (12.80) in 4-dose group
Gender (%): all participants were men
Participants with chronic CSC were included as defined as: ”persistent CSCR [CSC]
demonstrated by subfoveal fluid (SFF) on optical coherence tomography (OCT) for
greater than 3 months“
Inclusion criteria: age ≥ 18 years; ability to provide informed consent; persistent CSC
demonstrated by SFF on OCT for > 3 months; active leakage on FA at the time of
enrolment; evidence of hyperpermeability and abnormal dilation of choroidal vasculature
on ICGA; BCVA between 20/25 and 20/320. Only 1 eye for each participant was
included in participants with bilateral CSC
Exclusion criteria: concurrent progressive retinal or substantial ocular disease in the
study eye; prior treatment for CSC in the study eye (anti-VEGF, PDT, or laser) within
3 months prior to enrolment; presence of CNV or polypoidal choroidal vasculopathy
on enrolment imaging; history of intraocular surgery except uncomplicated cataract
surgery > 3 months prior to enrolment; prior treatment with systemic anti-VEGF agents
or steroid agents within the preceding 12 months; uncontrolled glaucoma; history of
cerebrovascular accident or myocardial infarction; pregnancy
Equivalence of baseline characteristics: NR
Interventions Intervention: 6-dose group (aflibercept)
Dose: 2.0 mg/0.05 mL
Duration: single dose at baseline, 1, 2, 3, 4, and 5 weeks
Control: 4-dose group (aflibercept)
Dose: 2.0 mg/0.05 mL
Duration: single dose at baseline, 1, 2, and 4 weeks
Outcomes Length of follow-up: 6 months
Primary and secondary outcomes not differentiated
Outcomes listed as: occurrence of ocular or systemic adverse events; mean change from
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baseline in ETDRS letter score; percentage of eyes with 20/40 or better vision; percentage
of eyes with ≥ 15-letter gain from baseline; percentage of eyes with < 15-letter loss from
baseline; mean change in CMT; mean change in SFF manually measured by a masked
observer; percentage of eyes with complete resolution of macular fluid on OCT; mean
change in subfoveal choroidal thickness as measured via enhanced depth imaging; and
percentage of eyes with absence of leakage on FA
Adverse events reported: yes
Intervals at which outcomes assessed: 6 months
Notes Full study name: A prospective pilot study of intravitreal aflibercept for the treatment
of chronic central serous chorioretinopathy: the CONTAIN study
Type of study: published full-text
Funding sources: Regeneron Pharmaceuticals
Disclosures of interest: ”none“
Trial registry: NCT01710332 (clinicaltrials.gov)
Study period: November 2012 to May 2013, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Patients were randomised to two groups“
p. 849
Did not clear describe method of random-
ization
Allocation concealment (selection bias) Unclear risk Did not describe clearly how the sequence
generation was assigned/stored
Masking of participants and personnel
(performance bias)
Unclear risk Masking not reported
Masking of outcome assessment (detection
bias)
Unclear risk SFF height was determined by a masked
observer using the digital caliper function
to measure distance from the hyper-reflec-
tive RPE to the photoreceptor outer seg-
ments on a b-scan through the foveal cen-
ter point. Choroidal thickness was deter-
mined by amasked observer using the digi-
tal caliper to measure distance from the in-
ner border of the choroido-scleral interface
to the hyper-reflective RPE
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) High risk Did not clearly define the primary and sec-
ondary outcomes in the published full-text,
while the trial registry had primary and sec-
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ondary outcomes were clearly defined. Re-
ported 5 additional outcomes not defined
in the trial registry: ”mean change in CMT;
mean change in SFFmanually measured by
a masked observer; percentage of eyes with
complete resolution of macular fluid on
OCT; mean change in subfoveal choroidal
thickness as measured via enhanced depth
imaging; and percentage of eyes with ab-
sence of leakage on FA
Other bias High risk Industry funding
Rahbani-Nobar 2011
Methods Study design: parallel randomized controlled trial
Number randomized:
NR eyes of 25 participants in Helicobacter pylori group
NR eyes of 25 participants in placebo group
Exclusions after randomization:
0 in H. pylori group
0 in placebo group
Number analyzed:
NR eyes of 25 participants in H. pylori group
NR eyes of 25 participants in placebo group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
0 in H. pylori group
0 in placebo group
How were missing data handled?: NA
Power calculation: NR
Participants Participants with acute CSC were included but definition not given
Country: Iran
Mean age (SD) (years):
NR in total
32.54 (4.57) in H. pylori group
34.24 (4.78) in placebo group
Gender (%):
41 men (82%) and 9 women (18%) in total
21 men (84%) and 4 women (16%) in H. pylori group
20 men (80%) and 5 women (20%) in placebo group
Inclusion criteria: to accept participation in the study by signing an informed consent;
not having been treated with antibiotics, a proton pomp inhibitor, corticosteroids, or
sympathomimetic drugs for 3 months before the study; no history of previous ocular
surgery
Equivalence of baseline characteristics: NR
74Interventions for central serous chorioretinopathy: a network meta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rahbani-Nobar 2011 (Continued)
Interventions Intervention: H. pylori
Drugs: metronidazole and amoxicillin
Dose: 500 mg
Frequency: 3 times daily
Duration: 2 weeks
Drug: omeprazole
Dose: NR
Frequency: once daily
Duration: 6 weeks
Control: observation
Outcomes Length of follow-up: 16 weeks
Primary and secondary outcomes not differentiated
Outcomes: average neuroretinal and/or pigment epithelial detachment; number of cases
that reached zero subretinal fluid value; subretinal fluid level; subretinal fluid reabsorption
time; mean visual acuity
Adverse events reported: yes
Intervals at which outcomes assessed: 2, 4, 6, 8, 12, and 16 weeks
Notes Full study name: The effect of Helicobacter pylori treatment on remission of idiopathic
central serous chorioretinopathy
Type of study: published full-text
Funding sources: NR
Disclosures of interest: NR
Trial registry: NCT00817245 (clinicaltrials.gov)
Study period: February 2008 to January 2010, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The patients were divided in two groups
using random allocation software” p. 100
Allocation concealment (selection bias) Unclear risk “The patients were divided in two groups
using random allocation software” p. 100,
but no information specifically on alloca-
tion concealment
Masking of participants and personnel
(performance bias)
High risk Groups different and no mention of mask-
ing
Masking of outcome assessment (detection
bias)
High risk Groups different and no mention of mask-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
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Selective reporting (reporting bias) Low risk Outcomes on clinical trials registry entry
(NCT00817245) were reported in the full
text
Other bias Unclear risk Conflict of interest and source of funding
not reported
Ratanasukon 2012
Methods Study design: parallel randomized controlled trial
Number randomized:
29 eyes of 29 participants in antioxidant group
29 eyes of 29 participants in placebo group
Exclusions after randomization: NR
Number analyzed:
26 eyes of 26 participants in antioxidant group
25 eyes of 25 participants in placebo group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
3 eyes of 3 participants in antioxidant group
4 eyes of 4 participants in placebo group
How were missing data handled?: NR
Power calculation: power = 80% and sample size = 58 participants in total (29 partici-
pant in each group)
Participants Country: Thailand
Mean age (SD) (years):
40.4 (NR) in total
41.28 (5.07) in antioxidant group
39.48 (6.95) in placebo group
Gender (%):
48 men (83%) and 10 women (17%) in total
23 men (79%) and 6 women (21%) in antioxidant group
25 men (86%) and 4 women (14%) in placebo group
Participants with acute CSC were included and defined as: “onset within 6 weeks”
Inclusion criteria: people with acute CSC (within 6 weeks of onset), aged 30-50 years,
new or recurrent attack (symptom-free ≥ 6 months), FA-confirmed diagnosis with
inkblot or smoke-stack leakage, OCT by Status OCT showing definite SRF and the
people’s ability for proper follow-up
Exclusion criteria: chronic CSC (> 6 weeks), multiple attacks (> 2 times), large pigment
epithelial detachment (> 1 disc diameter), multiple pigment epithelial detachment or
diffuse retinal pigment epitheliopathy, younger or older ages, follow-up time < 3months,
complicated CSC such as secondary CNV detected from FA, pregnancy, steroid use and
people with contraindication from high-dose antioxidant therapy such as heavy smokers,
and people with lung cancer, thyrotoxicosis, renal stones and anemia (hematocrit < 30%)
Equivalence of baseline characteristics: NR
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Interventions Intervention: antioxidant (Icaps: vitamin A (6600 IU); vitamin C (400 mg), vitamin E
(150 IU); riboflavin (10mg); zinc (60 mg); copper (4mg); selenium (40mg); manganese
(4 mg) and lutein/zeaxanthin (4000 µg))
Control: placebo
Outcomes Length of follow-up: 3 months planned but 12 months reported (with high attrition)
Primary outcome, as defined in study reports: change in visual acuity; change in CMT
recorded by OCT during every visit
Secondary outcomes, as defined in study reports: number of participants with SRF
at each follow-up time, the number of participants who showed FA leakage at the end
of the 3rd month and participants who received additional treatments in each group
Adverse events reported: yes
Intervals at which outcomes assessed: 1, 2, 3, 6, and 12 months
Notes Full study name: High-dose antioxidants for central serous chorioretinopathy; the ran-
domized placebo-controlled study
Type of study: published full-text
Funding sources: “study and placebo drugs were contributed by Alcon Laboratories
(Thailand)”
Disclosures of interest: reported explicitly none of the authors has any financial rela-
tionship
Trial registry: NCT00963131 (clinicaltrials.gov)
Study period: December 2004 to December 2008, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The patients were randomly assigned to
high-dose antioxidant or placebo drugs.
The randomization was computer gener-
ated with a 1:1 ratio, block lengths of 4 and
random numbers were coded to all bottles.
Moreover, the codes were in envelops until
the end of the study” p. 2
Allocation concealment (selection bias) High risk “The corresponding author generated the
allocation sequence, enrolled and assigned
the patients to any additional treatments
when needed” p. 2
Masking of participants and personnel
(performance bias)
Low risk “The patients were randomly assigned to
high-dose antioxidant or placebo drugs.
The randomization was computer gener-
ated with a 1:1 ratio, block lengths of 4 and
random numbers were coded to all bottles.
Moreover, the codes were in envelops until
the end of the study” p. 2
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Masking of outcome assessment (detection
bias)
Low risk “The patients were randomly assigned to
high-dose antioxidant or placebo drugs.
The randomization was computer gener-
ated with a 1:1 ratio, block lengths of 4 and
random numbers were coded to all bottles.
Moreover, the codes were in envelops until
the end of the study” p. 2
Incomplete outcome data (attrition bias)
All outcomes
High risk 3/29 lost to follow-up at 3 months in in-
tervention group and 4/29 lost to follow-
up in control group but at 12 months only
7 participants seen in each group. So low
risk of bias for 3 months and high risk of
bias for 12 months outcomes
Selective reporting (reporting bias) Low risk Trial registry entry was available for com-
parison, and all outcomes were reported as
per the trial registry
Other bias Unclear risk “Study and placebo drugs were contributed
by Alcon Laboratories (Thailand)” but au-
thors reported that none of the authors had
any financial relationship
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Robertson 1983
Methods Study design: parallel randomized controlled trial
Number randomized:
15 eyes of 15 participants in argon (direct) laser group
15 eyes of 15 participants in sham laser group
7 eyes of 7 participants in argon (direct) laser group
5 eyes of 5 participants in argon (indirect) laser group
Exclusions after randomization: NR
Number analyzed:
15 eyes of 15 participants in argon (direct) laser group
15 eyes of 15 participants in sham laser group
7 eyes of 7 participants in argon (direct) laser group
5 eyes of 5 participants in argon (indirect) laser group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:NR
How were missing data handled?: NR
Power calculation: NR
Unusual study design: eyes were divided into 2 groups depending on the site of leakage
(determined by FA)
“We assigned eyes in which the leakage site was in the papillomacular bundle or within
500 µm of the capillary-free zone of the macula to Group A”
“We assigned eyes in which the leakage site was outside the papillomacular bundle and
more than 500 µm from the capillary-free zone to Group B”
Participants Country: US
Mean age (SD) (years):
NR in total
39.7 (NR) in argon (direct) laser group
NR in sham laser group
41.3 (NR) in argon (direct) laser group
44.8 (NR) in argon (indirect) laser group
Gender (%):
29 men (69%) and 13 women (31%) in total
10 men (67%) and 5 women (33%) in (direct) laser group
9 men (60%) and 6 women (40%) in sham laser group
5 men (71%) and 2 women (29%) in (direct) laser group
5 men (100%) and 0 women (0%) in (indirect) laser group
Participants with acute CSC were included and defined as: “central serous chori-
oretinopathy of recent onset” p. 458
Inclusion criteria: no evidence of previous ocular surgery, trauma, photocoagulation,
cloudy media, vitreous inflammation, retinal vessel occlusion, hypertensive or diabetic
retinopathy, vitreoretinal traction, congenital optic pits, mass lesion, or any other unusual
retinal or choroidal abnormality
Equivalence of baseline characteristics: NR
Interventions Group A intervention: argon laser (indirect laser photocoagulation)
Group A control: sham laser
Group B intervention: argon laser (direct laser photocoagulation)
Group B control: argon laser (indirect laser photocoagulation
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Robertson 1983 (Continued)
Outcomes Length of follow-up: examined at 6 months recurrences reported to 18 months
Primary and secondary outcomes not differentiated
Outcomes: resolution of CSC as determined by 2 observers by following criteria: sub-
retinal fluid absent on biomicroscopic exam and stereoscopic FA showed no active leak-
age; visual acuity measured by Sloan chart; visual fields
Adverse events reported: no
Intervals at which outcomes assessed: 2 weeks, 6 months, 18 months
Notes Full study name:Direct, indirect, and sham laser photocoagulation in the management
of central serous chorioretinopathy
Type of study: published full-text
Funding sources: Grant EY0 1709 from the National Eye Institute and by the Mayo
Foundation
Disclosures of interest: NR
Trial registry: not registered
Study period:May 1977 to January 1981, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details on how the random allocation
generated: “After the patientwas positioned
at the laser, a sealed envelope containing
the randomized treatment assignment was
opened. The assignments, worked out and
kept by the statistician, directed the physi-
cian (D.M.R. in all cases) to administer di-
rect, indirect, or sham laser photocoagula-
tion” p. 459
Allocation concealment (selection bias) Low risk “After the patient was positioned at the
laser, a sealed envelope containing the
randomized treatment assignment was
opened. The assignments, worked out and
kept by the statistician, directed the physi-
cian (D.M.R. in all cases) to administer di-
rect, indirect, or sham laser photocoagula-
tion.” p. 459
Masking of participants and personnel
(performance bias)
Low risk “The subject did not learn which of the
three forms of treatment he or she had re-
ceived until the study ended six months
later” pp. 459-460
Masking of outcome assessment (detection
bias)
Unclear risk Similar groups (both groups’ treatment
were laser), but no information onmasking
of outcome assessor
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry entry not
available for comparison
Other bias Unclear risk Funded by government sources but con-
flicts of interest were not reported
Roisman 2013
Methods Study design: parallel randomized controlled trial
Number randomized:
10 eyes of 10 participants in micropulse diode laser group
5 eyes of 5 participants in placebo group
Exclusions after randomization:
0 in micropulse diode laser group
0 in placebo group
Number analyzed:
10 eyes of 10 participants in micropulse diode laser group
5 eyes of 5 participants in placebo group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
0 in micropulse diode laser group
0 in placebo group
How were missing data handled?: NR
Power calculation: NR
Participants Country: Brazil
Mean age (SD) (years):
NR in total
39.5 (7.7) in micropulse diode laser group
44.2 (5.8) in placebo group
Gender (%):
10 men (67%) and 5 women (33%) in total
7 men (70%) and 3 women (30%) in micropulse diode laser group
3 men (60%) and 2 women (40%) in placebo group
Participants with chronic CSC were included and defined as: “CSC lasting more
than 6 months were enrolled”
Inclusion criteria: NR
Equivalence of baseline characteristics: NR
Interventions Intervention: micropulse diode laser
Wavelength: 810 nm
FastPulse laser; Opto, Brazil
Control: sham laser
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Outcomes Length of follow-up: 12 months
Primary outcome, as defined in study reports: change in visual acuity after 3 months
Secondary outcomes, as defined in study reports: change in CMT after 3 months
Adverse events reported: no
Intervals at which outcomes assessed: 1, 3, 6, and 12 months
Notes Full study name: Micropulse diode laser treatment for chronic central serous chori-
oretinopathy: a randomized pilot trial
Type of study: published full-text
Funding sources: NR
Disclosures of interest: reported explicitly none of the authors has any financial rela-
tionship
Trial registry: NCT01327170 (clinicaltrials.gov)
Study period: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The 15 patients were randomized 2:1
through double-masked random draw into
two groups” p. 466
Allocation concealment (selection bias) Low risk “The 15 patients were randomized 2:1
through double-masked random draw into
two groups” p. 466
Masking of participants and personnel
(performance bias)
Low risk Double-masked with placebo group
Masking of outcome assessment (detection
bias)
Low risk Double-masked with placebo group
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk All primary and secondary outcomes stated
in the trial registry were reported
Other bias Low risk Source of monetary funding not reported
but the conflict of interest declared: “the
authors have no financial or proprietary in-
terest in the materials presented herein”
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Sawa 2014
Methods Study design: parallel randomized controlled trial
Number randomized:
Total number randomized was 44
Unclear number in each group
Exclusions after randomization: 5 people excluded after randomization but not re-
ported to which groups they belonged
Number analyzed:
NR eyes of 20 participants in antioxidant group
NR eyes of 19 participants in placebo group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:NR
How were missing data handled?: NR
Power calculation: NR
Participants The type of CSC was not specified
Country: Japan
Mean age (SD) (years):
49 (10) in total
51.2 (9) in antioxidant group
46.6 (8.3) in placebo group
Gender (%):
35 men (90%) and 4 women (10%) in total
19 men (95%) and 1 women (5%) in antioxidant group
16 men (84%) and 3 women (16%) in placebo group
Inclusion criteria: previous regular intake of lutein or zeaxanthin, or both; corticos-
teroid treatment; disturbance of ocular media; other retinal disorders such as age-related
macular degeneration, polypoidal choroidal vasculopathy, retinal vein occlusion, or di-
abetic retinopathy
Equivalence of baseline characteristics: NR
Interventions Intervention: antioxidant (lutein)
Dose: 20 mg/day
Control: placebo
Outcomes Length of follow-up: 4 months
Primary outcome, as defined in study reports: macular pigment optical density and
plasma lutein concentration
Secondary outcomes, as defined in study reports: NR
Adverse events reported: no
Intervals at which outcomes assessed: 1 and 4 months
Notes Full study name: Effects of a lutein supplement on the plasma lutein concentration and
macular pigment in patients with central serous chorioretinopathy
Type of study: published full-text
Funding sources: Santen Pharmaceutical Co., Ltd
Disclosures of interest: reported explicitly none of the authors has any financial rela-
tionship
Trial registry: not registered
Study period:March 2011 to June 2012, as reported in the full-text article
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk “The study was a randomized, double-
masked, placebo-controlled trial” p. 5239
Masking of participants and personnel
(performance bias)
Low risk “The study was a randomized, double-
masked, placebo-controlled trial” p. 5239
Masking of outcome assessment (detection
bias)
Low risk “The study was a randomized, double-
masked, placebo-controlled trial” p. 5239
Incomplete outcome data (attrition bias)
All outcomes
High risk 5 people excluded after randomization but
not reported to which groups they be-
longed
Selective reporting (reporting bias) High risk BCVAmeasured but not reported.Only re-
ported resolution of CSC for the interven-
tion (lutein) group
Other bias High risk Funded by manufacturer of the supple-
ment. Authors reported not having any
conflict of interest
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Semeraro 2012
Methods Study design: parallel randomized controlled trial
Number randomized:
12 eyes of 12 participants in anti-VEGF group
10 eyes of 10 participants in PDT group
Exclusions after randomization:
12 eyes of 12 participants in anti-VEGF group
10 eyes of 10 participants in PDT group
Number analyzed:
12 eyes of 12 participants in anti-VEGF group
10 eyes of 10 participants in PDT group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
0 in anti-VEGF group
0 in PDT group
How were missing data handled?: NR
Power calculation: NR
Participants Participants with chronic CSC were included and defined as: “...either persistence of
subretinal fluid detected on optical coherence tomography (OCT) for at least 3 months
after diagnosis or more than 3 recurrences in at least 3 months with gravitational RPE
atrophy” and “The inclusion criteria consisted of presence of CSC with chronic foveal
detachment of the neuroepithelium (C3 months) and no previous treatment for CSC”
Country: Italy
Mean age (SD) (years):
NR in total
35.2 (6) in anti-VEGF group
36 (8) in PDT group
Gender (%):
13 men (59%) and 9 women (41%) in total
7 men (58%) and 5 women (42%) in anti-VEGF group
6 men (60%) and 4 women (40%) in PDT group
Inclusion criteria: presence of CSC with chronic foveal detachment of the neuroep-
ithelium (≥ 3 months) and no previous treatment of CSC
Exclusion criteria: ages > 50 years; chronic systemic disease; pregnancy; any uncontrolled
ocular disease; and presence of occult or minimally classic choroidal neovascular lesions,
scarring, or atrophy within the lesion
Equivalence of baseline characteristics: NR
Interventions Intervention: anti-VEGF (bevacizumab)
Dose: 1.25 mg
Duration: single dose at baseline and then as needed after 4 weeks
Control: low fluence PDT
Light dose: 25 J/cm2
Verteporfin concentration: NR
Outcomes Length of follow-up: 9 months
Primary and secondary outcomes not differentiated
Outcomes: change in macular thickness; the number of eyes with recurrence; stabiliza-
tion of the lesions; the number of retreatments
Adverse events reported: no
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Intervals at which outcomes assessed: 9 months
Notes Full study name: Intravitreal bevacizumab versus low-fluence photodynamic therapy
for treatment of chronic central serous chorioretinopathy
Type of study: published full-text
Funding sources: NR
Disclosures of interest: NR
Trial registry: not registered
Study period: February 2009 to April 2010, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Enrolled patients were randomly assigned
to group 1 or group 2 by randomblock per-
mutation in accordance with a computer-
generated randomization list” p. 609
Allocation concealment (selection bias) Unclear risk Not reported
Masking of participants and personnel
(performance bias)
High risk Groups different and no mention of mask-
ing
Masking of outcome assessment (detection
bias)
High risk Groups different and no mention of mask-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry entry not
available for comparison
Other bias Unclear risk Conflict of interest and source of funding
not reported
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Shang 1999
Methods Study design: parallel randomized controlled trial
Number randomized:
NR eyes of 30 participants in yellow laser group
NR eyes of 30 participants in red laser group
NR eyes of 30 participants in green laser group
Exclusions after randomization:
0 in yellow group
0 in red group
0 in green group
Number analyzed:
NR eyes of 30 participants in yellow group
NR eyes of 30 participants in red group
NR eyes of 30 participants in green group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
0 in yellow group
0 in red group
0 in green group
How were missing data handled?: NR
Power calculation: NR
Participants The type of CSC was not specified
Country: China
Mean age (SD) (years):
40.0 (6.3) in total
43.7 (7.6) in yellow group
39.9 (7.0) in red group
39.5 (5.0) in green group
Gender (%):
79 men (89%) and 10 women (11%) in total
NR in yellow group
NR in red group
NR in green group
Inclusion criteria:
people with CSC validated by eye exam, Amsler chart examine and FFA;
duration of the disease > 8 weeks;
corrected visual acuity ≤ 0.8;
distance between fundus fluorescein leakage point showed by FFA and central fovea of
macula > 250 µm
Exclusion criteria: NR
Equivalence of baseline characteristics: NR
Interventions Intervention 1: yellow
Intervention 2: red
Control: green
Outcomes Length of follow-up: 12 months
Primary and secondary outcomes not differentiated
Outcomes: visual acuity; light sensitivity; recurrent rate; disease course; photocoagula-
tion energy; photocoagulation spot expansion
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Shang 1999 (Continued)
Adverse events reported: yes,mademention of protrusion, proliferation/diffusion, RPE
complications
Intervals at which outcomes assessed: 12 months
Notes Full study name:Wavelength selection inmanagement of central serous chorioretinopa-
thy
Type of study: published full-text
Funding sources: NR
Disclosures of interest: NR
Trial registry: not registered
Study period: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Masking of participants and personnel
(performance bias)
Unclear risk No mention of masking
Masking of outcome assessment (detection
bias)
Unclear risk No mention of masking
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry entry not
available for comparison
Other bias Unclear risk Conflict of interest and source of funding
not reported
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Verma 2004
Methods Study design: parallel randomized controlled trial
Number randomized:
NR eyes of 15 participants in micropulse diode laser group
NR eyes of 15 participants in argon laser group
Exclusions after randomization:
0 in micropulse diode laser group
0 in argon laser group
Number analyzed:
NR eyes of 15 participants in micropulse diode laser group
NR eyes of 15 participants in argon laser group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
0 in micropulse diode laser group
0 in argon laser group
How were missing data handled?: NR
Power calculation: NR
Participants Country: India
Mean age (SD) (years):
NR in total
34.06 (2.54) in micropulse diode laser group
34.66 (3.23) in argon laser group
Gender (%):
25 men (83%) and 5 women (17%) in total
12 men (80%) and 3 women (20%) in micropulse diode laser group
13 men (87%) and 2 women (13%) in argon laser group
The type of CSC was not specified
Inclusion criteria: ages < 50 years; type I central serous retinopathy with a single leak
on FA that was at least 300 µm away from fovea; presence of an indication for laser
treatment (recurrence, occupational, history of poor visual outcome in fellow eye); no
history of any treatment in the past
Exclusion Criteria: participants with multiple leak central serous retinopathy; type 2
or type 3 central serous retinopathy or leak at papillomacular bundle or leak within
300 µm from the foveal center; people with ocular pathology such as CNV, choroidal
inflammatory, or neoplastic disorder or a congenital optic nerve pit
Equivalence of baseline characteristics: NR
Interventions Intervention: micropulse diode laser
Wavelength: 810 nm
Control: argon laser (NR)
Wavelength: 514 nm
Outcomes Length of follow-up: 12 weeks
Primary and secondary outcomes not differentiated
Outcomes: mean BCVA; mean contrast sensitivity
Adverse events reported: no
Intervals at which outcomes assessed: 4, 8, and 12 weeks
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Verma 2004 (Continued)
Notes Full study name: Comparative evaluation of diode laser versus argon laser photocoag-
ulation in patients with central serous retinopathy: a pilot, randomized controlled trial
ISRCTN84128484
Type of study: published full-text
Funding sources: NR
Disclosures of interest: reported explicitly none of the authors has any financial rela-
tionship
Trial registry: ISRCTN84128484 (ICTRP)
Study period: January 1998 to June 2000, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “They were randomly assigned into 2
groups according to the statistical random
table using sequence generation” p. 2
Allocation concealment (selection bias) Unclear risk “The allocation of patients into 2 groups
was done by a person who was not involved
in the study and the sequence was con-
cealed until interventions were assigned to
prevent bias” p. 2
Masking of participants and personnel
(performance bias)
Unclear risk Similar groups but no information on
masking
Masking of outcome assessment (detection
bias)
Unclear risk Similar groups but no information on
masking
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry entry not
available for comparison
Other bias Low risk Source of monetary support not reported
and conflict of interest declared: “the au-
thor(s) declare that they have no compet-
ing interests”
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Zhang 2012
Methods Study design: parallel randomized controlled trial
Number randomized:
30 eyes of 30 participants in 30% PDT group
30 eyes of 30 participants in 50% PDT group
30 eyes of 30 participants in PDT group
Exclusions after randomization:
0 in 30% PDT group
0 in 50% PDT group
0 in PDT group
Number analyzed:
30 eyes of 30 participants in 30% PDT group
30 eyes of 30 participants in 50% PDT group
30 eyes of 30 participants in PDT group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
0 in 30% PDT group
0 in 50% PDT group
0 in PDT group
How were missing data handled?: NR
Power calculation: NR
Participants The type of CSC was not specified
Country: China
Mean age (SD) (years):
NR in total
33.8 (5.5) in 30% PDT group
34.2 (5.2) in 50% PDT group
32.0 (4.1) in PDT group
Gender (%):
25 men (83%) and 5 women (17%) in total
8 men (27%) and 22 women (73%) in 30% PDT group
11 men (37%) and 19 women (63%) in 50% PDT group
9 men (30%) and 21 women (70%) in PDT group
Inclusion criteria:
aged < 45 years with conscious visual distortion of imagery, darkened vision or changes
of smaller imagery vision;
anterior segments do not have anything in particular or abnormal. Fundus exam should
show macula regions or macula peripheral region gray spots with irregular formation or
circular type infection, arching or ring-shaped hemorrhage, including various degrees of
retinal edema;
through FFA exam, lowfluorescent shows in the early exudative lesion focus, hemorrhage
spots always cover the fluorescein, but exudative lesion focus and mild bleeding spot
could show CNV with typical petal shaped or trochoid shaped high fluorescent. As the
time of radiography gets longer, fluorescein leakage could be observed. It is splinter high
fluorescent, the scale and scope is similar to the gray exudative lesion focus;
excluding external injury related, myopia related, or other established causes of non-age-
related macular degeneration CNV;
people who have not received laser photocoagulation, intraocular injections, or invasive
surgical ocular treatments
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Exclusion criteria:
history of penicillin allergy or systemic illnesses or issues with fluorescence or other
systems of sexually transmitted disease that could cause intolerance of FFA treatment
and PDT treatment;
serious corneal illness, cataracts, blood volume, light opacity interfering mediums that
can disturb the treatment plan and examination plan of the study;
corneal endothelial cell scarring, shows FA has not created leakage;
poor participant compliance with those who cannot complete follow-up times
Equivalence of baseline characteristics: NR
Interventions Intervention: 30% PDT
Light dose: 50 J/cm2
Verteporfin concentration: 2 mg/m2
Intervention: 50% PDT
Light dose: 50 J/cm2
Verteporfin concentration: 3 mg/m2
Control: PDT
Light dose: 50 J/cm2
Verteporfin concentration: 6 mg/m2
Outcomes Length of follow-up: 12 months
Primary and secondary outcomes not differentiated
Outcomes: BCVA value change; number of eyes show CNV change; CFT value change;
number of treatments; recurrence of CSC
Adverse events reported: no
Intervals at which outcomes assessed: 3, 6, and 12 months, but not all participants
had 12 month
Notes Full study name: Different doses of verteporfin photodynamic therapy for central ex-
udative chorioretinopathy
Type of study: published full-text
Funding sources: NR
Disclosures of interest: NR
Trial registry: not registered
Study period: January 2006 to December 2009, as reported in the full-text article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization sequence specified and
outlined in methods. Low risk of ran-
dom sequence generation. The study used
a number sequence table to assign proper
randomization for groups. They used a ver-
ified and structured numbering sequence
of 1-90 that was aligned for row and col-
umn and considered from smallest value
to largest. They then randomized and
92Interventions for central serous chorioretinopathy: a network meta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Zhang 2012 (Continued)
recorded each randomly generated assign-
ment figure
Allocation concealment (selection bias) Unclear risk Not reported
Masking of participants and personnel
(performance bias)
Unclear risk Similar groups but no information on
masking
Masking of outcome assessment (detection
bias)
Unclear risk Similar groups but no information on
masking
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Unclear risk Study protocol and trial registry entry not
available for comparison
Other bias Unclear risk Conflict of interest and source of funding
not reported
Zhao 2015
Methods Study design: parallel randomized controlled trial
Number randomized:
65 eyes of 65 participants in 30% PDT group
64 eyes of 64 participants in 50% PDT group
Exclusions after randomization:
0 in 30% PDT group
0 in 50% PDT group
Number analyzed:
61 eyes of 61 participants in 30% PDT group
56 eyes of 56 participants in 50% PDT group
Unit of analysis: participant, 1 eye per person
Losses to follow-up:
4 eyes of 4 participants in 30% PDT group
9 eyes of 9 participants in 50% PDT group
How were missing data handled?: NR
Power calculation: power = 80% and sample size = 112 participants (56 participants in
each group)
Participants Country: China
Mean age (SD) (years):
NR in total
42.5 (5.6) in 30% PDT group
43.1 (5.3) in 50% PDT group
Gender (%):
87 men (74%) and 30 women (26%) in total
47 men (77%) and 14 women (23%) in 30% PDT group
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40 men (71%) and 16 women (29%) in 50% PDT group
Participants with acute CSC were included and defined as: “symptoms occurred for
the first time, as an episode duration of less than 6 months, or there was a medical record
that could prove the presence of subretinal fluid (SRF) for less than 6 months if the
patient was asymptomatic”
Inclusion criteria: symptoms occurred for the first time, as an episode duration of <
6 months, or there was a medical record that could prove the presence of SRF for < 6
months if the participant was asymptomatic; ages 18-50 years; presence of SRF involving
the macula and detected using OCT; active fluorescein leakage during FA and abnormal
dilated choroidal vasculature detected using ICGA
Exclusion criteria: previous PDT, focal photocoagulation, intravitreal injections of
anti-VEGF, or ocular surgery; other macular abnormalities such as CNV or polypoidal
choroidal vasculopathy; choroidopathy that may affect choroidal thickness; any retinal
vascular disease that may have fluorescein leakage during FA; history of porphyria or
photosensitivity; severe impaired kidney or liver function or unstable heart condition
(or a combination of these); pregnancy; inability to obtain photographs or to perform
FA or ICGA; use of steroid systemically or topically in the last 6 months
Equivalence of baseline characteristics: NR
Interventions Intervention: 30% PDT
Light dose: 50 J/cm2
Verteporfin concentration: 1.8 mg/m2
Control: 50% PDT
Light dose: 50 J/cm2
Verteporfin concentration: 3 mg/m2
Outcomes Length of follow-up: 12 months
Primary outcome, as defined in study reports: proportion of eyes with complete
absorption of SRF; proportion of eyes with complete disappearance of fluorescein leakage
at 6 and 12 months
Secondary outcomes, as defined in study reports: SRF recurrent rate; the fluorescein
leakage recurrent rate at 12 months; mean BCVA; the retinal thickness of the foveal
center; the maximum retinal thickness at each scheduled visit
Adverse events reported: yes
Intervals at which outcomes assessed: 2 weeks, 1, 3, 6, and 12 months
Notes Full study name: A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute
central serous chorioretinopathy: one-year results of a randomized clinical trial
Type of study: published full-text
Funding sources: Capital Health Research and Development of Special Funding
grant D101100050010026 and National Science and Technology Major Project grant
2011ZX09302-007-02
Disclosures of interest: reported explicitly none of the authors has any financial rela-
tionship
Trial registry: NCT01574430 (clinicaltrials.gov)
Study period:March 2011 to February 2012, as reported in the full-text
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization sequence was gener-
ated using a computerized randomization
table” p. 334
Allocation concealment (selection bias) Low risk “All patients, examiners, investigators, and
research assistants at the reading centers
were masked to the treatment
allocation group” p. 334
Masking of participants and personnel
(performance bias)
Low risk “All patients, examiners, investigators, and
research assistants at the reading centers
were masked to the treatment allocation
group” p. 334
Masking of outcome assessment (detection
bias)
Low risk “All patients, examiners, investigators, and
research assistants at the reading centers
were masked to the treatment allocation
group” p. 334
Incomplete outcome data (attrition bias)
All outcomes
High risk Level of lost to follow-up was not the same
in each group: 4/65 (6%) participants in
30% PDT group and 8/64 (13%) partici-
pants 50% PDT group
Selective reporting (reporting bias) High risk Primary outcome reported at clinicaltri-
als.gov (NCT01574430) was change from
baseline in BCVA, but study primary out-
come were OCT-based improvement rate
and FA-based improvement rate at 6 and
12 months. BCVA was reported, but not
defined as primary outcome
Other bias Low risk Reported no conflicts of interest and non-
industry funded
anti-VEGF: anti-vascular endothelial growth factor; BCVA: best-corrected visual acuity; CFT: central foveal thickness; CMT: central
macular thickness; CNV: choroidal neovascularization; CRT: central retinal thickness; CSC: central serous chorioretinopathy; FA:
fluorescein angiography; FFA: fundus fluorescein angiography; ICGA: indocyanine green angiography; logMAR: logarithm of the
minimal angle of resolution; NA: not applicable as no missing data or unclear if there is missing data; NR: not reported; OCT:
optical coherence tomography; p: page; PDT: photodynamic therapy; RPE: retinal pigment epithelium; SD: standard deviation;
SFF: subfoveal fluid; SRF: subretinal fluid; SLO-ICGA: scanning laser indocyanine green angiography.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ainiwaer 2014 Wrong treatment arms and included traditional Chinese medicine; compared Argon laser to xueshuantong
Arevalo 2013 Not RCT
Aydin 2013 Not RCT
Beger 2012 Not RCT
Behnia 2013 Not RCT
Bi 2000 Not RCT
Boscia 2007 Not RCT
Bruha 1972 Not RCT
Cervera 2008 Not RCT
Chrapek 2015 Not RCT; randomization not clearly described
Demirel 2014 Not RCT
Di 2013 Wrong treatment arms and included traditional Chinese medicine; compared argon laser to traditional
medication (vitamin C, E, inosine, rutin, xueshuantong, difrarel)
Earl 2014 Not RCT
Fang 2013 Wrong treatment arms and included traditional Chinese medicine; compared jolethin combined with argon
laser (argon laser and oral jolethin, vitamin B1, inosine and venoruton tablets) to traditional medication
(oral lecithin complex iodine, vitamin B1, inosine, venoruton tablets)
Feily 2009 Not RCT
Haas 2004 Not RCT
Heinrich 1974 Not RCT
Huang 2006 Wrong treatment arms and included traditional Chinese medicine; compared argon laser and iodine treat-
ment to argon laser
Khosla 1997 Not RCT
Koss 2012 Not RCT
Kurimoto 1969 Not RCT
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Lee 2011 Not RCT
Li 2010 Not RCT
Lim 2011 Not RCT
Liu 2009 Not RCT
Long 2011 Wrong treatment arms and included traditional Chinese medicine; compared krypton laser combined with
danshen and inosine to krypton laser combined with anisodine
Lyons 1977 Not RCT
Mackowiakowa 1987 Not RCT
Miyashita 1971 Not RCT
NCT01256580 Wrong participants. RCT enrolled participants with age-related macular degeneration
NCT01585441 This study was terminated early due to lack of enrollment
Novak 1987 Not RCT
Okamoto 2015 Not RCT
Ozdemir 2014 Not RCT
Peng 2010 Not RCT
Radian 1984 Not RCT
Sanchez-Pacheco 2010 Not RCT
Takagi 1965 Not RCT
Tewari 1986 Not RCT; randomization not clearly described
Wang 2009a Not RCT
Wang 2009b Wrong treatment arms and included traditional Chinese medicine; compared therapeutic alliance group
(injected subcutaneously compound anisodine injection 2 mL combined with joletion tablets taking) to
joletion tablets group
Watzke 1974 Wrong participants
Watzke 1979 Wrong participants
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Wu 2010 Wrong treatment arms and included traditional Chinese medicine; compared jolethin combined with argon
laser to argon laser
Xu 2013 Not RCT
Xu 2014 Wrong treatment arms and included traditional Chinese medicine; compared anisodine injection to tradi-
tional medication (oral medication such as adenosine triphosphate, inosine, vitamin)
Ye 2013 Wrong treatment arms and included traditional Chinese medicine; compared argon laser combined with
xueshuantong (laser combined with compound xueshuantong capsule) to argon laser
Zhang 2014 Not RCT
Zheng 2013 Wrong treatment arms and included traditional Chinesemedicine; compared hyperbaric oxygen and iodized
lecithin to hyperbaric oxygen
RCT: randomized controlled trial.
Characteristics of ongoing studies [ordered by study ID]
EUCTR2009-017959-98-NL
Trial name or title Early Treatment of Patients with Central Serous Retinopathy: a Randomized Controlled Trial - CSR & PDT
Methods Study design: parallel group RCT
Participants Population age: adults, elderly
Gender: men and women
“Poor prognostic acute CSR [CSC]”
Interventions NR PDT versus observation
Outcomes Primary outcomes: visual acuity (BCVA ETDRS) at 1 year of follow-up
Secondary outcomes: NR
Starting date 25 March 2010
Contact information NR
Notes Sponsor name: Rotterdam Eye Hospital
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JPRN-UMIN000005372
Trial name or title Study on the Effects of Supplements Containing Lutein on Chronic Central Serous Chorioretinopathy
Methods Study design: parallel group RCT
Participants Population age: ≤ 40 years
Gender: male and female
Interventions Intervention 1: multivitamins, minerals, and lutein
Control: placebo
Outcomes Primary outcomes: rate of spontaneous resolution of CSC, changes in macular volume measured by OCT
Secondary outcomes: NR
BCVA
Starting date NR
Contact information Tsutomu Yasukawa
Nagoya City University Graduate School of Medical Sciences
Department of Ophthalmology and Visual Science
Notes Sponsor name: Nagoya City University Graduate School of Medical Sciences
Source of funding: Santen Pharmaceutical Co., Ltd
NCT01019668
Trial name or title Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy
Methods Study design: parallel group RCT
Participants Population age: 18-75 years
Gender: men and women
Interventions Intervention 1: verteporfin PDT, half-dose
Intervention 2: verteporfin PDT, half-fluence
Outcomes Primary outcomes: effectiveness of both modification for the treatment of chronic CSC, fluorescent leakage
as regards to BCVA OCT changes
Secondary outcomes: detrimental influence on choroidal perfusion, represented by the decrease of fluorescent
intensity in ICGA
Starting date November 2008
Contact information Cheng-Kuo Cheng, MD
Assistant Professor and Attending Physician of Ophthalmology
Shin-Kong Wu Ho-Su Memorial Hospital, School of Medicine, Fu-Jen Catholic University
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Notes Sponsor name: Shin Kong Wu Ho-Su Memorial Hospital
Source of funding: NR
NCT01552044
Trial name or title Effect of Spironolactone in Treating Chronic Non-Resolutive Central Serous Chorioretinitis
Methods Study design: parallel group RCT
Participants Population age: 18-60 years
Gender: male and female
Interventions Intervention 1: spironolactone 25 mg/day
Intervention 2: placebo
Outcomes Primary outcomes: change in central macular thickness at 1 and 3 months, subretinal fluid decrease of 40
microns or more
Secondary outcomes: NR
Starting date January 2012
Contact information Francine Behar-Cohen, MD, PhD
Hotel-Dieu of Paris, France
Notes Sponsor name: Institut National de la Santé Et de la Recherche Médicale, France
Source of funding: NR
NCT01630863
Trial name or title The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
Methods Study design: parallel group RCT
Participants Population age: 20-70 years
Gender: men and women
Interventions Intervention 1: 50% group (power of PDT is applied to the participants at 50% of the full energy based on
TAP study)
Intervention 2: 40% group (power of PDT is applied to the participants at 40% of the full energy based on
TAP study)
Intervention 3: 30% group (power of PDT is applied to the participants at 30% of the full energy based on
TAP study)
Outcomes Primary outcomes: change in BCVA at 1, 3, 6 and months
Secondary outcomes: change in central retinal thickness, success rate, recurrence rate, and complications at
1, 3, and 6 months
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Starting date June 2012
Contact information Min Sagong
Yeungnam University College of Medicine
Daegu, Republic of Korea
Notes Sponsor name: Yeungnam University College of Medicine
Source of funding: NR
NCT01797861
Trial name or title Prospective Randomized ControlledTreatment Trial for Chronic Central SerousChorioretinopathy (PLACE)
Methods Study design: parallel group RCT
Participants Population age: ≥ 18 years
Gender: men and women
Interventions Intervention 1: half-dose PDT
“In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2)
verteporfin (Visudyne ®) is administered, with an infusion time of 10 minutes. At 15 minutes after the start
of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm,
and a treatment duration of 83 seconds. If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-
8 weeks after Treatment Visit 1 / the first treatment with half-dose PDT), a second treatment with half-dose
PDT will be performed (Treatment Visit 2)”
Intervention 2: micropulse laser (ML) treatment
ML treatment with an 810 nm diode laser will be performed of the areas identified on mid-phase ICG angiog-
raphy. Multiple laser spots will be applied, covering the leakage area on mid-phase ICG angiography. The area
(s) that has to be treated is determined based on those hyperfluorescent area(s) on mid-phase (approximately
10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT
scan and hyperfluorescent “hot spots” on the mid-phase (3 minutes) fluorescein angiogram. If there still is
subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the firstML treatment)
, a second ML treatment will be performed (Treatment Visit 2)
Outcomes Primary outcomes: absence of subretinal fluid on OCT scan
Secondary outcomes: BCVA
Starting date December 2013
Contact information Camiel JF Boon, MD PhD FEBO
Leiden University Medical Center, Netherlands
Myrte Breukink, MD
Radboud University Nijmegen Medical Centre, Institute of Ophthalmology, Netherlands
Notes Sponsor name: Radboud University
Source of funding: NR
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Trial name or title Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy
Methods Study design: parallel group RCT
Participants Population age: 18-60 years
Gender: men and women
Interventions Intervention 1: aflibercept (Eylea) 2 mg intravitreal injection at baseline, 1 and 2 months
Control: sham injection at baseline, 1 and 2 months
Outcomes Primary outcomes: change in central subfield thickness from baseline to 1, 2, 3, 4, 5, and 6 months
Secondary outcomes: percentage of eyes achieving complete resolution of subretinal fluid at 6 months,
percentage of eyes achieving 20/20 vision at 6 months, number of aflibercept injections needed to achieve a
complete resolution at 6 months, change in subfoveal choroidal thickness from baseline using EDI-OCT at
1, 2, 3, 4, 5, and 6 months, adverse effects of intravitreal aflibercept (Eylea) injection up to 6 months
Starting date October 2013
Contact information Young Hee Yoon, MD
Asan Medical Center, Republic of Korea
Notes Sponsor name: Asan Medical Center
Source of funding: NR
NCT01982383
Trial name or title Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy
Methods Study design: parallel group RCT
Participants Population age: 30-60 years
Gender: men and women
“New diagnosis of CSC”
Interventions Intervention 1: micropulse laser treatment
“Patient’s randomized to ML treatment would be treated with the following settings: 200 micron spot size, 0.
2 second duration, 15% duty cycle, and 300 milliWatt power. Their eyes would be dilated prior to treatment
with standard mydriatic medications, including Tropicamide and Phenylephrine”
Control: no treatment
“Patients randomized to this treatment arm, will not receive treatment for CSC. They will continue to be
observed at month 1 and month 3. If any worsening of pathology is found during the follow-up visits, the
patient will be removed from the study and given appropriate standard of care by the attending”
Outcomes Primary outcomes: resolution of fluid build-up within 1 week to 3 months after the laser procedure is
completed
Secondary outcomes: NR
Starting date November 2012
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Contact information Khadijah Abdallah, MPH
George Washington University, District of Columbia, United States
Notes Sponsor name: George Washington University
Source of funding: NR
NCT01990677
Trial name or title Eplerenone for the Treatment of Central Serous Chorioretinopathy
Methods Study design: parallel group RCT
Participants Population age: ≥ 18 years
Gender: men and women
Interventions Intervention 1: eplerenone 25 mg - chronic CSC diagnosis
“Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 58 days. Throughout the 58
day treatment period dosage will be adjusted. The adjustment will be based on serum potassium and creatine
levels from blood draws done at Day 12 and Day 33. From the 25 mg starting dosage, the dosage will either
be increased to 50 mg a day or reduced to placebo, one time, each day”
Intervention 2: placebo - chronic CSC diagnosis
“Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken
orally, once daily, for 58 days. The placebo pills will be compounded to be of similar composition to the
eplerenone tablets, without the active ingredient”
Intervention 3: eplerenone 25 mg - acute CSC diagnosis
“Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 28 days. Throughout the 28
day treatment period, dosage will be adjusted based on serum potassium and creatine levels from blood draws
done on Day 12. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or
reduced to placebo, one time, each day”
Intervention 4: placebo - acute CSC diagnosis
“Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken
orally, once daily, for 28 days. The placebo pills will be compounded to be of similar composition to the
eplerenone tablets, without the active ingredient”
Outcomes Primary outcomes: absence of subfoveal (retinal) fluid based on spectral domain OCT measurement at 1
month in acute CSC and 2 months in chronic CSC participants
Secondary outcomes: mean change in subfoveal fluid height based on OCT measurement at 1 month in
acute CSC and 2 months in chronic CSC participants
Starting date October 2013
Contact information Brian Burke, MPH
Wills Eye Hospital
Notes Sponsor name: Wills Eye Hospital, Philadelphia, United States
Source of funding: NR
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Trial name or title Eplerenone for the Treatment of Chronic Central Serous Chorioretinopathy
Methods Study design: parallel group RCT
Participants Population age: 18-65 years
Gender: men and women
Interventions Intervention 1: eplerenone 25 mg given daily for 1 week, followed by 50 mg given for a total of 3 months
since commencement of treatment
Intervention 2: placebo
Outcomes Primary outcomes: decrease of at least 10% in subretinal fluid thickness as measured by OCT at 6 months
Secondary outcomes: NR
Starting date April 2014
Contact information Michaella Goldstein, MD
Tel Aviv Souraski Medical Center, Israel
Notes Sponsor name: Tel-Aviv Sourasky Medical Center
Source of funding: NR
NCT02215330
Trial name or title A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy
Methods Study design: parallel group RCT
Participants Population age: ≥ 21 years
Gender: men and women
Interventions Intervention: eplerenone 25 mg pills triturated and filled into capsules
Control: sugar pill (maltodextrin filled into capsules)
Outcomes Primary outcomes: difference in the number of successful treatments after 16 weeks, defined as complete
absence of subretinal fluid on SD-OCT
Secondary outcomes: change in visual acuity between eplerenone and placebo at 16 weeks, change in retinal
thickness between eplerenone and placebo at 16 weeks, change in retinal volume between eplerenone and
placebo at 16 weeks
Starting date October 2014
Contact information Oliver Findl, MD, Prof, MBA
Vienna Institute for Research in Ocular Surgery, Department of Ophthalmology
Hanusch Hospital Vienna, Vienna, Austria
Notes Sponsor name: Oliver Findl, MD, Prof, MBA
Source of funding: NR
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Trial name or title Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
Methods Study design: parallel group RCT
Participants Population age: ≥ 18 years
Gender: men and woman
Interventions Intervention 1: 1 x 300 mg mifepristone tablet, taken once daily for 4 weeks
Intervention 2: 3 x 300 mg mifepristone tablets (900 mg dose), taken once daily for 4 weeks
Control: placebo taken once daily for 4 weeks
Outcomes Primary outcomes: resolution of sub-retinal fluid at 4 weeks after treatment, presence or absence of subretinal
fluid on spectral-domain OCT after 4 weeks of treatment with mifepristone 300 or 900 mg daily, compared
with placebo
Secondary outcomes: change in subretinal fluid or intraretinal fluid (or both) at weeks 1, 2, 4, and 8, BCVA
at weeks 1, 2, 4, and 8, change in ETDRS BCVA compared with baseline at weeks 1, 2, 4, and 8, change
in macular thickness at weeks 1, 2, 4, and 8, change in foveal thickness at weeks 1, 2, 4, and 8, change
compared with baseline in thickness of subretinal fluid under the fovea on OCTat weeks 1, 2, 4, and 8,
change in choroidal thickness at weeks 1, 2, 4, and 8, dye leakage in vasculature at week 4 and 8, change in
OCT characteristics in the fellow eye at week 8, proportion of acute versus chronic CSC participants at week
8, proportion of acute versus chronic CSC participants as determined at baseline, with the above outcomes
analyzed for each subgroup; safety and tolerability characteristics at week 8
Starting date January 2015
Contact information Roger A Goldberg, MD, MBA
Bay Area Retina Associates
Walnut Creek, California, United States
Jeffery S Heier, MD
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
Notes Sponsor Name: Roger Goldberg, MD, MBA
Source of funding: Bay Area Retina Associates, Ophthalmic Consultants of Boston
BCVA: best-corrected visual acuity; CSC: central serous chorioretinopathy (also known as CSR: central serous retinopathy); ETDRS:
Early Treatment Diabetic Retinopathy Study; ICGA: indocyanine green angiography; NR: not reported; OCT: optical coherence
tomography; PDT: photodynamic therapy; RCT: randomized controlled trial.
105Interventions for central serous chorioretinopathy: a network meta-analysis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Anti-VEGF versus observation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change in BCVA at 12
months
2 64 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.02, 0.03]
2 Mean change in CRT at 12
months
2 64 Mean Difference (IV, Fixed, 95% CI) 8.73 [-18.08, 35.54]
Comparison 2. Anti-VEGF versus low fluence PDT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change in BCVA at 12
months
2 56 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.08, 0.15]
2 Recurrence of CSC at 12 months 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Persistent CSC at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Mean change in CRT at 12
months
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 3. Anti-VEGF plus 50% PDT versus 50% PDT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change in BCVA at 12
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Persistent CSC at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Mean change in CRT at 12
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Comparison 4. Six-dose anti-VEGF versus four-dose anti-VEGF
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change in BCVA at 12
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Mean change in CRT at 12
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 5. 50% PDT versus sham treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean BCVA at 12 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Recurrence/persistence CSC at
12 months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Recurrence of CSC at 12
months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Persistent CSC at 12
months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Mean CRT at 12 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 6. 30% PDT versus PDT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean BCVA at 12 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Recurrence of CSC at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Mean change in CRT at 12
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Comparison 7. 50% PDT versus PDT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean BCVA at 12 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Recurrence of CSC at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Mean change in CRT at 12
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 8. 30% PDT versus 50% PDT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change in BCVA at 12
months
2 177 Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.15, -0.08]
2 Recurrence of CSC at 12 months 2 153 Risk Ratio (M-H, Fixed, 95% CI) 2.50 [1.54, 4.06]
3 Persistent CSC at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Mean change in CRT at 12
months
2 177 Mean Difference (IV, Fixed, 95% CI) 44.90 [42.57, 47.23]
Comparison 9. Laser versus observation or sham treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean change in BCVA at 12
months
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Recurrence of CSC at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Mean change in CRT at 12
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 10. Indirect argon laser versus direct argon laser
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrence of CSC at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Comparison 11. Comparison of different laser wavelengths
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrence of CSC at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Yellow compared with red 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Yellow compared with
green
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Red compared with green 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 12. Antioxidant supplements versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 BCVA at 12 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Recurrence at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Persistence at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 CRT at 12 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 13. Beta-blocker versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean BCVA at 12 months 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Recurrence of CSC at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 BCVA ≥ 20/40 at 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 14. Carbonic anhydrase inhibitors versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrent/persistent CSC at 12
months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Recurrence of CSC at 12
months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Persistent CSC at 12
months
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 15. Helicobacter pylori treatment versus placebo or observation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean BCVA at 12 months 2 103 Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.07, -0.02]
2 Persistent CSC at 12 months 2 103 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.36, 1.22]
A D D I T I O N A L T A B L E S
Table 1. Assessment of transitivity across treatment comparisons: visual acuity
Treatment comparison Study Type of CSC Date study conducted Industry sponsored
Anti-VEGF vs. PDT Bae 2011
Semeraro 2012
Chronic
Chronic
2009-2012
2009-2010
Yes
NR
PDT vs. no treatment Chan 2008 Acute 2004-2005 NR
Laser vs. no treatment Robertson 1983 Acute 1977-1981 No
One additional study for the comparison PDT vs. no treatment was reported in abstract form only and no data on outcome so was not
included in the network meta-analysis (Boscia 2008).
anti-VEGF: anti-vascular endothelial growth factor; CSC: central serous chorioretinopathy; NR: not reported; PDT: photodynamic
therapy.
Table 2. Comparative effects of ocular interventions for central serous chorioretinopathy: visual acuity
Anti-VEGF -0.08 (-0.14 to -0.01) -0.20 (-0.30 to -0.11) 0.00 (-0.02 to 0.03) 0.22 (0.01 to 0.44)
0.08 (0.01 to 0.14) PDT -0.13 (-0.24 to -0.01) 0.08 (0.01 to 0.15) 0.30 (0.09 to 0.51)
0.20 (0.11 to 0.30) 0.13 (0.01 to 0.24) Laser 0.21 (0.11 to 0.31) 0.43 (0.19 to 0.66)
-0.00 (-0.03 to 0.02) -0.08 (-0.15 to -0.01) -0.21 (-0.31 to -0.11) Anti-VEGF and PDT 0.22 (0.00 to 0.44)
-0.22 (-0.44 to -0.01) -0.30 (-0.51 to -0.09) -0.43 (-0.66 to -0.19) -0.22 (-0.44 to -0.00) Control (no treatment or
sham treatment)
Effect estimate is the mean difference (95% confidence interval). Negative values favor the first intervention. In the lower left hand
triangle, the first intervention is anti-VEGF, PDT, laser etc. In the upper right hand triangle, the first intervention is control, anti-
VEGF and PDT, laser etc. So, for example, visual acuity with anti-VEGF was 0.22 logMAR units better than control 95% CI 0.44
better to 0.01 better.
anti-VEGF: anti-vascular endothelial growth factor; logMAR: logarithm of the minimal angle of resolution; PDT: photodynamic
therapy.
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Table 3. Assessment of transitivity across treatment comparisons: recurrence
Treatment comparison Study Type of CSC Date study conducted Industry sponsored
Anti-VEGF vs. no treat-
ment
Kim 2013
Lim 2010
Acute
Acute
2010-2011
2008
No
No
Anti-VEGF vs. PDT Bae 2011
Semeraro 2012
Chronic
Chronic
2009-2012
2009-2010
Yes
NR
Anti-VEGF + PDT vs.
PDT alone
Coskun 2014 Chronic NR (published 2014) NR
PDT vs. no treatment Chan 2008 Acute 2004-2005 NR
Laser vs. no treatment Klatt 2011
Robertson 1983
Roisman 2013
Acute
Acute
Chronic
2007-2008
1977-1981
NR (published 2013)
NR
No
NR
One additional study for the comparison PDT vs no treatment was reported in abstract form only and no data on outcome so was not
included in the network meta-analysis (Boscia 2008).
anti-VEGF: anti-vascular endothelial growth factor; CSC: central serous chorioretinopathy; NR: not reported; PDT: photodynamic
therapy.
Table 4. Comparative effects of ocular interventions for CSC: recurrence
Anti-VEGF 0.27 (0.02 to 3.73) 3.34 (0.01 to 788.57) 2.67 (0.03 to 234.08)
3.77 (0.27 to 52.94) PDT 12.58 (0.11 to 1503.87) 10.07 (0.27 to 371.91)
0.30 (0.00 to 70.79) 0.08 (0.00 to 9.50) Laser 0.80 (0.03 to 18.46)
0.37 (0.00 to 32.83) 0.10 (0.00 to 3.67) 1.25 (0.05 to 28.85) Control
Effect estimate is the risk ratio (95% CI).
anti-VEGF: anti-vascular endothelial growth factor; logMAR: logarithm of the minimal angle of resolution; PDT: photodynamic
therapy.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We made the following amendments to our protocol (Salehi 2015).
• We excluded trials of traditional Chinese medicine. This is because we did not have a clear rationale for these treatments and
these interventions may not be applicable to the settings covered by this review.
• We restricted the network to interventions applied directly to the eye (ocular interventions) because we felt that a key
assumption of the network - participants should be equally likely to be randomized to any of the interventions - would be unlikely to
hold otherwise.
• We did not consistently contact trial investigators for clarification of risk of bias as ’unclear’ based on unreported or poorly
reported information: some of the studies were completed many years ago and we took the judgment that the information was
unlikely to be forthcoming.
We omitted to describe the GRADE assessment and ’Summary of findings’ table in our protocol and have included that in the review
methods.
The following methods set out in our protocol were not done due to lack of data. They may be applicable in future editions of the
review.
Unit of analysis
If any studies enroll bilateral CSC cases and randomize eyes in participants to intervention versus comparator (within-person study),
we will refer to Chapter 16 of the Cochrane Handbook for Systematic Reviews of Interventions as a guide for analysis of matched data (
Higgins 2011b).
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Assessing reporting bias
When future versions of this review’s meta-analysis include 10 or more studies, we will investigate small-study effects using a funnel
plot. The funnel plot will have the effect estimate on the horizontal axis and the standard error on the vertical axis for each trial. We will
conduct a qualitative interpretation of funnel plot asymmetry using guidance from Chapter 10 of the Cochrane Handbook for Systematic
Reviews of Interventions (Sterne 2011).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Carbonic Anhydrase Inhibitors [therapeutic use]; Central Serous Chorioretinopathy [∗therapy]; Helicobacter Infections [drug therapy];
Helicobacter pylori; Laser Therapy [methods]; Photochemotherapy [methods]; Propranolol [therapeutic use]; Randomized Controlled
Trials as Topic; Remission, Spontaneous; Treatment Outcome; Vascular Endothelial Growth Factor A [antagonists & inhibitors]; Visual
Acuity; Watchful Waiting
MeSH check words
Humans
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